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Abstract 
 
Background 
Reflux of acid and bile into the distal oesophagus induces inflammation, which in 
certain individuals leads to metaplastic cellular changes in the normal squamous cell 
lining, termed Barrett’s oesophagus. Further cellular changes can occur resulting in 
formation of low grade then high grade dysplastic cells, increasing an individual’s risk 
of progressing to oesophageal adenocarcinoma. The prognosis, once cancer develops, 
is poor and thus understanding the cellular mechanisms contributing to the 
progression from squamous through Barrett’s metaplasia to cancer, and treatment 
options for dysplasia to prevent cancer, are important. This thesis explores these two 
areas, specifically looking at the role of the 5-lipoxygenase (5-LOX) pathway in the 
progression to oesophageal adenocarcinoma, and the cost-effectiveness of 
radiofrequency ablation as a new treatment for high grade dysplasia.  
 
The 5-LOX pathway catalyses the biosynthesis of leukotrienes, potent inflammatory 
mediators. Upregulation of this pathway is found in numerous tumour types and linked 
to promotion of cancer cell growth, but the role of leukotrienes and their cellular 
sources in Barrett’s metaplasia and oesophageal adenocarcinoma are not fully 
understood. 
 
If high grade dysplasia is detected at endoscopy then national guidance in the UK 
recommends oesophagectomy as definitive treatment. Radiofrequency ablation is an 
alternative new technology with promising early trial results, but whether it represents 
a cost-effective alternative to oesophagectomy is unknown. 
 
Hypothesis 
(1)  5-LOX pathway activity is up-regulated progressively through metaplasia to 
adenocarcinoma, by induction of enzyme expression and/or infiltration by 
inflammatory cell-types. 
(2)  Radiofrequency ablation is a cost-effective option for treatment of high-grade 
dysplasia in Barrett’s in a UK setting. 
 
Methods 
Tissue samples were collected at endoscopy from patients with Barrett’s metaplasia 
and oesophageal adenocarcinoma, with proximal squamous oesophagus samples used 
as controls. The diagnosis was histologically confirmed from adjacent sections by a 
gastrointestinal pathologist. Immunohistochemical analyses were performed on 
stromal and epithelial areas (5 squamous, 16 Barrett’s, 7 oesophageal 
adenocarcinoma) with optimized concentrations of primary antibodies for 5-LOX, 5-
LOX activating protein (FLAP), and the distal enzymes leukotriene A4 hydrolase (LTA4H) ii 
 
and LTC4 synthase (LTC4S). Epithelial and stromal areas of squamous (n=7), Barrett’s 
metaplasia (n=12), and oesophageal adenocarcinoma (n=9) were isolated using laser 
capture microdissection. mRNA was then extracted, reverse transcribed and real time 
quantitative polymerase chain reaction (RT-qPCR) assays were performed for the 5-LOX 
pathway genes ALOX5, ALOX5AP, LTA4H, LTC4S, LTB4R, CYSLTR1. 
 
A cost-utility analysis was undertaken using a Markov model to simulate the natural 
history of a cohort of patients with high-grade dysplasia in Barrett’s oesophagus 
undergoing one of two treatment options: (i) oesophagectomy or (ii) radiofrequency 
ablation followed by endoscopic surveillance with oesophagectomy for high-grade 
dysplasia recurrence or persistence. 
 
Results 
Significant increases in stromal immunoexpression of 5-LOX pathway enzymes were 
seen in adenocarcinoma tissue, with correlation of FLAP and LTA
4H immunostaining 
with elevated neutrophil counts (p<0.001). LTC
4S immunostaining was also notably 
overexpressed within epithelial cells in both Barrett’s (p<0.001) and adenocarcinoma 
(p<0.01) tissue. Transcript levels for all 5-LOX pathway enzymes were higher in stromal 
area compared with epithelial areas of all tissue types, but in particular in oesophageal 
adenocarcinoma tissue. mRNA transcripts of the cysteinyl leukotriene receptor 1 
(CYSLT1R) and leukotriene B
4 receptor 1 (LTB4R) genes were expressed most 
prominently in Barrett’s stromal and oesophageal adenocarcinoma epithelial areas 
respectively.  
 
In the health economic analysis, radiofrequency ablation dominated as it generated 0.4 
extra quality of life years at a cost saving of £1902. For oesophagectomy to be the 
most cost-effective option required a radiofrequency ablation treatment failure rate 
(high-grade dysplasia persistence or progression to cancer) of >44%, or an annual risk 
of high-grade dysplasia recurrence or progression to cancer in the ablated oesophagus 
of >15% per annum. There was an 85% probability that radiofrequency ablation 
remained cost-effective at the NICE willingness to pay threshold range of £20,000–
30,000. 
 
Conclusions 
Key biosynthetic enzymes of the LTB
4 and LTC
4 biosynthetic pathways are incrementally 
expressed across the spectrum of squamous, Barrett’s metaplasia and oesophageal 
adenocarcinoma tissues, suggesting for the first time a role of both leukotriene sub-
families in disease progression. Transcriptional upregulation of mRNA was highest in 
the stromal area of oesophageal adenocarcinoma tissue, although marked sample to 
sample variation was observed, suggesting an important role for post-transcriptional 
factors of 5-LOX pathway protein translation. Expression of LTB4R by epithelial cells of iii 
 
oesophageal adenocarcinoma tissue infers a functional role for LTB
4 acting on BLT1 
receptors in carcinogenesis. 
 
In the prevention of oesophageal adenocarcinoma, radiofrequency ablation is likely to 
be a cost-effective option for treating high-grade dysplasia in Barrett’s oesophagus in a 
UK setting. Long term outcome data are required to achieve certainty as to the optimal 
management strategy. However, if initial eradication of high-grade dysplasia is 
achievable in over 60% of patients, then radiofrequency ablation with oesophagectomy 
for high-grade dysplasia persistence or recurrence will be the preferred strategy. iv 
 
   v 
 
Contents 
CHAPTER 1:  INTRODUCTION ............................................................................................. 1 
  Overview ...................................................................................................................... 1  1.1
  Definition of Barrett’s metaplasia .............................................................................. 2  1.2
  Historical perspective.................................................................................................. 3  1.3
  Epidemiology of Barrett’s oesophagus and oesophageal adenocarcinoma ........... 4  1.4
  The role of acid reflux and inflammation in the pathogenesis of Barrett’s  1.5
Metaplasia and Oesophageal Adenocarcinoma  ................................................................... 5 
  Eicosanoids in cancer  .................................................................................................. 8  1.6
  The 5-lipoxygenase pathway  .................................................................................... 11  1.7
  Current management strategies for high grade dysplasia in Barrett’s oesophagus 1.8
  ……………………………………………………………………………………………………27 
  Summary and Aims of thesis  .................................................................................... 37  1.9
 
CHAPTER 2:  METHODOLOGY OF LABORATORY STUDIES  ............................................... 39 
  Patient recruitment ................................................................................................... 39  2.1
  Immunohistochemistry ............................................................................................. 40  2.2
  Isolation, extraction, and gene expression analysis of cellular RNA using laser  2.3
captured micro-dissection .................................................................................................. 46 
  Statistical analysis and choice of statistical test  ..................................................... 61  2.4
 
CHAPTER 3:  COST-UTILITY ANALYSIS.............................................................................. 63 
  Review of Existing cost-effective analyses on ablative therapies for Barrett’s  3.1
metaplasia ............................................................................................................................ 63 
  Defining the research question  ................................................................................ 65  3.2
  Construction of a decision analytic model  .............................................................. 66  3.3
  Transition probabilities............................................................................................. 70  3.4
  Utilities ....................................................................................................................... 79  3.5
  Costs .......................................................................................................................... 84  3.6
  Analysis  ...................................................................................................................... 85  3.7
 vi 
 
CHAPTER 4:  IMMUNOHISTOCHEMICAL ANALYSIS OF 5-LIPOXYGENASE PATHWAY IN 
BARRETT’S ADENOCARCINOMA.......................................................................................... 87 
  Summary  .................................................................................................................... 87  4.1
  Immunostaining for 5-LOX pathway proteins in oesophageal biopsies ............... 88  4.2
  Leukocyte subtype counts and correlation with 5-LOX pathway proteins  ............ 97  4.3
  Recruitment and group demographics.................................................................. 107  4.4
  Discussion ............................................................................................................... 111  4.5
 
CHAPTER 5:  ISOLATION AND EXTRACTION OF CELLULAR RNA BY LASER CAPTURE 
MICRO-DISSECTION, REVERSE TRANSCRIPTION AND REAL-TIME POLYMERASE CHAIN 
REACTION    .................................................................................................................... 115 
  Summary  .................................................................................................................. 115  5.1
  RNA extraction and Validation of Laser capture micro-dissection  ...................... 116  5.2
  LMD results  .............................................................................................................. 123  5.3
  Discussion ............................................................................................................... 137  5.4
 
CHAPTER 6:  COST–UTILITY ANALYSIS OF RADIOFREQUENCY ABLATION OR 
OESOPHAGECTOMY FOR THE MANAGEMENT OF HIGH-GRADE DYSPLASIA IN BARRETT’S 
METAPLASIA    .................................................................................................................... 143 
  Summary  .................................................................................................................. 143  6.1
  Deterministic Model - Base case analysis  .............................................................. 144  6.2
  Deterministic sensitivity analysis  ........................................................................... 147  6.3
  Probabilistic sensitivity analysis ............................................................................ 150  6.4
  Discussion ............................................................................................................... 153  6.5
 
CHAPTER 7:  CONCLUSIONS AND FUTURE STUDY ........................................................ 157 
  Expression of The 5-LOX pathway in Barrett’s metaplasia and oesophageal  7.1
carcinogenesis and impact on future research  ............................................................... 157 
 
BIBLIOGRAPHY  .................................................................................................................... 163 
 
 vii 
 
APPENDIX 
A – Ethical approval ...........................................................................................................  189 
B - Consent form and patient information sheet.............................................................  191 
C - Solutions/laboratory protocols………………………………………………………………187 
D - Search strategies for parameters used in the model……………………………………189 
E - Utilities…………………………………………………………………………………………….191 
F - Costs used in the model……………………………………………………………………….193 
G - Full publications arising from thesis……………………………………………………….195 
 
   viii 
 
   ix 
 
List of figures 
Figure 1-A: Appearance of Barrett’s oesophagus at white light upper gastrointestinal 
endoscopy. ............................................................................................................................. 3 
Figure 1-B: Cyclo-oxygenase pathway with examples of available pathway protein 
inhibitors. ............................................................................................................................... 9 
Figure 1-C: 5-LOX pathway with examples of available pathway protein inhibitors or 
receptor antagonists ........................................................................................................... 13 
Figure 1-D: Actions of LTB
4 ................................................................................................. 14 
Figure 1-E: Summary of known actions of the cysteinyl leukotrienes mediated through 
cysLT1 and 2 receptors  ....................................................................................................... 16 
Figure 1-F: Possible role of the 5-LOX pathway in carcinogenesis demonstrated in 
published studies. ............................................................................................................... 19 
Figure 1-G: The Bârrx HALO system  ................................................................................... 31 
Figure 1-H: Illustration of ablation of a Barrett’s segment using the 360⁰ device ......... 32 
Figure 1-I: Treatment of Barrett’s metaplasia by the HALO 90 device ............................ 34 
Figure 2-A: Example of titration curve used to calculate the optimum antibody dilution.
 .............................................................................................................................................. 41 
Figure 2-B: Avidin Biotin Complex (ABC) method ............................................................. 43 
Figure 2-C: Use of image analysis software to measure percentage epithelial area 
staining.  ................................................................................................................................ 45 
Figure 2-D: Identification, laser dissection and procurement of tissue area during laser 
capture micro-dissection..................................................................................................... 48 
Figure 3-A: Transition state diagram (Markov model) of oesophagectomy strategy ..... 67 
Figure 3-B: Transition state diagram (Markov model) of RFA strategy  ............................ 69 
Figure 4-A: Stromal 5-LOX positive cell count in different tissue types.  ......................... 88 
Figure 4-B: Stromal FLAP positive cell count per mm
2 in different tissue types.  ............ 89 
Figure 4-C: Stromal LTA
4H positive cell count in different tissue types  .......................... 90 
Figure 4-D: Stromal LTC
4S positive cell count in different tissue types. ......................... 91 
Figure 4-E: Epithelial immunostaining for LTC
4S in different tissue types.  ..................... 92 
Figure 4-F: Immunostaining for 5-LOX pathway enzymes in stromal area of 
oesophageal adenocarcinoma tissue. ................................................................................ 93 
Figure 4-G: Immunostaining for LTC
4 synthase in epithelial area of tissue.  ................... 95 x 
 
Figure 4-H: Leukocyte counts in squamous tissue, Barrett’s metaplasia and 
oesophageal adenocarcinoma.  ........................................................................................... 97 
Figure 4-I: Correlation of 5-LOX pathway protein immunoexpression with neutrophil 
counts. ................................................................................................................................. 99 
Figure 4-J: Correlation of 5-LOX pathway protein immunoexpression with 
monocyte/macrophage counts. ....................................................................................... 101 
Figure 4-K: Correlation of 5-LOX pathway protein immunoexpression with eosinophil 
counts. ............................................................................................................................... 103 
Figure 4-L: Correlation of 5-LOX pathway protein immunoexpression with T-lymphocyte 
counts. ............................................................................................................................... 105 
Figure 4-M: Patient characteristics  ................................................................................... 107 
Figure 4-N: Histogram showing frequency and distribution of length of Barrett’s 
segment. ............................................................................................................................ 108 
Figure 4-O: Effect of PPI use at time of tissue acquisition on mean cell count per mm
2 
of (A) 5-LOX pathway proteins and (B) inflammatory cell subtype.  ............................... 109 
Figure 5-A: Comparison of filter based and TRIzol
® reagent based extraction methods 
from laser captured material.  ........................................................................................... 116 
Figure 5-B: Amplification and standard curves ............................................................... 118 
Figure 5-C: Melt curve for PTPRC ..................................................................................... 119 
Figure 5-D: Performance of housekeeping genes measured by the ratio of difference in 
expression between housekeeper pairings.  .................................................................... 120 
Figure 5-E: PTPRC transcript expression in laser captured samples of epithelial cell 
populations from different tissue types. ......................................................................... 121 
Figure 5-F: mRNA transcript levels of 5-LOX pathway genes of interest in epithelial and 
stromal areas.  .................................................................................................................... 123 
Figure 5-G: ALOX5 gene transcript levels in (A) Epithelial and (B) Stromal areas ........ 125 
Figure 5-H: ALOX5AP gene transcript levels in (A) epithelial and (B) Stromal areas.  ... 127 
Figure 5-I: LTA4H gene transcript levels in (A) Epithelial area (B) Stromal areas. ........ 129 
Figure 5-J: LTC4S gene transcript levels in (A) Epithelial area (B) Stromal areas  .......... 131 
Figure 5-K: LTB4R gene transcript levels in (a) Epithelial and (b) Stromal areas.  ......... 133 
Figure 5-L: CYSLT1R gene transcript levels in (A) Epithelial and (B) Stromal areas. .... 135 
Figure 6-A: Base case analysis - cost-effectiveness plane. ............................................. 145 
Figure 6-B: Base case analysis - survival curve (Markov trace)  ....................................... 147 xi 
 
Figure 6-C: Threshold analysis – altering transition probability of outcome after RFA is 
HGD ....................................................................................................................................  148 
Figure 6-D: Threshold analysis – altering transition probability of recurrence of HGD or 
progression to OA during post RFA surveillance ............................................................  149 
Figure 6-E: Cost-effectiveness plane of results of probabilistic sensitivity analysis ....  151 
Figure 6-F: Cost-effectiveness acceptability curve ..........................................................  152 
Figure 7-A: Illustration of the potential role of 5-LOX pathway in Barrett’s 
adenocarcinoma ................................................................................................................  159 
Figure 7-B: Metabolism of arachidonic acid by lipoxygenase and cyclo-oxygenase 
pathways and role in carcinogenesis ...............................................................................  160 
 
   xii 
 
   xiii 
 
List of tables 
Table 1-A: Summary of studies examining the role of the 5-lipoxygenase pathway in 
cancer. .................................................................................................................................. 21 
Table 1-B: Summary of outcomes and complications of endoscopic techniques used to 
eradicate HGD in Barrett’s oesophagus ............................................................................. 30 
Table 2-A: RT-qPCR Primer reaction set up table  .............................................................. 52 
Table 2-B: RT-qPCR master mix set up table ..................................................................... 52 
Table 2-C: Summary of gene expression assays used in real time RT-qPCR experiments
 .............................................................................................................................................. 57 
Table 3-A: Summary of Transition probabilities ............................................................... 78 
Table 3-B: Summary of health state utilities used in the model ...................................... 80 
Table 3-C: Utility values reported by de Boer et al. (2002) .............................................. 82 
Table 3-D: Utility values reported in the study by Hur et al. (2006)  ................................ 83 
Table 3-E: Summary of the costs used in the model. ....................................................... 85 
Table 5-A: Efficiency and error of gene expression assays used in real time RT-qPCR 
experiments. ......................................................................................................................  117 
Table 5-B: Patient characteristics of laser capture micro-dissected samples. ..............  136 
Table 6-A: base case results of the deterministic model. ..............................................  144 
Table 6-B: Base case analysis - morbidity ........................................................................  145 
Table 6-C: Base case analysis - cause of death ...............................................................  146 
Table 6-D: Base case analysis - 5-year survival ...............................................................  146 
Table 6-E: Probabilistic sensitivity analysis – Base case results  .....................................  150 
   xiv 
 
   xv 
 
Declaration of Authorship 
 
I, Dr Christopher Philip Coryndon Boger 
 
declare that the thesis entitled 
 
Barrett’s dysplasia – adenocarcinoma: role of the leukotriene pathway and treatment 
with radiofrequency ablation 
 
and the work presented in the thesis is both my own, and have been generated by me 
as the result of my own original research. I confirm that: 
 
•  this work was done wholly or mainly while in candidature for a research degree at 
this University; 
•  where any part of this thesis has previously been submitted for a degree or any 
other qualification at this University or any other institution, this has been clearly 
stated; 
•  where I have consulted the published work of others, this is always clearly 
attributed; 
•  where I have quoted from the work of others, the source is always given. With the 
exception of such quotations, this thesis is entirely my own work; 
•  I have acknowledged all main sources of help; 
•  where the thesis is based on work done by myself jointly with others, I have made 
clear exactly what was done by others and what I have contributed myself; 
•  parts of this work have been published as:  
 
Boger CP, Shutt J, Neale J, Wilson S, Bateman A, Holloway J, Patel P, Sampson AP. 
Increased expression of 5-lipoxygenase pathway proteins and cellular localisation in 
Barrett’s Adenocarcinoma. Histopathology 2012; 61: 509-17. 
 
Boger CP, Turner D, Roderick P, Patel P. A UK-based cost–utility analysis of 
radiofrequency ablation or oesophagectomy for the management of high-grade 
dysplasia in Barrett’s oesophagus. Alimentary Pharmacology & Therapeutics 2010; 32: 
1332-42. 
 
Signed: ……………………………………………………………………….. 
 
Date:……………………………………………………………………………. 
   xvi 
 
   xvii 
 
Acknowledgments 
 
I would like to thank all those who have helped me undertake this work, providing 
moral and inspirational support throughout. In particular I’d like to thank my two 
supervisors Dr Praful Patel and Dr Tony Sampson. Their unlimited patience and hours 
of effort in the production of this work is much appreciated. 
I would like to thank the Wessex Cancer trust who provided financial support for the 
laboratory work. 
I would also like to thank Professor Paul Roderick and Dr David Turner for their 
collaboration on the health economic analysis, and Professor John Holloway and Dr 
Susan Wilson for their help with the immunohistochemical and laser capture 
microdissection work. The support of their laboratory staff was fantastic and I must 
thank Jon Ward, Helen Rigby, and Dr Matt Rose Zerilli who were instrumental in 
facilitating and troubleshooting the laboratory studies. 
Lastly and most important of all, I would like to thank my wife for providing the 
support and patience, without which none of this would have been possible. 
   xviii 
 
   xix 
 
Commonly used Abbreviations 
 
OA – oesophageal adenocarcinoma 
BM – Barrett’s metaplasia 
GORD – gastro-oesophageal reflux disease 
LGD – low grade dysplasia 
HGD – high grade dysplasia 
NHS – National Health Service 
RFA – radiofrequency ablation 
UK – United Kingdom 
IL - interleukin 
DNA – deoxyribonucleic acid 
RNA – ribonucleic acid 
COX – cyclo-oxygenase 
NF-κβ  - nuclear factor kappa β 
TGFβ – transforming growth factor β 
AA – arachidonic acid 
LT - leukotriene 
5-LOX – 5-lipoxygenase 
FLAP – 5-lipoxygenase activating protein 
LTA
4H – leukotriene A
4 hydrolase 
LTC
4S – leukotriene C
4 synthase 
PG – Prostaglandin 
cysLT – cysteinyl leukotriene 
NSAID – non-steroidal anti-inflammatory drug 
RCT – randomised controlled trial 
RT-qPCR – real time quantitative polymerase chain reaction 
EMR – endoscopic mucosal resection 
PDT – photodynamic therapy 
VAS – visual analogue score 
NICE – national institute for Health and Clinical Excellence 
PPI – proton pump inhibitor 
LCM – laser capture microdissection 
ICER – incremental cost-effectiveness ratio 
QALY – quality of life 
IHC – immunohistochemistry 
AEC - 3-amino-9-ethylcarbazole 
DAB - 3, 3’-diaminobenzidinetrahydrochloride 
GM – geometric mean 
   xx 
 
   Dr CPC Boger  Introduction 
1 
 
CHAPTER 1:   Introduction 
 
This thesis is submitted in consideration of a Doctorate of Medicine award. It outlines 
the findings of several studies on aspects of Barrett’s oesophagus and oesophageal 
adenocarcinoma. This introductory chapter describes the development and context of 
the research. Chapter two concerns the methodology of the laboratory studies and 
protocol. Chapter three outlines the methodology of the health economic analysis, 
including literature review, model design, and formulation of data parameters and 
costs. Results and discussion of the studies are presented in chapters four through six, 
with final conclusions and scope for future study presented in chapter seven. 
 
  Overview  1.1
 
The incidence of oesophageal adenocarcinoma (OA) is highest in the United Kingdom 
(UK) and rising faster than any other solid tumour in western countries (Blot et al. 
1991; Jankowski et al. 2002). It is associated with a poor prognosis, with a 5-year 
survival of 10-13% (Rachet et al. 2009; Sant et al. 2009). OA arises in metaplastic 
columnar epithelium in the distal oesophagus, named Barrett’s metaplasia (BM). BM 
confers a 1 in 20 life time risk of developing OA, which equates to an increase of 
between 30 to 125 times greater than that of the general population (Provenzale et al. 
1999; Wild and Hardie 2003). BM is estimated to be prevalent in 0.5-2% of adults in the 
western world, rising to up to 15% in those with chronic gastro-oesophageal reflux 
disease (GORD), suggesting that GORD is an important risk factor (Corder et al. 1996; 
Csendes et al. 2000; Ronkainen et al. 2005). Reflux of acid and bile results in an 
inflammatory injury to the lower oesophagus, which leads to the development of BM, 
and subsequent OA in a proportion of patients (Jankowski and Anderson 2004). 
 
Chronic inflammation is a well-established risk factor for cancer, providing a micro-
environment rich in molecules which enhance cell growth and survival (Coussens and 
Werb 2002; Aggarwal et al. 2006; Lu et al. 2006). 5-lipoxygenase (5-LOX) and its 
constituent pathway proteins metabolise arachidonic acid to leukotrienes, potent pro-
inflammatory mediators (Funk 2001). Up-regulation of this pathway is evident in a 
variety of tumour types and has been shown to play a role in promotion of cancer cell 
growth (Romano and Claria 2003). The 5-LOX pathway is increased in oesophagitis, BM 
and OA, but their role has yet to be fully elucidated (Triadafilopoulos et al. 1996, Chen 
et al. 2002). 
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Due to the dismal prognosis associated with OA, efforts have focused on detection of 
BM in high risk groups and subsequent 2-3 yearly surveillance (Watson et al. 2005). At 
this juncture, endoscopy is performed and multiple biopsies are taken with the aim 
that early precancerous changes (dysplasia) are detected, signalling the need for more 
intensive surveillance or intervention. The development of high-grade dysplasia (HGD) 
within a Barrett’s segment is associated with progression to invasive cancer in 30-35% 
within 5-years (Rastogi et al. 2008). The recommended management of patients in the 
UK with persistent HGD, despite intensive acid suppression, is oesophagectomy 
(Watson et al. 2005). However, surgical oesophagectomy is a high-risk procedure, even 
in tertiary centres, with a 30-day mortality rate of 3.2%, significant post-operative 
complications in up to 40%, and long-term morbidity (Palser et al. 2009). 
Oesophagectomy has an approximate cost to the National Health Service (NHS) of 
£7500/person. 
 
A new, alternative management strategy for patients with HGD in BM is radiofrequency 
ablation (RFA) using the HALO device. Results from a randomised sham-controlled 
study have shown that it is effective at eliminating HGD in BM in up to 90% of patients 
at 12 months follow up, with minimum treatment-related side effects or reduction in 
quality of life (Shaheen et al. 2008a; Shaheen et al. 2009). Furthermore there is 
complete reversion to squamous oesophageal lining in 80% of patients. The cost per 
patient to the NHS is currently unknown and to date there has been no randomised 
controlled trial comparing RFA and oesophagectomy outcomes. 
 
The aim of this thesis was thus two-fold; firstly to explore the expression of the 5-LOX 
pathway proteins in BM and OA, and secondly to evaluate the health economic impact 
on the introduction of RFA for the treatment of HGD in the UK. 
 
  Definition of Barrett’s metaplasia  1.2
 
BM is visualised and suggested by findings at endoscopy, which reveal that the normal 
paler lining of the oesophagus, has been replaced by salmon pink mucosa, extending 
proximally from the gastro-oesophageal junction (Figure 1-A). Confirmation is by 
histological evaluation of biopsy samples from the affected area of the oesophagus, 
which reveal characteristic columnar epithelium with a brush border and goblet cells, 
termed specialised intestinal metaplasia. Although the definition of Barrett’s as above 
is now accepted, there has been great controversy and debate to reach this clarity. 
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Figure 1-A: Appearance of Barrett’s oesophagus at white light upper gastrointestinal 
endoscopy. 
 
  Historical perspective  1.3
 
In 1906 an American pathologist named Tileston described several patients with peptic 
ulcer of the oesophagus, commenting on “the close resemblance of the mucous 
membrane about the ulcer to that found in the stomach” (Tileston 1906). Further 
similar observations were made and then in 1950, Norman Barrett, a surgeon working 
at St. Thomas’s Hospital, London, wrote a paper in the British Journal of Surgery 
describing a ‘columnar lined intra-thoracic structure’ (Barrett 1950). At this point 
Barrett, along with a number of others, argued that this was likely to represent a 
tubular segment of stomach, pulled into the thorax by a congenitally short squamous 
oesophagus. In 1953, Allison and Johnstone correctly interpreted 'Barrett's 
oesophagus' as being due to metaplasia of the normally squamous oesophageal 
mucosa (Allison and Johnstone 1953). However, it was not until 1957 that Barrett 
revised his opinion and conceded this point, although at that stage he felt the most 
likely explanation was that of failure of the embryonic lining of the gullet to reach 
normal maturity (Barrett 1957). This explanation was widely accepted until Hayward 
published his own opinions. He summarised by stating that the changes in the lower 
oesophagus were “.....probably neither ectopic, nor congenital, nor permanent, nor in 
need of resection but metaplastic and reversible” (Hayward 1961). 
 
A detailed study of manometric guided oesophageal biopsies published in 1976 
described the histological features of the Barrett’s segment (Paull et al. 1976). They 
described the more proximal segment of the columnar lined epithelium as displaying a 
“distinctive specialised columnar epithelium with a villiform surface, mucous glands 
and intestinal-type goblet cells”. This is now accepted this as the histological 
diagnostic feature of Barrett’s oesophagus (Fléjou 2007). 
 
Barrett’s 
metaplasia  Normal 
squamous 
oesophageal 
lining 
Barrett’s 
metaplasia Dr CPC Boger  Introduction 
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The finding of OA in association with intestinal-type mucosa containing goblet cells 
was described in a case report by Morson and Belcher (1952), although at that point 
they still felt they were dealing with a congenitally short oesophagus. Further 
observations in oesophagectomy specimens in the 1960’s and 1970’s cemented the 
association between Barrett’s oesophagus and OA (Adler 1963; Hawe et al. 1973; 
Haggitt et al. 1978). By the late 1980’s it was appreciated that specialised intestinal 
metaplasia in particular predisposed to OA (Reid and Weinstein 1987). 
 
  Epidemiology of Barrett’s oesophagus and  1.4
oesophageal adenocarcinoma 
 
The incidence of OA has risen inexorably over the last two decades, so that now it 
accounts for over 50% of histological subtypes (Lagergren 2005). In the 1970s, 
adenocarcinoma of the oesophagus accounted for less than 5% of oesophageal 
malignancies, with squamous cell carcinoma of the oesophagus accounting for the 
majority. The precise reasons for the rapid rise are unknown, but of importance is the 
paralleled increase in BM, now acknowledged to be the precursory lesion for OA. 
 
1.4.1  Prevalence of Barrett’s oesophagus and epidemiological evidence linking 
reflux with Barrett’s 
BM is thought to be resultant from chronic GORD which is present in up to 18% of the 
UK population (Lagergren et al. 1999; Dent et al. 2005). Longer duration and increased 
frequency of symptoms of reflux are important risk factors for development of BM 
(Eisen et al. 1997; Conio et al. 2002). BM per se is asymptomatic and thus exact true 
prevalence is unknown. Estimates range widely depending on the study population. For 
example, a study in Sweden undertook gastroscopy on a representative random 
subsample of 1000 of the adult population and found BM present in 1.6% overall, with 
a higher prevalence of 2.3% in those with reflux symptoms (Ronkainen et al. 2005).  
Other studies have found higher prevalence figures, but the populations have been 
different.  For example, a prevalence of 25% was found in 108 mainly male patients 
who underwent a gastroscopy, whilst attending for flexible sigmoidoscopy for bowel 
cancer screening purposes (Gerson et al. 2002). Another study undertook a 
gastroscopy in 931 patients attending for colonoscopy for all indications (Rex et al. 
2003). In this group the prevalence was 6.8% overall, again with a higher prevalence of 
8.3% in those with reflux symptoms. Although differing prevalence figures may be 
accounted for by different population demographics, a finding mirrored in all these 
studies is the higher prevalence rate of BM amongst those with symptomatic reflux. 
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Factors that increase an individual’s chances of GORD may also be important. These 
include increasing body mass index, and eradication of Helicobacter pylori (El-Serag et 
al. 2007; Corley et al. 2008). Body mass index is additionally an independent risk 
factor for the development of OA, although the mechanisms are not clear (El-Serag 
2008). Medications that relax the lower oesophageal sphincter, such as aminophylline 
and calcium channel blockers could theoretically increase an individual’s risk for GORD 
and thus BM and OA, but the literature is conflicting (Lagergren 2006, Vaughan 1998). 
 
  The role of acid reflux and inflammation in the  1.5
pathogenesis of Barrett’s Metaplasia and Oesophageal 
Adenocarcinoma 
 
The understanding of the malignant degeneration to OA has advanced and the 
consensus is that it is a multistep process, in which BM progresses through worsening 
stages of dysplasia to early carcinoma, and then eventually invasive cancer. This is 
termed the metaplasia-dysplasia-adenocarcinoma sequence (Jankowski et al. 1999). 
 
1.5.1   Reflux and inflammation 
Chronic acid and bile reflux into the lower oesophagus with resulting inflammation 
appear to be important initiating events in BM and the progression to OA. Along with 
the epidemiological evidence described earlier, studies have demonstrated that 
patients with both BM and early OA have more frequent and longer periods of both 
oesophageal acid and bile salt exposure when compared with healthy controls or those 
with uncomplicated GORD (Iascone et al. 1983; Vaezi and Richter 1996; 
Niemantsverdriet et al. 1997; Stein et al. 1998). This exposure of the lower 
oesophagus to the gastro-duodenal refluxate induces injury to the oesophageal 
mucosa, and a subsequent inflammatory response. The mechanism by which this 
injury triggers metaplasia, and why this occurs in some but not all individuals, is 
unknown. 
 
1.5.2  Linking inflammation and cancer 
Inflammation and cancer have a well-recognised association, first described by Virchow 
in 1863, and now demonstrated in a variety of tissue types (Macarthur et al. 2004). In 
the gastrointestinal tract there is an association between chronic inflammation in the 
colon seen with inflammatory bowel disease and increased risk of colorectal dysplasia 
and OA (Vagefi and Longo 2005). Chronic hepatitis C virus infection and resultant 
hepatic inflammation predisposes to hepatocellular carcinoma (Di Bisceglie 1997). 
Metaplasia occurs in the context of chronic inflammation in other tissue sites, carrying 
an increased risk of cancer (Slack 2000). For example, gastric Helicobacter pylori Dr CPC Boger  Introduction 
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infection may result in chronic inflammation and subsequent intestinal metaplasia and 
cancer (Akiyama and Uemura 2009). In these examples it is the potent mix of 
inflammatory mediators, such as cytokines, chemokines, lipids, reactive oxygen 
species (ROS), and metalloproteinases, that are thought to be important in the 
tumorigenic process, through promotion of growth, suppression of apoptosis, 
angiogenesis, invasion and metastasis (Coussens and Werb 2002).  
 
1.5.3  Inflammation leads to deoxyribonucleic acid damage 
Inflammation in GORD induces oxidative stress, and increased levels of ROS are found 
in BM, with an associated decrease in antioxidant defences (Olyaee et al. 1995). 
Exposure of BM and OA cell lines to components of the refluxate further increases 
formation of ROS. This in turn leads to subsequent deoxyribonucleic acid (DNA) 
damage through induction of double stranded DNA breaks, which promotes genomic 
instability and may lead to carcinogenesis (Wiseman and Halliwell 1996; Clemons et al. 
2007). It is the progressive accumulation of genetic and epigenetic aberrations that is 
believed to lead to one or more clones with malignant potential. Many genetic 
abnormalities have been reported in patients with BM and OA, such as gene mutations, 
gene deletions, loss of heterozygosity (LOH), aberrant methylation and aberrant gene 
expression (McManus et al. 2004). 
 
Aneuploidy (abnormal number of chromosomes) reflects widespread DNA changes due 
to genomic instability (Morales et al. 2002). It is found in over 90% of HGD and OA, and 
may predict progression to cancer in those with BM (Reid et al. 1992). Loss of p53 
function is a common genetic abnormality seen in the metaplasia-dysplasia-
adenocarcinoma sequence. The p53 gene is a cell-cycle control gene that prevents cells 
with genome damage from entering DNA synthesis during which the breaks could be 
replicated, cause chromosome damage, and lead to progressive genetic instability and 
cancer. Mutation causing loss of one allele of the p53 gene occurs in up to 60% with 
BM, and up to 66% with HGD (Altorki et al. 1997). Loss of further genetic information 
as a result of deletion of a portion of the chromosome or other events is termed LOH, 
and results in gene inactivation. In a study by Reid et al., 77% of those with BM who 
progressed to cancer had LOH at baseline endoscopy, suggesting a possible role for it 
as a biomarker (Reid et al. 2001). 
 
Abnormalities in the expression of cyclins are found through the metaplasia-dysplasia-
adenocarcinoma sequence. Cyclins are promoters of cell-cycle progression through 
their ability to phosphorylate retinoblastoma protein after complexing with cyclin-
dependent kinases (CDK) (Weinberg 1995). For example, expression of cyclins D1 and 
E increases with worsening degrees of dysplasia. In addition, LOH and promoter Dr CPC Boger  Introduction 
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hypermethylation of the CDK inhibitor, p16, occurs in up to 80% of patients with BM, 
and p16 hypermethylation correlates with the degree of dysplasia in intestinal 
metaplasia (Eads et al. 2000; Kawakami et al. 2000). 
 
1.5.4  Mediators of Inflammation in Barrett’s adenocarcinoma 
In other premalignant conditions that develop in the setting of chronic inflammation 
there are associated changes in the inflammatory response, such as down-regulation of 
cell-mediated immunity (Th1) and the presence of a more humoral (Th2) infiltrate 
(Coussens and Werb 2002). Similarly, BM is associated with a more pronounced Th2 
response compared with reflux oesophagitis. The total numbers of inflammatory cells 
increase, with the relative proportion of plasma cells increased, whilst the proportion 
of macrophages and CD8+ cytotoxic T-cells decreases (Moons et al. 2005). These 
infiltrating inflammatory cells contribute to a highly complex inflammatory 
microenvironment, rich in biological mediators with pro-tumour effects. 
 
Differences in cytokine profile exist between oesophagitis, BM and OA. In oesophagitis, 
IL-1β, IL-8 and interferon (IFN) -γ are increased compared to BM, even in the presence 
of continuing reflux (Fitzgerald et al. 2002b). 
 
An inflammatory gradient exists within BM, with inflammation maximal in areas close 
to the squamo-columnar junction, characterised by elevation in the pro-inflammatory 
cytokines IL-1β and IL-8 (Fitzgerald et al. 2002a). More distally, less inflammation is 
observed, suggesting that factors other than acid must be responsible for driving the 
inflammatory response, as acid exposure reduces proximally in the oesophagus. The 
anti-inflammatory cytokine IL-10 is elevated distally. This is particularly interesting as 
IL-10 can also influence tumour growth by affecting cell proliferation and 
angiogenesis, through a variety of pathways including up-regulation of signal 
transducers and activators of transcription (STAT3), and down-regulation of cyclo-
oxygenase (COX) -2 and vascular endothelial growth factor (VEGF) (Mocellin et al. 
2005). Other cytokines are also implicated. IL-6, a cytokine associated with a Th2 
response, is increased in BM compared to normal oesophagus, and has an anti-
apoptotic role through STAT3 (Dvorakova et al. 2004). Interestingly, this pathway was 
induced by short exposure of OA cells to an acid/bile mix at low pH, again providing 
evidence for the important role of acid/bile reflux (Dvorak et al. 2007). 
 
1.5.5  The role of nuclear factor kappa β 
The transcription factor nuclear factor kappa β (NF-κβ) is an important regulator of 
genes that control cell proliferation and cell survival. It is increased progressively 
through the sequence of normal oesophagus, oesophagitis, BM, and OA (Lee et al. Dr CPC Boger  Introduction 
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2001; Konturek et al. 2004). Activated NF-κβ stimulates IL-1β and IL-8, which in turn 
feedback to increase NF-κβ. NF-κβ is involved in the regulation of a multitude of 
mechanisms that contribute to cancer development, such as anti-apoptosis, 
inflammatory genes, oncogenes and angiogenesis factors (Chen et al. 1999). In 
particular it can promote the transcription of COX-2, c-myc and cyclin D1. Additionally, 
NF-κβ can induce caudal type homeobox transcription factors (cdx) 1 and 2, key 
regulators of intestinal epithelial cell phenotype, and thought to be important in the 
development of BM (Colleypriest et al. 2009). 
 
The expression of TNF-α, one of the major mediators of inflammation, is regulated by 
NF-κβ. TNF-α has been linked to all steps of tumorigenesis by mediating proliferation 
and by inducing invasion and angiogenesis (Aggarwal et al. 2006). Levels of TNF-α 
increase along the metaplasia-dysplasia-adenocarcinoma sequence, and can induce 
expression of the transcription factor c-myc via β-catenin signalling in columnar 
epithelial cell lines (Tselepis et al. 2002). This action was independent of NF-κβ.  
 
  Eicosanoids in cancer  1.6
 
Eicosanoids are lipid mediators involved in modulating the intensity and duration of 
inflammatory and immune responses. Arachidonic acid (AA) is a polyunsaturated fatty 
acid (PUFA) obtained through the diet or by conversion from the n-6 PUFA linoleic acid 
(the main PUFA in human diets) by chain elongation and then desaturation. It is found 
esterified within phospholipids such as phosphatidylinositol by the action of acyl 
transferases on both the plasma membrane and in intracellular membranes. Only low 
levels are present in the cytosol, but hydrolysis of membrane phospholipids by 
stimulated lipases produces free AA, which may then serve as a substrate for 
cytochrome P450, cyclooxygenase (COX) and lipoxygenase (LOX) enzymes (Funk 
2001). AA is of particular importance as it is the precursor substrate for eicosanoid 
synthesis. 
 
COX catalyses the formation of AA to prostaglandin (PG) H
2, the immediate precursor 
of biologically important lipid mediators, the prostanoids, which include the 
prostaglandins and thromboxane. The prostanoids have diverse roles coordinating 
cellular signalling by binding trans-membrane G-protein coupled receptors. These 
range from the regulation of vascular tone, permeability, and platelet function to the 
induction of hyperalgesia and fever. 
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1.6.1  Cyclo-oxygenase 
COX has two distinct isoforms. COX-1 is constitutively expressed in most tissues, and 
plays an important role in platelet aggregation and gastric cytoprotection. Although 
COX-2 is expressed constitutively in the kidney and brain, in many tissues it is only 
induced in response to inflammation, wound healing, and neoplasia. This pathway is 
clinically relevant, as it is the main target for non-steroidal anti-inflammatory drugs 
(NSAIDs), COX-2 selective inhibitors (coxibs), and aspirin (see figure 1-B). Therapeutic 
concentrations of NSAIDs and aspirin are not known to influence other pathways of AA 
metabolism except indirectly by increasing the intracellular concentration of free AA, 
which potentially causes shunting of arachidonic acid through other metabolic 
pathways, such as the LOX pathway. 
 
 
 
Figure 1-B: Cyclo-oxygenase pathway with examples of available pathway protein 
inhibitors. 
Abbreviations; COX – cyclo-oxygenase, PG – prostaglandin, TX – thromboxane, NSAID – 
non-steroidal anti-inflammatory drug 
 
1.6.2  Evidence for the role of eicosanoids in cancer  
A direct role for eicosanoids in cancer was first suggested by studies in animals 
showing that dietary fats enhance carcinogenesis. In particular, n-6 PUFAs are 
associated with promotion of tumorigenesis, whereas n-3 PUFAs have anti-tumorigenic 
effects (Broitman et al. 1977; Singh et al. 1997; Chang et al. 1998). A key 
epidemiological study by Kune et al. then showed that subjects using NSAIDs for 
various indications had a significantly lower incidence of colon cancer (Kune et al. 
1988), a finding since confirmed by numerous epidemiological studies (Thun et al. 
2002). NSAID use is also associated with a lower incidence of cancers at other sites 
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including the oesophagus (Thun et al. 1993). Randomised controlled trials (RCT) in 
patients with familial adenomatous polyposis have shown that NSAIDs, including the 
COX-2 specific inhibitor, celecoxib, can decrease the number or cause complete 
regression of colonic polyps (Nugent et al. 1993; Steinbach et al. 2000). However, 
there has been conflicting evidence in other clinical trials. A RCT of male physicians 
investigated the effects of aspirin versus placebo administered every other day for 5 
years with a planned 12-year follow up (Steering Committee of the Physicians' Health 
Study Research Group 1989). The study terminated after 5 years with no evidence of 
reduction in incidence of colorectal cancer or reduction in colorectal cancer mortality. 
These studies have also been hampered by treatment-related side effects of 
gastrointestinal ulceration, and increased risk of acute myocardial infarction in those 
on COX-2 specific inhibitors, which have raised questions over the tolerability of their 
long term use. The subsequent finding that the cardiovascular side-effects may be due 
to inhibition of endothelial cell-derived COX-2 activity and prostacyclin generation 
highlights the importance of having a full understanding of the cellular mechanisms 
underlying drug effects before embarking on large, population-based studies. 
 
The role of COX-2 in the formation of OA has been extensively studied. Acid and bile 
can up-regulate COX-2 expression and lead to an increase in prostaglandin (PG) E
2 
(Shirvani et al. 2000; Kaur and Triadafilopoulos 2002). Selective inhibition of COX-2 
leads to a reduction in the proliferation of Barrett’s epithelial and OA cells (Souza et al. 
2000; Buttar et al. 2002). Whether COX-2 is constitutively expressed in BM and OA is 
open to debate. A systematic review incorporated 27 studies that assessed COX-2 
protein or gene expression in BM, dysplastic or adenocarcinoma tissue (Mehta et al. 
2006). There was considerable variability between studies with some studies showing 
no or only very low levels of expression in BM and dysplasia. COX-2 was generally 
found to be expressed in OA, although there was considerable variation in the levels of 
its expression.  
 
A meta-analysis by Corley et al. summarised the observational studies evaluating the 
association between aspirin, NSAIDs, and oesophageal cancer (Corley et al. 2003). Nine 
studies were included containing a total of 1813 cancer cases. The findings of this 
study were that any use of aspirin or NSAID was associated with a 33% reduction in the 
odds of developing OA. There appeared to be a greater effect with aspirin (50% 
reduction) compared with NSAIDs (25% reduction), and also a dose-dependent effect, 
with frequent use associated with a 46% reduction of developing either squamous cell 
or adenocarcinoma of the oesophagus. The findings of this meta-analysis imply a 
protective effect of regular aspirin or NSAID use in oesophageal cancer. However, there 
are a number of limitations of this study which include the use of observational data, Dr CPC Boger  Introduction 
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lack of clarity of dosing, and the lack of differentiation between squamous cell and 
adenocarcinoma of the oesophagus. Thus definite conclusions cannot be reached. The 
on-going Aspirin Esomeprazole Chemoprevention (AspECT) study hopes to clarify this. 
In this RCT, patients have been randomised to receive acid suppression using the 
proton pump inhibitor (PPI) esomeprazole with or without aspirin. The final analysis of 
this multicentre study is expected in 2016. 
 
Initially it was felt that COX-2 was the major target of NSAID effects on colorectal and 
other cancers, but the discrepancy in the published studies point towards the 
involvement of other molecular targets. Numerous COX-independent targets have been 
demonstrated including inhibition of NF-κβ, extracellular-signal-regulated kinases 1/2 
(ERK1/2), Wnt signalling including c-myc, cyclin D1 and peroxisome proliferator-
activated receptor-γ (PPAR-γ) and PPAR-δ, and proteins of the lipoxygenase family 
(Kashfi and Rigas 2005).  
 
  The 5-lipoxygenase pathway  1.7
 
1.7.1  Source, cellular localisation, and biosynthesis of leukotrienes 
5-LOX is a non-haem dioxygenase which catalyses the biosynthesis of leukotrienes 
(LTs). It is a 674 amino acid, 78 kilodalton (kDa) protein, consisting of an amino acid 
terminal, a β barrel domain capable of binding two calcium ions and protein kinase C, 
and a carboxy (catalytic) terminal domain (Funk 2001). Additional alpha helices hold 
iron through histidine and isoleucine residues. The human 5-LOX gene (ALOX5) is 
located to chromosome 10q11.2 and is over 82 kilo-base pairs (kbp), containing 14 
exons (Funk et al. 1989). Optimal activity of 5-LOX requires cofactors calcium, 
adenosine-5'-triphosphate, 5-LOX activating protein (FLAP), and additional oxidation of 
the ferrous iron of the resting form to the ferric form by lipid hydroperoxide. 
 
FLAP, an 18kDa protein containing 161 amino acids, is integral to the nuclear envelope 
and facilitates the docking of AA to 5-LOX (Funk 2001). The human FLAP gene 
(ALOX5AP) is located on chromosome 13q12 and is over 31 kbp, containing 5 exons 
(Kennedy et al. 1991). Significant expression of 5-LOX and FLAP is confined to bone 
marrow derived cells, including neutrophils, eosinophils, monocytes/macrophages, 
mast cells, certain lymphocyte populations, and dendritic cells. Additionally, lower level 
expression has been documented in other cells and tissues, such as epithelial cells, 
fibroblasts, and in various parts of the brain (Peters-Golden and Brock 2003). 
 
In metabolically resting cells, 5-LOX is distributed throughout the cytoplasm and 
nucleus. On cellular activation 5-LOX translocates to, and/or across the nuclear Dr CPC Boger  Introduction 
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envelope. On either side of the nuclear envelope 5-LOX encounters arachidonate- 
specific phospholipase A
2 (PLA
2) and FLAP. PLA
2 hydrolyses membrane phospholipids 
liberating AA and donating it to FLAP. The crystal structure of FLAP reveals a 
homotrimer, with the transmembrane region of each monomer providing a lipophilic 
pocket for the binding of AA (or of FLAP inhibitors) (Ferguson et al. 2007; Evans et al. 
2008). FLAP donates the AA to 5-LOX, which catalyses its oxygenation to 5-S- 
hydroperoxyeicosatetraenoic acid (5-S-HPETE). This can be reduced non-enzymatically 
to 5-hydroxyeicosatetraenoic acid (5-S-HETE) or transformed by 5-LOX to a highly 
unstable allylic epoxide, leukotriene A
4 (LTA
4). LTA
4 has three possible fates depending 
on the cellular context. 
 
Firstly, as occurs preferentially in neutrophils and monocytes, hydrolytic attack by LTA
4 
hydrolase (LTA
4H) in the cytoplasm and possibly the nucleus adds an hydroxyl group at 
the 12 position to generate a dihydroxylated product, leukotriene B
4 (LTB
4; 5,12-
dihydroxy-eicosatetraenoic acid). LTB
4 may interact with intracellular PPAR receptors, or 
be exported from the cell by an as yet unknown transporter to act at extracellular 
receptors. Secondly, as occurs preferentially in mast cells, eosinophils, and to a lesser 
extent in monocytes and macrophages, conjugation with glutathione catalysed by 
leukotriene C
4 synthase (LTC
4S) produces leukotriene C
4 (LTC
4). LTC
4 is transported out 
of the cell by transporters such as the multi-drug resistance protein (MRP)-1. LTC
4 may 
be converted extra-cellularly to leukotriene D
4 (LTD
4) by gamma-glutamyl 
transpeptidase, and then to leukotriene E
4 (LTE
4) by a dipeptidase. LTE
4 is excreted in 
the urine. Collectively LTC
4, D
4, and E
4 are termed the cysteinyl leukotrienes (cysLTs). 
Lastly, transcellular metabolism may occur to generate bioactive eicosanoids. For 
example, LTA
4 generated by leukocytes may be exported into endothelial cells 
expressing LTA
4 or LTC
4S, and thus be converted to LTB
4 or LTC
4 (Fabre et al. 2002). 
 
LTA
4H is a 69 kDa soluble monomeric protein containing 610 amino acids, with bi-
functional enzymatic activity; epoxide hydrolase (LTA
4 to LTB
4)
 and peptide-cleaving 
activity (Haeggstrom 2000). The human LTA
4H gene (LTA4H) is located on chromosome 
12q22 and is over 35 kilo-base pairs (kbp), containing 19 exons (Mancini and Evans 
1995). It resides in the cytosol of a myriad of organs, tissues and individual cell types. 
In the blood, neutrophils, monocytes, lymphocytes, and erythrocytes are rich sources. 
In contrast, eosinophils have low levels and basophils and platelets seem to be virtually 
devoid of the enzyme. 
 
LTC
4S is an 18 kDa protein, containing 150 amino acids, with synthase enzymatic 
activity (Lam and Austen 2002). It is found in cells exclusively of haematopoietic origin, 
specifically eosinophils, basophils, mast cells, macrophages/monocytes, and platelets, Dr CPC Boger  Introduction 
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where it is localised to the nuclear envelope and adjacent endoplasmic reticulum. The 
human LTC
4S gene (LTC4S) is located to chromosome 5q35 and spans 2.5 kbp, 
containing 5 small exons (Penrose et al. 1996). 
 
 
 
Figure 1-C: 5-LOX pathway with examples of available pathway protein inhibitors or 
receptor antagonists 
 
1.7.2  Mechanisms of action 
LTs exert their actions through one or more of at least four distinct hepto-helical 
receptors located on the outer membrane of structural and inflammatory cells, the 
leukotriene B receptors 1 and 2 (BLT1 and BLT2) and the cysteinyl- leukotriene 
receptors 1 and 2 (cysLT1R or cysLT2R). These G-protein coupled receptors initiate 
calcium-dependent or –independent activation of downstream kinase cascades and 
thus alter cellular activity. 
 
The BLT1 and BLT2 receptors are products of the LTB4R1 and LTB4R2 genes located on 
chromosome 14q11.2-q12. The LTB4R2 locus is approximately 3kb 5’ of the LTB4R1 
gene (Nilsson et al. 2000), such that the third exon of LTB4R2 overlaps with the 
promoter region and first exon of LTB4R1. The BLT1 receptor is expressed mainly on 
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leucocytes, in particular neutrophils, macrophages, and eosinophils, although a murine 
T cell lymphoma model suggested low levels of BLT1 may be expressed by T-cells 
(Huang et al. 1998). In contrast, BLT2 expression is present in most human tissues, 
with expression highest in spleen, liver, ovary and peripheral blood leucocytes. LTB
4 
through the BLT1 receptor plays a key role in leukocyte recruitment to sites of 
inflammation, both by directing cellular migration and by facilitation of endothelial cell 
binding, a prerequisite of leukocyte migration into tissues (Tager and Luster 2003). In 
addition LTB
4 may prolong neutrophil survival by preventing apoptosis (Hebert et al. 
1996). LTB
4 has lower affinity for BLT2 receptors than for BLT1, but is shown to 
mediate similar, calcium-dependent signalling and cellular responses. A clearer role for 
this low-affinity receptor has yet to be defined, although unlike BLT1, which is highly-
selective for LTB
4, the BLT2 receptor also binds some other lipoxygenase products 
including 12-HETE and 15-HETE (Yokomizo et al. 2001). A summary of the roles of LTB
4 
is shown in figure 1-D. 
 
 
 
Figure 1-D: Actions of LTB
4 
 
The cys-LTs are thought to act in humans mainly through the cysLT1 and cysLT2 
receptors, which are analogous to the LTC
4 receptor and the LTD
4 receptor identified in 
rodents, respectively. A human LTC
4/LTD
4 receptor, known as GPR17, has also been 
identified in human brain (Ciana et al. 2006). An LTE
4-selective receptor (CysTL
E) has 
also been described in rodents (Maekawa et al. 2008). In humans, LTE
4 has some 
specific effects not shared with the other cysLTs, such as eosinophilotaxis, and LTE
4 is 
now recognised as a potent ligand of the P2Y
12 purinoceptor, the target of clopidogrel 
and related anti-platelet drugs (Paruchari et al.2009). There is increasing recognition of 
the family relationships between cysLT receptors and purinoceptors and other 
examples of cross-affinity for cys-LT and purine ligands may emerge.    
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The gene encoding the cysLT1 receptor (CYSLTR1) is located to chromosome Xq13.2-
q21.1 and consists of at least 3 exons (Lynch et al. 1999). The gene encoding the 
cysLT2 receptor (CYSLTR2) is located to chromosome 13q14.12-q21.1 and consists of 
a single exon (Heise et al. 2000). CysLT1R is found mainly on airway smooth muscle 
cells and vascular endothelial cells, but additionally may be found on peripheral 
leukocytes (mast cells, eosinophils, neutrophils, monocytes and macrophages). 
CysLT2R is expressed in smooth muscle cells, peripheral blood leukocytes (monocytes 
and eosinophils), lymph nodes, spleen, heart, and the central nervous system.  
 
Cys-LTs were initially discovered to be potent bronchoconstrictors (‘slow-reacting 
substance of anaphylaxis’) and play a role in asthma exacerbations (Holgate et al. 
2003). Subsequently a wide variety of roles have been demonstrated. In the 
inflammatory response, they act through cysLT1R to mediate activation of leukocytes 
and chemotaxis (Kanaoka and Boyce 2004). A variety of cytokines may play a role in 
alteration of cysLT receptor expression. For example, IL-4 and IL-13 can up-regulate 
cysLT1R in human peripheral monocytes (Thivierge et al. 2001). There is also evidence 
that cys-LTs may play an autocrine or paracrine role in the production of cytokines, for 
example stimulating IL-4 primed mast cells to produce cytokines such as IL-5 and TNF-
α (Mellor et al. 2002). In animal models of inflammation additional roles have been 
demonstrated including induction of airway remodelling (smooth muscle hyperplasia 
and subepithelial hyperplasia) and increases in microvascular permeability resultant in 
protein leakage. A summary of the role of the cys-LTs is illustrated in Figure 1-E. 
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Figure 1-E: Summary of known actions of the cysteinyl leukotrienes mediated through 
cysLT1 and 2 receptors 
 
 
1.7.3  The 5-Lipoxygenase pathway in disease 
In addition to their role in orchestrating facets of inflammation, products of the 5-LOX 
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inhibits 5-LOX, and with antagonists of cysLT1R, such as montelukast (Kanaoka and 
Boyce 2004). Evidence from a mouse model of asthma demonstrated that CysLT1R 
antagonists can inhibit the airway remodelling processes (Holgate et al. 2003).  
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known specific at-risk variants of the 5-LOX pathway showed a significant dose-
dependent suppression of biomarkers associated with an increased risk of myocardial 
events (Hakonarson et al. 2005).  
 
1.7.4  The role of 5-lipoxygenase pathway in Cancer 
A role for the 5-LOX pathway in cancer was first suggested by Tsukada et al. who 
demonstrated that specific 5-LOX inhibitors showed potent antiproliferative effects on 
human leukaemic cell lines (Tsukada et al. 1986). Further work was undertaken by Avis 
et al. (1996) on lung cancer cell lines which, when subjected to various growth factors, 
increased their expression of 5-LOX and the generation of its products (5-HETE, 5-
HPETE, LTB
4 and cys-LTs). Inhibitors of 5-LOX (AA861) and FLAP (MK886) impaired 
tumour cell growth (Avis et al. 1996) and the findings were repeated in breast cancer 
cell lines (Avis et al. 2001). Additionally they found that the administration of 
exogenous 5-HETE and cys-LT resulted in tumour cell proliferation of approximately 
20-40% above control. Again FLAP inhibition resulted in reduced levels of 5-LOX and its 
metabolites, which was mirrored by a reduced expression of the apoptosis regulatory 
protein B-cell lymphoma 2 (Bcl-2) and an increase in the apoptosis promoter protein 
Bcl-2–associated X protein (Bax) as measured by immunocytochemistry and Western 
blotting. Of interest they demonstrated a concurrent elevation in other members of the 
LOX family, such as 15-LOX and its products including lipoxin A
4 raising the possibility 
of diversion down alternative eicosanoid pathways (Avis et al. 2001). 
 
The effects of inhibition of the 5-LOX pathway on tumorigenesis have also been 
demonstrated in vivo (Rioux and Castonguay 1998). Mice were given a tobacco 
carcinogen along with aspirin, the 5-LOX inhibitor A79175, the FLAP inhibitor MK886, 
or a combination of both drugs. Mice fed a combination of aspirin and A79175 showed 
a reduction in lung tumour multiplicity of 87%, compared with mono-therapy with 
A79175 (75%), MK886 (52%), or aspirin (44%). In addition lung tumour volume reduced 
by 65% with A79175, 44% with MK886, and 35% with aspirin. 
 
A number of investigators have demonstrated a role of the 5-LOX pathway in prostate 
cancer. Ghosh and Myers (1998) followed their initial observation that n-6 fatty acids 
stimulate proliferation of prostate cancer cells in vitro through production of 5-HETE, 
by demonstrating that both AA861 and MK886 completely blocked 5-HETE production 
and induced massive apoptosis in a human prostate cancer cells in vitro. The cells 
were protected from apoptosis by the addition of exogenous 5-HETE. Gupta et al. then 
demonstrated that 5-LOX mRNA transcription was 6-fold greater and that of 5-HETE 
mRNA was 2.2-fold greater in malignant human prostatic tissue when compared with 
benign tissue (Gupta et al. 2001). Dr CPC Boger  Introduction 
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In pancreatic cancer tissue, immunohistochemical staining demonstrated expression of 
5-LOX and BLT1, and reverse transcription PCR showed increased levels of LTB4R 
mRNA when compared with normal pancreatic tissue (Hennig et al. 2002). This group 
then subsequently showed that LTB
4 can stimulate proliferation and activation of the 
signalling molecules extracellular related kinases 1/2 in multiple human pancreatic cell 
lines (Tong et al. 2002). 
 
A critical role for the ALOX5 gene in leukaemia stem cells in vivo has recently been 
documented (Chen et al. 2009). They used a mouse model in which transplanted bone 
marrow cells treated with a retroviral vector of BCR-ABL fusion protein induces chronic 
myeloid leukaemia (CML). In mice with ALOX5 gene deletion, BCR-ABL failed to induce 
CML, as they had depleted leukaemia stem cells (but not normal haematopoietic stem 
cells), with effects at the levels of differentiation, cell division, and long-term survival. 
Treatment with the 5-LOX inhibitor, zileuton, suppressed leukaemic stem cells in BCR-
ABL-induced CML mice and prolonged their survival. 
 
A role of the 5-LOX pathway in cell growth pathways in the gastrointestinal tract was 
shown in vitro by Ohd et al. (2000). The addition of LTB
4 and LTD
4 to intestinal cell 
lines led to an increase in expression and/or membrane accumulation of COX2, β-
catenin, Bcl-2 and prostaglandin E
2 (PGE
2) production, in a time- and dose dependent 
manner. The associated reduction in cell death correlated well with LTB
4 and LTD
4 
levels. The same group then investigated the expression of cysLT1R, along with other 
factors they had demonstrated to be up-regulated by LTD
4, in tissue arrays from 
colorectal adenocarcinoma specimens (Ohd et al. 2003). Increased expression of 
cysLT1R predominantly in the epithelial cells was shown in tumour tissue when 
compared with controls taken from the margins of the surgical specimens. Expression 
of 5-LOX, COX and the anti-apoptotic trans-membrane molecule, Bcl-XL (Bcl extra-
large), but not Bax, was found to be elevated in tumour tissue that also demonstrated 
heightened levels of cysLT1R expression. Higher levels of cysLT1R expression were 
also associated with poorer survival. A further group from Japan used 
immunohistochemistry and Western blotting to demonstrate up-regulation of BLT1 
receptors in human colon cancer cell lines (Ihara et al. 2007). Both inhibition of 5-LOX 
by AA861 or blockade of BLT1 receptors by the specific antagonist U-75302 
suppressed cell survival and proliferation in a dose-dependent manner, which was 
attributable to an increase in apoptosis.  
 
A summary of the 5-LOX molecular pathways implicated in carcinogenesis is shown in 
figure 1-F. Dr CPC Boger  Introduction 
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Figure 1-F: Possible role of the 5-LOX pathway in carcinogenesis demonstrated in 
published studies. 
 
 
1.7.5  Evidence implicating the 5-lipoxygenase pathway in Barrett’s 
adenocarcinoma 
The first suggestion that LTs may play a role in Barrett’s adenocarcinoma was made by 
Triadafilopoulos et al. who measured both PGE
2 and LTB
4 levels in normal squamous 
(control), reflux oesophagitis, and BM mucosal biopsy specimens taken at endoscopy 
(Triadafilopoulos et al. 1996). LTB
4, but not PGE
2, was significantly increased in both 
oesophagitis and BM biopsy specimens. In this study, treatment with the PPI 
omeprazole resulted in significant reductions of 30% in LTB
4 and 35% in PGE
2 levels. 
Chen et al. then reported first in 2002, with a subsequent paper in 2003 (Chen et al. 
2002; Chen et al. 2003), showing that LTA
4H was over-expressed in rat OA compared 
with matched normal tissue samples, and that LTA
4H was expressed in infiltrating 
inflammatory cells and in the columnar cells in human OA. Bestatin, a LTA
4H inhibitor, 
reduced the incidence of OA by approximately 30% in a rat oesophageal carcinoma 
model. A further publication in 2004 reported on an increase in LTA
4H immunostaining 
intensity in BM, dysplasia and OA biopsies when compared with squamous controls, 
although the measurements used for analysis were open to observer bias (Chen et al. 
2004). In an oesophago-gastro-duodenal anastamotic rat model of OA, they 
demonstrated that the 5-LOX inhibitor, zileuton, and the COX-2 selective inhibitor 
celecoxib, given either as mono-therapies or in combination, reduced the number of 
visible tumours (Chen et al. 2004). This corresponded with a significant reduction in 
the levels of both LTB
4 and PGE
2.  Dr CPC Boger  Introduction 
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Hoque et al. (2005) showed immunohistochemical over-expression of 5-LOX in both 
squamous carcinoma and adenocarcinoma of the oesophagus, with no difference 
between histological types of cancer. In oesophageal cancer cell lines the 5-LOX 
inhibitor AA861 suppressed LTB
4 production and caused apoptosis. The BLT1 receptor 
antagonist U-75302 reversed the AA861-induced apoptosis, suggesting that BLT1 
receptors mediate the action of endogenous LTB
4 on survival.  
 
In summary, increased expression of proteins of the 5-LOX pathway is linked to cancer 
cell survival and proliferation in a number of tumour types. Furthermore, increased 
expression of this pathway occurs in BM and OA, and inhibition can result in reduced 
formation of OA in vivo. Important studies to date linking the 5-LOX pathway with 
cancer are summarised in table 1-A.Dr CPC Boger  Introduction 
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Table 1-A: Summary of important studies examining the role of the 5-lipoxygenase pathway in cancer. 
   
Study 
(Year) 
Tissue  Findings 
Tsukada 
(1986) 
Leukaemia cell lines  5-LOX inhibitors (Cirsiliol and AA861) showed potent anti-proliferative effects. 
Avis 
(1996) 
Small cell lung cell lines  5-LOX, FLAP, 5-HETE, LTB
4 expressed after exposure various growth factors. AA861 resulted in 
inhibition of cell line growth. 
Ghosh 
(1998) 
Prostate cancer cell lines  5-HETE expressed with massive apoptosis resultant from addition of FLAP inhibitor (MK886). 
Anderson 
(1998) 
Prostate cancer cell lines  5-LOX and FLAP expressed and inhibitors initiate cell death. 
Rioux 
(1998) 
Mice exposed to NNK (induces 
lung tumour formation) 
Combination of aspirin and 5-LOX inhibitor (A-79175) most effective at reducing lung tumour 
multiplicity and incidence. LTB
4 increased and returned to that of controls on treatment inhibitors. 
Ding 
(1999) 
Human pancreatic cell lines  5-LOX (and 12-LOX) expressed (no expression in normal ductal pancreatic tissue). Inhibitors 
inhibited cell proliferation. 5-HETE, 12-HETE, AA and linoleic acid stimulated pancreatic cancer 
cell proliferation. 
Ohd 
(2000) 
Human intestinal cell line  LTB
4 and LTD
4 caused increase expression COX2, β catenin, bcl-2, PGE
2 and correlated with 
reduction in cell death 
Sjolinder 
(2000) 
Chronic myeloid leukaemia  Increased LTC
4S in neutrophils from patients with chronic myeloid leukaemia Dr CPC Boger  Introduction 
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Study 
(Year) 
Tissue  Findings 
Gupta 
(2001) 
Human prostate benign and 
malignant tissue 
ALOX5 mRNA increased in malignant v benign (6-fold mRNA levels). 5-HETE increased. 
Romano 
(2001) 
Human malignant mesothelioma 
cell lines 
5-LOX increased. AA861 inhibited malignant mesothelioma cell proliferation. 5LOX and 5-HETE 
upregulate VEGF. 
Hennig 
(2002) 
Human pancreatic cell lines  Increase 5-LOX and LTB
4 (versus normal pancreatic tissue) 
Chen 
(2002) 
Rat surgical OA model  Increase 5-LOX and 5-HETE (and 8-, 12-, 15-HETE) compared to proximal normal oesophagus. 
The NSAID (Sulindac) + nordihydroguaiaretic acid (NDGA) reduced incidence of tumour. NDGA 
alone reduced but not statistically significant. 
Chen 
(2003) 
Rat and human OA  Increased LTA
4H expression (versus adjacent normal tissue). 
Localised to inflammatory cells and columnar in human tissue. 
Intraperitoneal LTA
4H inhibitor (Bestatin) reduced incidence of OA in rat model. 
Ohd 
(2003) 
Tissue arrays from colorectal 
cancer samples 
Increase in cysLT1, 5-LOX (and COX-2). 
Expression cysLT1R correlated with poorer survival in Duke’s B patients. 
Chen 
(2004) 
Rat and human OA  Progressive increase 5-LOX through oesophagitis to Barrett’s to OA. High dose 5-LOX inhibitor 
(Zileuton) and COX-2 inhibitor (Celecoxib) reduced LTB
4 levels and incidence of tumour (dose 
dependent) in rat surgical model 
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Study 
(Year) 
Tissue  Findings 
Ye 
(2004) 
Mice exposed to dextran sulphate 
sodium (induces colonic 
inflammation) and cigarette 
smoke 
Cigarette smoke increased 5-LOX expression in inflammation associated colonic adenomas. 
Associated upregulation of MMP-2 and VEGF. 5-LOX inhibition (AA861) reduced incidence of 
adenoma formation and reduced angiogenesis with associated reduction in MMP-2 activity and 
VEGF expression. 
Hoque 
(2005) 
Human oesophageal squamous 
and OA 
5-LOX increased (versus normal) 
AA861 suppressed LTB
4 production. LTB
4R antagonist (U-7530) blocked AA861 induced 
apoptosis. 
Hennig 
(2005) 
Mice pancreatic cancer  LTB
4R antagonist (LY293111) reduced tumour growth and incidence of metastasis. Effect most 
marked when combined with Gemcitabine. 
Cianchi 
(2006) 
Colon cancer cell lines  Increased expression COX2 and 5-LOX. Single inhibition increased opposite pathway activation. 
Dual inhibition prevented this and resulted in apoptosis, prevention tumour cell proliferation, 
decrease Bcl-2, increase Bax. 
Ihara 
(2007) 
Human colon cancer  Increase BLT1 expression (versus normal) including adenocarcinoma cells. 
AA861 and LTB
4 receptor antagonist (U75302) had negative effect on cell survival. 
Schroeder 
(2007) 
Pre- and malignant lung cell lines  COX2, MK886, and cysLTR antagonist (REV5901) more potent than single or dual inhibition. 
Sensitivity correlated with production of metabolites (not 5-LOX or FLAP). Partial protection 
afforded when PGE
2 or 5HETE added. 
Tong 
(2007) 
Pancreatic cell line  LTB
4 receptor antagonist (LY293111) induced apoptosis and S-phase cell cycle arrest with 
downregulation of CDK2, cyclin A and cyclin E. Dr CPC Boger  Introduction 
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Study 
(Year) 
Tissue  Findings 
Hennig 
(2008) 
Human pancreatic tissue  BLT2 overexpressed in malignant intraductal papillary mucinous neoplasia and adenocarcinoma 
tissue. Treatment of pancreatic cancer cell lines with selective BLT2 agonist resulted in tumour 
cell proliferation. 
Funao 
(2008) 
Human renal cell cancer and 
cell lines 
CysLT1R overexpressed and receptor antagonist induced apoptosis. 
Rocconi 
(2008) 
Human ovarian cancer tissue  5-LOX, BLT1 and 2 expressed. BLT2 expression correlated with advanced disease. 
Melstrom 
(2008) 
Colonic adenomatous polyps 
and cancer + colon cancer 
mouse model 
Increase in 5-LOX expression (versus normal colonic tissue). 
Inhibition in 5-LOX resulted in reduction in tumour growth. 
Sveinbjörnsson 
(2008) 
Human neuroblastoma tissue 
and cell lines 
Overexpression of 5-LOX, FLAP, LTA
4H, and LTC
4S. Inhibition of 5-LOX (AA-861), FLAP (MK-886) 
and Cys-LT1R (montelukast) inhibited cell growth through induction of G(1)-cell cycle arrest and 
apoptosis. 
Chen 
(2009) 
Mouse BMT model of CML  Absence Alox5 led to failure of chronic myeloid leukaemia development and impairment function 
leukaemia stem cells (LCS). Treatment with zileuton impaired LCS and prolonged survival. 
Matsuyama 
(2009) 
Human testicular cancer  CysLT1R expressed strongly in testicular cancer cells. Receptor antagonist inhibited cell growth 
through early apoptosis. 
Wasilewicz 
(2010) 
Colonic adenomas  5-LOX expression correlated with risk factors for malignant transformation (size, high grade 
dysplasia) 
Fischer 
(2010) 
Various tumour cell lines  Certain 5-LOX (AA861, MK-886, REV-5901) inhibitor resulted in cytotoxic and antiproliferative 
effects independent of 5-LOX activity. Dr CPC Boger  Introduction 
25 
 
 
 
   
Study 
(Year) 
Tissue  Findings 
Wang 
(2011) 
Glioma stem-like cells  Inhibition of 5-LOX by dl-nordihydroguaiaretic induced differentiation in glioma stem-like cells. 
Amirian 
(2011) 
Prostate cancer  Single nucleotide polypmorphism in LTA4H (rs1978331) was inversely associated with prostate 
cancer risk. 
Sarveswaran 
(2011) 
Prostate cancer cell lines  5-LOX inhibition-induced apoptosis occurs via inactivation of protein kinase C-epsilon. 
Mohammed 
(2011) 
Mouse model for familial 
adenomatous polyposis 
(APC
min/+ mice) 
The dual 5-LOX/COX-2 inhibitor licofelone suppressed small intestinal and colonic tumour 
formation in APC
min/+ mice. 
Park 
(2012) 
Head and neck squamous cell 
cancer cell lines 
Inhibition of COX-2 increased LTB
4 but showed little growth inhibitory effects. Combined COX-2 
and 5-LOX inhibition resulted in decrease in cell proliferation dependent on 5-LOX expression in 
cells. 
Zhao 
(2012) 
Hepatoma cell lines  LTB
4 activated NF-κβ in a dose-dependent manner. 
Kummer 
(2012) 
Papillary thyroid cancer cell 
lines 
Transfection with ALOX5 increased MMP-9 secretion and invasion across the extracellular matrix 
barrier. 5-S-HETE increased MMP-9 in a dose-dependent manner. 5-LOX and MMP-9 inhibitors 
reversed ALOX5 enhanced invasion. Dr CPC Boger  Introduction 
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  Current management strategies for high grade  1.8
dysplasia in Barrett’s oesophagus   
 
1.8.1  Current practice 
Difficulties with the management of HGD in BM derive from problems inherent with the 
endoscopic diagnosis of the disease. Barrett’s segments are heterogeneous and 
diagnosis by endoscopic biopsy can sample only a fraction of the whole segment. 
Concerns arise around the risk of missing invasive carcinoma, despite biopsies 
demonstrating HGD only. A number of retrospective studies have demonstrated the 
presence of metachronous invasive cancer in up to 40% of those with an initial pre-
operative diagnosis of HGD (Edwards et al. 1996; Heitmiller et al. 1996).  Based on 
these arguments, the British Society of Gastroenterologists issued guidance in 2005 
suggesting that surgical oesophagectomy should be the first line therapeutic option 
for HGD in those fit for the procedure (Watson et al. 2005). However, surgical 
oesophagectomy remains a high risk procedure, even in tertiary centres, with modern 
operative mortality of approximately 3.2%, and post-operative complications in up to 
40% (Palser et al. 2009). Data also suggests that even 3-years after oesophagectomy, 
patients suffer significant morbidity (Lagergren et al. 2007). The adoption of a first line 
surgical strategy has therefore been called into question. 
 
1.8.2  Alternative therapies 
Given the drawbacks of oesophagectomy as a first line treatment strategy, a variety of 
alternative endoscopic options for the management of HGD in BM have been tried (see 
Table 1-B). Thermal ablation involves using either multi-polar electro-coagulation 
(MPEC), argon plasma coagulation (APC), or radiofrequency ablation (RFA) to induce 
very high tissue temperatures and subsequent cell death. Although MPEC has been 
utilised widely in non-dysplastic Barrett’s, only APC and RFA have been used with any 
success in dysplastic Barrett’s. The role of RFA in Barrett’s is discussed in detail further 
on in this section. 
 
1.8.2.1  Argon Plasma coagulation 
APC uses high-frequency, monopolar current of ionized argon gas resulting in 
coagulation of the epithelium. Only three small observational studies have reported 
use with APC in HGD (Morris et al. 2001; Van Laethem et al. 2001; Attwood et al. 
2003). Although eradication of dysplasia was achieved in up to 100%, perforation 
occurred in up to 4%, and in one case series, one (out of 7) progressed to OA (Van 
Laethem et al. 2001). 
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1.8.2.2  Laser therapy 
Two types of lasers have been used in dysplastic Barrett’s: neodymium-yttrium 
aluminium garnet (Nd-YAG) and potassium titanyl phosphate (KTP). Both use an intense 
beam of light to produce injury to the target epithelium. Experience is limited to the 
treatment of only 18 patients with HGD. Eradication of dysplasia was variable, and in 
one mixed case series (5 with HGD, 16 LGD, and 10 non-dysplastic Barrett’s) one out of 
5 with HGD at baseline progressed to OA requiring oesophagectomy (Fisher et al. 
2003). 
 
1.8.2.3  Endoscopic mucosal resection 
Endoscopic mucosal resection (EMR) of the entire affected mucosa has been explored. 
It has the added advantage of allowing histological assessment of the entire Barrett’s 
segment, with the potential of a more sustained treatment response. None have 
progressed to OA thus far in any of the studies (Ell et al. 2000; Seewald et al. 2003; 
Peters et al. 2006; Soehendra et al. 2006; Lopes et al. 2007; Pech et al. 2008). High 
technical expertise is nevertheless required to accomplish the technique with a low 
complication rate. Oesophageal perforation may occur in up to 5% and bleeding in up 
to 25%. Strictures are mainly described in those undergoing EMR of greater than 75% of 
the circumference of the oesophagus, and in this situation may occur in up to 70% of 
cases (Soehendra et al. 2006; Pech et al. 2008). 
 
1.8.2.4  Cryotherapy 
Cryotherapy is a promising evolving technique that involves applying liquid nitrogen 
directly onto the mucosa using a spray catheter introduced through the working 
channel of the endoscope. The tissue is frozen for approximately 40 seconds either in 
two cycles of 20 seconds or in four cycles of 10 seconds. Results from a retrospective 
cohort study demonstrated that of 60 patients with HGD who completed the 
cryotherapy sessions, 58 had complete eradication of HGD (97%), 52 (87%) had 
complete eradication of all dysplasia, and 34 (57%) had complete eradication of 
intestinal metaplasia (Shaheen et al. 2010). Complications included chest pain (2) and 
strictures (3), but no perforations. These early results would appear to suggest 
cryotherapy is a highly effective and safe technique. It was however a non-randomised, 
retrospective study without a control group and with only limited (10.5 month) follow 
up. Further data are required before cryotherapy can be envisaged as an alternative 
ablative technique. 
 
1.8.2.5  Photodynamic therapy 
Ablation of the Barrett’s segment with photodynamic therapy (PDT) involves 
intravenous administration of a photosensitising agent, either intravenous sodium Dr CPC Boger  Introduction 
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porfimer, oral 5-aminolaevulinic acid (5-ALA), or meta-tetrahydroxyphenyl chlorin 
(mTHPC), followed by endoscopic light laser exposure to the Barrett’s segment. This 
results in the generation of oxygen radicals in the photosensitised tissues which leads 
to cell death. A large randomised multicentre multinational trial has demonstrated that 
treatment with sodium porfimer based PDT is superior to omeprazole alone at 
eliminating HGD (77% vs 39%, p<0.0001), and additionally in preventing progression to 
invasive cancer (15% v 29%, p=0.027) (Overholt et al. 2007). Experience with mTHPC 
PDT is limited to a case series of less than 10 patients (Etienne et al. 2004; Lovat et al. 
2005). 5-ALA PDT is associated with fewer side-effects and success rates of up to 
100%, but experience is limited to single centre case series, with no RCT to date (May 
et al. 2002; Pech et al. 2005). Three prior cost-effective analyses have demonstrated 
PDT’s superiority when compared with oesophagectomy or surveillance only (Hur et al. 
2003; Shaheen et al. 2004; Vij et al. 2004). However, the widespread acceptance of 
PDT has been held back by treatment-related adverse events in up to 94% of patients 
and by a high incidence of oesophageal stricturing in 39% with sodium porfimer based 
PDT (Overholt et al. 2005). Furthermore, it has been associated with the presence of 
‘buried’ foci of residual Barrett’s tissue (sub-squamous metaplasia), which are 
associated with the emergence of OA at a later date (Fitzgerald 2003; Bergman and 
Fockens 2006; Overholt et al. 2007). As such, PDT is only undertaken by a limited 
number of centres, and is not currently recommended as first line treatment in those 
fit for surgery (Watson et al. 2005). Dr CPC Boger  Introduction 
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Table 1-B: Summary of outcomes and complications of endoscopic techniques used to eradicate HGD in Barrett’s oesophagus 
Modality 
(Author, Year) 
Study design  Eradication of dysplasia  Stricture rate  Perforation  Other  
PDT 
(Overholt, 2005; Overholt, 2007) 
 
RCT  77-97%  Up to 36%  <1%  69% photo-sensitivity 
EMR 
(Ell, 2000; Seewald 2003; Peters, 2006; 
Soehendra, 2006; Lopes, 2007; Pech, 2008) 
Case series  75-100%  14-70%  Up to 5%  Bleeding 20% 
APC 
(Morris, 2001; Van Laethem, 2001; Attwood, 
2003) 
Case series  86-100%  0-9%  Up to 4%  Chest pain 2% 
Laser (Nd-YAG or KTP) 
(Gossner, 1999; Weston, 2002; Fisher, 2003) 
Case series  62-100%  0-12%  3%  Bleeding  6% 
Cryotherapy 
(Shaheen, 2010) 
Case series  87%  3%  0  Chest pain 2% 
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1.8.3  Radiofrequency ablation 
1.8.3.1  The Technique 
RFA utilises a high frequency alternating current and generates tissue injury by 
converting electrical energy into heat. Delivery of continuous, un-modulated, sine wave 
alternating current results in heat-induced coagulation necrosis. The Bârrx HALO 
device is an endoscopic delivered, novel, balloon-based therapy capable of delivery of 
radiofrequency energy to the oesophagus in a controlled fashion. It consists of an 
energy generator and then two different devices (Figure 1-G). The HALO
360 is a catheter 
passed by endoscopic wire guidance and can deliver a pre-set amount of 
radiofrequency energy density to a 360° ablation field. On the surface of the balloon is 
a 3-cm-long bipolar microelectrode consisting of 60 tightly spaced electrode rings. The 
electrode rings each completely encircle the balloon and alternate in polarity. Each ring 
is approximately 250 µm wide and is approximately 250 µm from their neighbouring 
electrode. The HALO
90 ablation catheter attaches to the end of the endoscope and has a 
smaller electrode surface area, approximately 20 mm long and 13 mm wide, and 
covers an approximate 90° radius. This allows a more focal selective ablation of 
residual Barrett’s tissue. The electrode array is identical in pattern to the 360⁰. 
 
Figure 1-G: The Bârrx HALO system 
(a) Energy generator (b) 360⁰ ablation catheter (c) 90⁰ ablation catheter 
 
The procedure is undertaken as a day case procedure under conscious sedation. After 
assessment of the area to be treated, the inner diameter of the oesophagus is first 
sized using a separate inflatable sizing balloon, and utilising an automatic pressure: 
volume algorithm. An ablation catheter with a size commensurate with the measured 
internal diameter is then passed over a guide wire, and ablation delivered, starting 
proximally, by inflation of the balloon and then delivery of energy by the energy 
generator. The catheter is then realigned with the distal edge of the ablation zone 
(with a slight overlap), and further ablation applied. This process is then repeated until Dr CPC Boger  Introduction 
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complete ablation of the Barrett’s segment, with the ablation zone extending to the 
top of the gastric folds (Figure 1-H). 
 
 
Figure 1-H: Illustration of ablation of a Barrett’s segment using the 360⁰ device 
 
1.8.3.2  Initial dosimetry studies 
Initial studies evaluated the endoscopic and histological effects of circumferential RFA 
in porcine models as well as in the normal squamous portion of the human 
oesophagus in patients undergoing oesophagectomy for OA (Ganz et al. 2004). In this 
multi-phase study, the authors demonstrated that complete circumferential ablation of 
porcine and human oesophageal epithelium could be achieved without injury to the 
sub-mucosa. Ablation depth was found to be linearly related to the energy density 
delivered. This led to further dosimetry studies to assess the optimal energy density 
and treatment parameters to achieve complete ablation (Dunkin et al. 2006). In this 
study, patients underwent circumferential ablation of a 3cm section of squamous 
oesophageal epithelium just prior to oesophagectomy. They found 12 joules/cm
2 
(J/cm
2) was the optimum energy density, with lower densities resulting in only partial 
ablation. Mean residual tissue depth was 35 µm, with no burn deeper than the 
muscularis mucosa. The final dosimetry study was conducted on patients just prior to 
oesophagectomy on areas with HGD in Barrett’s oesophagus undergoing two, three or 
four applications of circumferential ablation at 10, 12, or 14J/cm
2 (Smith et al. 2007). 
Complete ablation of intestinal metaplasia and HGD was achieved in nine out of ten 
ablation zones (at 12J/cm
2), with one failure attributed to incomplete overlap. Again 
ablation depth was dose related, and limited to the muscularis mucosa. 
 
1.8.3.3  Studies evaluating radiofrequency ablation in Barrett’s metaplasia 
Studies were then undertaken in non-oesophagectomy patients with non-dysplastic 
Barrett’s oesophagus. The Ablation of Intestinal Metaplasia trial (AIM-trial) included 
patients with non-dysplastic Barrett’s and was conducted in two phases; a dosimetry 
(AIM-I) and effectiveness (AIM-II) phase (Sharma et al. 2007). The initial dosimetry 
phase demonstrated 10J/cm
2 or 12J/cm
2 were superior to lower energy levels, without 
any serious adverse events. 10J/cm
2 (x2) was selected for the effectiveness phase. 
Twenty-four adverse events were reported in 16 patients: transient nausea (8), mucosal 
injury or scarring (2), chest pain or throat pain (9), fever (2), mild bleeding which 
stopped spontaneously (1), and sedation related events (2). At 12-month follow up 
complete remission of intestinal metaplasia was achieved in 48 of 69 patients (70%). Dr CPC Boger  Introduction 
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Further published articles have reported on the longer term follow-up of the AIM-II 
cohort (Fleischer et al. 2008). In the study by Fleischer et al., further circumferential 
ablation therapy was performed at 4 months, followed by focal ablation of residual 
segments on up to 3 occasions as necessary. Complete response to intestinal 
metaplasia was seen in 60 of 61 patients (98%) at 30 month follow up. There were no 
strictures, no serious adverse events, and no buried glandular mucosa. Five-year follow 
up data have now been published. Of the 50 patients they contacted, 46 had complete 
response to intestinal metaplasia (92%). Of the four with residual Barrett’s, they 
demonstrated that re-establishment of complete response was achievable by delivering 
one further treatment session with focal ablation at 12J/cm
2 (Fleischer et al. 2010). 
 
1.8.3.4  Studies evaluating radiofrequency ablation in dysplastic Barrett’s 
The role of RFA in LGD has been evaluated in two studies. In a case series of 39 
patients with LGD treated with circumferential and focal ablation, complete eradication 
of dysplasia was achieved in 95%, and complete eradication of IM in 87% at 2-year 
follow up (Sharma et al. 2009). The only published RCT on RFA included 64 patients 
with LGD, of whom 42 were assigned RFA and 22 to a sham procedure (Shaheen et al. 
2009). Complete eradication of LGD was achieved in 90% in the RFA group (v 23% 
sham, p<0.001), with complete eradication of IM in 81% (v 4% sham, p<0.001). Two 
patients did progress to HGD during the trial period. 
 
Initial studies included only very small numbers of patients with HGD (Roorda et al. 
2007; Hernandez et al. 2008). Subsequent case series suggested that eradication of 
HGD could be achieved in 90.2% (Ganz et al. 2008) and 98% (Pouw et al. 2008). The 
most robust data on the role of RFA in HGD has come from a multicentre sham-
controlled RCT in the US
* (Shaheen et al. 2009). Sixty-three patients with HGD were 
included, of whom 42 were assigned RFA and 21 to a sham procedure. Complete 
eradication of dysplasia was achieved in 81% on an intention to treat protocol at 12-
month follow up. One out of the 42 patients with HGD (2%) (versus 4/21 – 19% in the 
sham group) progressed to cancer during the trial period. The disease was intra-
mucosal cancer which, although not stated, could be removed endoscopically without 
need for oesophagectomy. The authors measured chest pain using a visual analogue 
score (VAS, scale 0-100). On day one, mean VAS was 22 (versus zero in the sham 
group), dropping to zero by day eight. Serious adverse events were infrequent, with 
one upper gastrointestinal haemorrhage treated endoscopically (patient was taking 
anti-platelets), and two episodes of chest pain requiring overnight admission. The 
                                                 
* This trial included patients with both LGD and HGD. The results of those with LGD are 
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stricture rate was 6%, all of which resolved with oesophageal dilatation (average of 2.6 
sessions required).  
 
Figure 1-I: Treatment of Barrett’s metaplasia by the HALO 90 device 
(A) During treatment and (B) appearance of the oesophagus under narrow band 
imaging (NBI) three months later. The lining of the oesophagus has reverted to 
squamous mucosa. 
 
1.8.4  Current guidance from the National Institute for Health and Clinical 
Excellence (NICE) 
NICE issued initial guidance in December 2007 on the use of circumferential RFA for 
the ablation of Barrett’s oesophagus. The conclusion of the guideline was that evidence 
was insufficient to recommend the use of circumferential RFA in non-dysplastic 
Barrett’s oesophagus, and thus stated that the procedure should only be used in the 
context of clinical research. Of note this guidance only dealt with the issue of non-
dysplastic Barrett’s; a different subset of patients with a much lower risk of developing 
OA (estimated rate of conversion to cancer of 0.5% per annum). Additionally, the HALO 
system now utilises two complementary delivery methods to achieve ablation of the 
affected tissue (the HALO
360 and HALO
90). Recent experience appears to demonstrate 
that combining the two techniques results in improved outcome (Gondrie et al. 2008a), 
although this has not been subjected to a randomised clinical trial. 
Since the development of the model in this thesis, NICE have issued further guidance 
(NICE 2010a). This is included in the discussion chapter. 
 
1.8.5  Current economic studies evaluating the role of RFA in Barrett’s 
oesophagus 
At the time of this work, no economic studies had been published looking at the cost-
effectiveness of RFA in the treatment of HGD. A subsequent study from the US has 
been published (Inadomi et al. 2009), and this is discussed later. The economic models 
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evaluating ablative studies in the treatment of Barrett’s and HGD, and their relevance 
to the construction of the model in this study are discussed in the methods section. 
 
1.8.6  Current economic cost of the problem in the UK 
The true incidence of HGD in the UK is not currently known, but it is estimated that 
between 0.5-2% of the adult population in the Western world have Barrett’s 
oesophagus (Corder et al. 1996; Csendes et al. 2000; Ronkainen et al. 2005).  The 
annual incidence of HGD in those undergoing surveillance is 0.9% per annum (Sharma 
et al. 2006). Based on the 2001 census and a screening pick up rate of 30-35% per 
annum one would expect 2000-3000 cases HGD in the UK per year. If all were to 
undergo oesophagectomy as per current guidance, one would expect a cost to the NHS 
of £15-20 million per year. 
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  Summary and Aims of thesis  1.9
 
1.9.1  The role of leukotrienes in the pathogenesis of Barrett’s adenocarcinoma  
A mounting body of evidence suggests a key role for LTs in promoting cancer cell 
growth, possibly by suppression of apoptosis and promotion of neo-angiogenesis. 
Their precise roles and cellular sources are nevertheless poorly defined. Preliminary 
work by our group has established by enzyme immunoassay that tissue levels of LTB
4 
and LTC
4 are significantly increased in OA tissue, following ex vivo stimulation of 
cultured biopsies from patients with BM and OA. This study aims to relate the 
generation of these lipid products to the expression of 5-LOX pathway proteins within 
the biopsies. 
 
1.9.1.1  Hypothesis 
5-LOX pathway activity is up-regulated progressively through metaplasia to 
adenocarcinoma, by induction of enzyme expression and/or infiltration by 
inflammatory cell-types. 
 
1.9.1.2  Aims 
To facilitate a greater understanding of the cellular sources of eicosanoid products 
implicated in the molecular pathogenesis of BM and OA, immunohistochemistry and 
laser microdissection will be utilised to localise and quantify 5-LOX pathway 
expression. 
 
1.9.2  Cost–utility analysis of radiofrequency ablation or oesophagectomy for the 
management of high-grade dysplasia in Barrett’s oesophagus 
Options for the treatment of HGD in BM are imperfect. Current guidance recommends 
oesophagectomy, which is associated with high morbidity and mortality. RFA is a 
promising new technology, with early trial results demonstrating its efficacy in the 
treatment of HGD in BM, with minimum morbidity and mortality. The cost per patient 
to the NHS is not currently known and there has been no RCT comparing RFA and 
oesophagectomy. 
The cost-effectiveness of introducing RFA for the treatment of HGD in the UK is 
unknown. It is this group of patients, with the highest risk of development of OA and 
currently such limited treatment options that are likely to be the initial target group for 
therapy with RFA.  Before introducing such a treatment into the UK, it is important to 
evaluate the lifetime benefits and costs of RFA compared with the standard current 
practice of oesophagectomy. This will help bring clarity to the difficult clinical situation 
of selecting the most appropriate strategy in managing patients with HGD in BM. 
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Health economic evaluation using a cost utility analysis allows us to consider the costs 
and, using utility as a measure of health state preference, estimate quality-adjusted life 
years, prior to the introduction of a new technology into a health care setting. This is 
especially relevant to the appropriate allocation of health care expenditure within a 
limited budget. In addition, when uncertainty exists, it allows us to interrogate the 
available data and form conclusions about where further study might be needed. 
 
1.9.2.1  Hypothesis 
Radiofrequency ablation is a cost-effective option for treatment of high-grade dysplasia 
in Barrett’s in a UK setting. 
 
1.9.2.2  Aim 
To model whether RFA followed by oesophagectomy for persistence or recurrence of 
HGD is a cost-effective option for the treatment of BM with HGD when compared with 
the current UK recommendation of oesophagectomy, and to identify critical parameters 
to guide further research.Dr CPC Boger  Methodology of laboratory studies 
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CHAPTER 2:   Methodology of laboratory 
studies 
 
This chapter outlines the methodology used for the laboratory studies evaluating 
expression and localisation of the 5-lipoxygenase (5-LOX) pathway in Barrett’s 
metaplasia (BM) and oesophageal adenocarcinoma (OA). Patient recruitment, sample 
collection, ethical approval and choice of control tissue are discussed in section 2.1. 
The protocol for immunohistochemical analysis of 5-LOX pathway proteins in the 
sample tissue is outlined in section 2.2. The devised protocol for the laser capture of 
cellular areas from the tissues for mRNA analysis is presented in section 2.3. Section 
2.4 concerns itself with statistical considerations for data handling. 
 
  Patient recruitment  2.1
 
2.1.1  Patient selection and biopsy collection 
Ethical approval for the study was granted by Isle of Wight, Portsmouth and Southeast 
Hampshire Research Ethics Committee (REC reference number: 08−H0501−3) (see 
appendix A). All patients gave informed consent, after both a written explanation 
(provided at least 24 hours in advance of signing consent) and a verbal explanation of 
the study to be undertaken (see appendix B).  
Patients were included in the study if they had a diagnosis of: 
i)  BM with a segment length of at least 3 cm 
ii)  OA 
 
44 patients were recruited in total; 31 with Barrett’s oesophagus, 13 with a prior 
diagnosis of oesophageal cancer. Of these 6 with oesophageal cancer were excluded 
due to the finding of junctional tumours (3), undifferentiated carcinoma (1), and lack of 
OA tissue in the sample taken (2). The individual patient characteristics can be found 
in the results section for the immunohistochemistry study (section 4.4) and gene 
expression analysis (section 5.3.3). 
 
Fresh and adjacent formalin-fixed oesophageal biopsies were then obtained at upper 
gastrointestinal endoscopy. Biopsies from those with BM were taken 2cm proximal to 
the top of the gastric folds. Length of Barrett’s segment and current use of proton 
pump inhibitors (PPI) and aspirin were recorded. Adjacent biopsies were taken and 
submitted for formalin fixation, processed using routine methods into haematoxylin 
and eosin-stained sections and assessed by a histopathologist expert in the field of Dr CPC Boger  Methodology of laboratory studies 
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gastrointestinal pathology, blinded to any study results. BM was defined as the 
visualisation of metaplastic columnar epithelium with the histological finding of 
intestinal metaplasia. 
 
2.1.2  Choice of control tissue 
The normal lining of the oesophagus is with squamous tissue, and this therefore is the 
starting point in the progression to BM and then OA. Therefore from a subset of 
patients, samples were taken from of squamous tissue from an area just proximal to 
the diseased oesophagus. 
 
  Immunohistochemistry  2.2
 
2.2.1  Introduction 
Immunohistochemistry (IHC) allows the detection of specific antigens in cells within 
tissue sections by the use of antibodies specific to the antigen of interest. Advantages 
of the technique include the ability to directly visualise the location of positively 
stained cells within the tissue section. This technique was utilised to examine 
expression within BM and OA biopsies of the four main enzymatic proteins of the 5-
LOX pathway: 5-LOX, FLAP, LTA
4H, and LTC
4S. The aim was to correlate the expression 
of these proteins with tissue staining of white cell subsets, namely neutrophils, 
macrophages/monocytes, eosinophils, and lymphocytes, 
 
2.2.2  Fixing media for immunohistochemical analysis 
Glycol methacrylate is a hard resin which can be utilised in biopsy fixation and allows 
cutting of ultra-fine 2µm sections, whilst preserving tissue morphology and preserving 
antigens for immunohistochemistry. 
 
2.2.3  Biopsy processing 
The fresh biopsy specimens were immediately fixed in ice-cold acetone containing the 
protease inhibitors phenylmethylsulphonylfluoride (PMSF, 2mM) and iodoacetamide 
(20mM) (Sigma, Poole, UK) for 16-24h at -20⁰C, then embedded in glycol methacrylate 
resin (Park Scientific Ltd, Northampton, UK) as previously described (Britten et al. 
1993). The biopsies were then stored in secure -20⁰C freezers until required. 
 
2.2.4  Biopsy quality assessment 
Biopsies can be of varying quality and thus were assessed individually before IHC 
staining was undertaken. The resin blocks containing each biopsy were trimmed and 
filed to size and then, using the microtome, 2µm sections were cut and stained with 
toluidine blue. The biopsy was assessed under the light microscope for tissue type, Dr CPC Boger  Methodology of laboratory studies 
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epithelial quality, quality of stromal area, and overall quality. If the section seen was of 
poor standard then further sections were taken from deeper within the biopsy and 
reassessed as above. Thus a level in the biopsy was found which was deemed to be of 
adequate histological standard. If no such level was found then the biopsy was 
excluded from further immunohistochemical analysis. 
 
2.2.5  Primary Antibody titration 
Optimum antibody titre was determined by serial dilutions using human tonsillar 
tissue, known to express all of the antigens of interest. Titrations started at a 1:50 
dilution and were progressively titrated out until disappearance of positive staining. 
Slides were then assessed by light microscopy and number of positive staining cells 
per high powered field (x 40 magnification) was recorded, in 6 separate random fields. 
A titration curve was plotted to demonstrate the antibody titre prior to a reduction in 
the number of positive cells. Optimum antibody titre was then defined as the dilution 
of antibody resulting in the maximum specific staining (i.e. highest cell count) but with 
the least amount of background under conditions in the used laboratory (Figure 2-A). 
 
 
Figure 2-A: Example of titration curve used to calculate the optimum antibody dilution. 
Here FLAP is shown, and although 1:1000 titre resulted in most number of positive 
cells, a 1:1200 titre was chosen as a compromise to minimise the impact of 
background staining.   
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The following primary antibodies were used at the following dilutions: 
 
Antibody  Source  Host  Class  Optimal 
dilution 
µg/ml 
5-Lipoxygenase (5-
LOX) 
Cayman Chemical Co. 
(Tallinn, Estonia) 
Rabbit  IgG  2 
5-Lipoxygenase 
Activating Protein 
(FLAP) 
Kind gift from Dr John 
Menke, Merck & Co. 
Inc. 
Rabbit  Uncertain  1:1200 titre 
used* 
Leukotriene A
4 
Hydrolase 
Kind gift from Dr John 
Menke, Merck & Co. 
Inc. 
Rabbit  Uncertain  1:2500 titre 
used* 
Leukotriene C
4 
Synthase 
Kind gift from Dr John 
Menke, Merck & Co. 
Inc. 
Rabbit  Uncertain  1:1800 titre 
used* 
Pan-cytokeratin  Dako  Mouse  IgG1  0.34 
Neutrophil elastase 
(NE) 
Dako  Mouse  IgG1  0.07 
CD68  Dako  Mouse  IgG3kappa  0.2 
CD3  Dako  Mouse  IgG1  1 
EG2  Diagnostics 
Development 
Mouse  IgG1  0.8 
*Concentration of original stock unknown 
 
2.2.6  Immunohistochemistry 
All steps were carried out at room temperature unless mentioned. 
Firstly 2µm tissue sections were cut, floated out on ammonia water (1ml ammonia in 
500ml distilled water), and picked up on glass slides coated with poly-L-lysine, which 
enhances tissue adhesion to the slide. Two sections were placed on each slide. The 
slides were air dried for at least 60 minutes and then either stored for a maximum of 2 
weeks at -20⁰C, or used immediately. 
 
Slides were laid in staining trays and then treated with the membrane solubiliser 
Tween-20 wash. Endogenous peroxidases were then inhibited by the application of 
0.1% sodium azide containing 1/100th volume of 0.3% hydrogen peroxide and 
incubated at room temperature for 30 minutes. The reaction was stopped by three 
Tris-buffered saline (TBS) washes of five minutes each. 
 Dr CPC Boger  Methodology of laboratory studies 
43 
 
 
2.2.6.1  Blocking steps 
The avidin/biotin blocking kit (Vector Laboratories, Peterborough, UK) was used to 
block endogenous biotin, biotin receptors and avidin binding sites (Cowburn et al. 
1998). Avidin block was applied for 20 minutes, washed briefly three times with TBS 
for 2 minutes per wash. Biotin block was then added and left for a further 20 minutes, 
followed by a repeat brief wash, and then culture medium was added for 30 minutes. 
The culture medium was removed by gentle drainage and the primary antibody added 
to each section at the appropriate titre. Cover-slips were used to avoid drying out of 
the section and even antibody distribution. Slides were incubated overnight at room 
temperature with monoclonal primary antibody or at 4⁰C with polyclonal primary 
antibody. 
 
2.2.6.2  Avidin-Biotin Complex method 
In the avidin-biotin complex (ABC) method secondary antibodies are conjugated to 
biotin and function as links between tissue-bound primary antibodies and an avidin-
biotin-peroxidase complex, as shown in Figure 2-B (Hsu et al. 1981). 
 
 
Figure 2-B: Avidin Biotin Complex (ABC) method 
 
 
If slides were incubated at 4⁰C they were allowed to equilibrate to room temperature 
for 30-60 minutes prior to removal of the primary antibody by washing in TBS for five 
minutes three times. The second stage biotinylated antibodies were then added at the 
following concentrations, and incubated for 2 hours: 
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Secondary biotinylated 
antibody 
Source  Host  Optimal dilution 
(µg/l) 
Anti-rabbit  Dako  Swine  0.81µg/ml 
Anti-mouse  Dako  Rabbit  0.77ug/ml 
 
The slides were drained and washed in TBS for five minutes three times. The ABC was 
made up at least 30 minutes prior to adding to slides by diluting both avidin and biotin 
at a 1:75 dilution in TBS and then mixing by gentle inversion. The ABC was then added 
to the sections and incubated for 2 hours. The slides were drained and washed in TBS 
for five minutes three times prior to addition of the chromagen. 
 
2.2.6.3  Choice of chromagen 
Chromagen’s are substances which upon being oxidized become coloured insoluble 
products, and thus allow visualisation of the primary antibody. The choice of 
chromagen depends upon the type of quantification of staining required. 3, 3’-
diaminobenzidinetrahydrochloride (DAB) produces a brown end product which varies in 
staining intensity dependent on the degree of oxidation. It is thus suitable for 
measuring staining intensity. 3-amino-9-ethylcarbazole (AEC) produces a rose-red end 
product, which when used with Mayer’s haematoxylin, provides valuable contrast with 
the dark purple staining nuclei, and thus is a good choice for assessing the number of 
cells expressing the antigen of interest. AEC was chosen for the majority of the 
samples when assessment by cell counting was anticipated. DAB was used to look at 
specific binding on the epithelium by assessment of intensity of staining. 
 
AEC was applied for 20 minutes and DAB for 10 minutes, prior to washing with TBS 
and then running tap water for five minutes. A counter-stain Mayer’s haematoxylin was 
used. This was a water based stain to prevent solubilisation of AEC which is alcohol 
soluble. The slides were immersed for one and half minutes in this counter-stain, 
followed by further washing in running tap water. Cover slips were applied with an 
aqueous mount and allowed to dry prior to analysis. 
 
2.2.7  Negative controls 
Primary antibody specificity is of utmost importance in immunohistochemistry, and for 
polyclonal antibodies the use of non-immune serum of the same animal source is 
considered appropriate to control against non-specific binding (Dako 2006). Non-
immune rabbit serum was therefore chosen as the negative control, applied at a 
concentration of 2µg/ml, corresponding to the known concentration of 5-LOX antibody 
used in this study. The concentration for antibodies against FLAP, LTA
4H and LTA
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were unknown. The serum was applied to sections with known positive staining, and in 
addition to the positive control of human tonsillar tissue. Previous work by our group 
has demonstrated the specificity of antibodies to FLAP, LTA
4H and LTC
4S, as described 
(Cowburn et al. 1998). Each immunohistochemical run included an antibody negative 
control for each tissue sample under interrogation, where the primary antibody was 
replaced by TBS. 
 
2.2.8  Quantification of staining 
Positive cells were defined as distinct nucleated cells exhibiting staining following 
exposure to the chromagen. Positive cells observed near the edge of a section where a 
wash of stain was apparent were ignored. All other immunopositive cells were counted 
in each tissue section and the average count in two non-adjacent sections was 
recorded. The total area of the counted tissue sections was measured in mm
2, ignoring 
sections of tissue disruption or folding, using a computer-assisted image analyser 
(Image Associates, Bicester UK). Immunopositive cell prevalence was documented as 
positive cells per mm
2 of tissue. 
 
When epithelial staining was observed, image analysis software (Zeiss KS-400) was 
used (Figure 2-C) to measure percentage epithelial area staining based on 
red/green/colour composition as previously described (Puddicombe et al. 2000). 
 
 
Figure 2-C: Use of image analysis software to measure percentage epithelial area 
staining. 
   Dr CPC Boger  Methodology of laboratory studies 
46 
 
  Isolation, extraction, and gene expression analysis of  2.3
cellular RNA using laser captured micro-dissection 
 
2.3.1  Introduction 
Laser capture micro-dissection (LCM) allows procurement of individual cellular types 
under direct microscopic visualisation for subsequent downstream analysis (Espina et 
al. 2007). Multiple steps are required with a potential for degradation of mRNA at each 
juncture and introduction of experimental error (Pinzani et al. 2006). The aim was to 
perfect this technique to isolate mRNA from laser captured samples, and to reverse 
transcribe and perform real time quantitative polymerase chain reaction (RT-qPCR). 
This technique was then used to study the association between stromal and epithelial 
expression of 5-LOX pathway mRNA levels between tissue types. 
 
2.3.2  Laser capture micro-dissection 
2.3.2.1  Tissue assessment 
Fresh biopsy specimens were wrapped in RNaseZAP (Ambion, Paisley, UK) treated foil, 
placed in a cryo-tube, and then immediately snap frozen in liquid nitrogen. Samples 
were stored securely in liquid nitrogen until use. A cryo-stat (Leica CM1850UV, Leica 
Microsystems UK, Milton Keynes, Buckinghamshire) was pre-cooled to -30⁰C. To ensure 
removal of any potential RNA contamination the cryostat along with instruments to be 
used for handling the samples were treated for 3 hours with ultraviolet-C rays. A 
sample was removed from liquid nitrogen storage, placed in the cryostat and allowed 
to equilibrate for 10 minutes. The sample was orientated, placed in optimal cutting 
medium, and placed on dry ice to allow the optimal cutting medium to harden. 
Sections of 8µm were cut, placed on poly-L-lysine treated slides, and allowed to air dry 
for 30 minutes. The section was stained with haematoxylin for 40 seconds and briefly 
washed in running tap water. Average cells per mm
2 were calculated for each 
histological subtype by use of a graticule under the light microscope. In addition, 
tissues were assessed to ensure the correct histological subtype, and overall tissue 
quality including the presence of both epithelial and stromal areas. If the biopsy 
fulfilled these criteria, then further sections were cut and placed on a PEN-membrane 
slide (Molecular Devices, Wokingham, Berkshire). A total of four sections per slide were 
cut, with approximately four slides per biopsy sample. Time per slide was kept to a 
minimum (ideally less than 1 minute), and slides were then placed immediately in a 
slide box (also pre-treated with RNaseZAP) on dry ice. The slides then either underwent 
a quick stain procedure (see section 2.3.2.2), or were stored in -80⁰C in a tightly sealed 
box with desiccant. 
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2.3.2.2  Preparation of tissue sections for laser capture using quick stain technique 
A quick, less intense, histological staining procedure is recommended for LCM, as 
warming of tissue sections even for short periods of time can allow activation of 
resident ribonucleases in the tissue, and result in degradation of RNA (Goldsworthy et 
al. 1999). The following protocol was thus developed to ensure minimum but 
adequate, staining of the tissue and fixing. All ethanol dilutions were made with 
nuclease-free water (Ambion, Life Technologies Ltd, Paisley, UK). The PEN-membrane 
slides were removed from dry ice and allowed to air dry for 30 seconds. They were 
then fixed and hydrated in 75% ethanol for 45 seconds. Cresyl violet is a hydrophilic, 
basic stain that binds to negatively charged nucleic acids. The resulting nuclear 
staining, allows for visualisation of variations in cell morphology, which is useful for 
identifying malignant cells. It was applied for 30 seconds, tapped off, and then the 
slides were then dehydrated as follows: 30 seconds in sequential order of 75%, 95%, 
100%, 100% ethanol. They were then place under a fume hood and allowed to dry for 
approximately 1 hour before being place in a well-sealed slide box with desiccant. 
 
2.3.2.3  Laser capture micro-dissection 
A PEN-membrane slide was placed in the slide holder and mounted into the Leica Laser 
MicroDissector (LMD6500), which utilises gravity to allow the sample to fall into the 
cap of a PCR tube (certified RNase free). 
 
 
 
Cellular areas of interest were identified, marked on screen using the computer mouse, 
and then dissected with the UV laser (see Figure 2-D). The area of each section cut was 
noted. An area was dissected to achieve a cellular capture of between 5000-10000 
cells per tissue area. All samples were collected directly into lysis buffer (Ambion) or 
TRIzol
® reagent (Invitrogen, Life Technologies Ltd, Paisley, UK), mixed by vortexing for 
10 seconds, spun for 10 seconds and then placed on dry ice, prior to either immediate 
RNA extraction, or storage at -80⁰C. Dr CPC Boger  Methodology of laboratory studies 
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Figure 2-D: Identification, laser dissection and procurement of tissue area during laser 
capture micro-dissection. 
 
2.3.3  RNA extraction and reverse transcription 
2.3.3.1  Methods of normalisation 
Normalisation is required at each step to control for the possibility of experimental 
error, which may be introduced during the multistage process required to extract and 
process RNA from laser captured tissue (Huggett et al. 2005; Nolan et al. 2006). The 
following diagram illustrates the stages at which the process was normalised in this 
study. 
 
 
 
In summary, sample size was normalised by dissecting approximately 5000-10000 
cells per sample. After RNA extraction, the quantity of RNA in each sample was 
measured and normalised to 5 nanograms/microlitre (ng/µl) prior to pre-amplification 
reaction (see section 2.3.3.5). Four housekeeping genes were assessed in samples (see 
section 2.3.4.4), and the best combination of two selected. This pair of housekeeping 
Sample
RNA
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Sample size
Similar RNA concentration
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genes was then included for each sample. A positive control was used as a calibrator in 
each run of quantitative PCR, allowing not only normalisation between samples, but 
also between individual runs. 
 
2.3.3.2  Comparison of TRIzol and column based method for RNA isolation from laser 
captured samples 
A variety of different methods for extraction of RNA are available and it is recommend 
that each user should optimise their own protocol to allow maximal retrieval of RNA 
from the LCM samples (Pinzani et al. 2006). The performances of two techniques for 
RNA retrieval were compared on four samples of mixed cellular material captured at 
LCM: extraction of RNA using TRIzol
® reagent and a column based method using the 
RNAqueous Micro Kit (Ambion). 
 
2.3.3.3  Isolation of RNA using a column based method 
The RNAqueous-Micro kit (Ambion) uses a guanidinium thiocyanate based lysis 
solution, capable of disrupting cell membranes and rapidly inactivating ribonucleases. 
The laser dissected samples were captured into lysis solution as previous described. 
Captured samples stored in -80⁰C were allowed to thaw, and then were mixed by 
vortexing for 15 seconds, before incubating for 30 minutes at 42⁰C to improve cell 
disruption. A micro filter cartridge was assembled and 30µl of lysis buffer was applied 
to the centre of the filter and allowed to soak whilst the next steps were completed. 
After the incubation period, the samples were briefly mixed by vortexing, spun on a 
desk top centrifuge before 3µl of LCM additive per 100µl of lysis solution were added 
and mixed. Then, 0.5 volumes of 100% ethanol was added to the lysate mixture and 
mixed by gentle pipetting. The micro filter cartridge assembly was centrifuged at 
13000 x g for 30 seconds to remove the lysis buffer from the filter. Following this the 
lysate/ethanol mixture was loaded onto the prepared assembly and centrifuged for 1 
minute at 10000 x g to bind the RNA to the filter. 180µl of wash solution (number 1) 
was added to the filter and centrifuged for 1 minute at 10000 x g to pass solution 
through filter. A further wash solution (number 2/3) warmed to room temperature (RT) 
was passed through the filter by addition of a 180µl aliquot and centrifuged at 13000 
x g for 30 seconds. This wash was repeated, before the filter was removed, the flow-
through discarded, and centrifuged at 13000 x g for 1 minute to remove any residual 
fluid and dry the filter. The filter was then transferred to a fresh elution tube, and 10µl 
of preheated elution solution to 95⁰C was added and stored at RT for 5 minutes, and 
then centrifuged at 13000 x g for 1 minute. This step was repeated with a second 
aliquot of elution solution. 2µl of 10x DNase buffer and 1µl of DNase were added to 
the elutate and incubated at 37⁰C for 30 minutes. 2µl of DNase inactivation reagent 
was then added, mixed, and stored at RT for 2 minutes. The reaction was centrifuged Dr CPC Boger  Methodology of laboratory studies 
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at 13000 x g for 1.5 minutes, and the supernatant was transferred to fresh tubes, the 
RNA content measured by the Nano-drop method (see section 2.3.3.5), and then stored 
at -80⁰C. 
 
2.3.3.4  Isolation of RNA using the TRIzol method 
Extraction of RNA using TRIzol
® reagent is well validated for the retrieval of RNA from 
tissues and cell preparations. Each laser captured sample was made up to 0.5 
millilitres (ml) for ease of handling. The sample was mixed thoroughly by vortexing for 
a minimum of 30 seconds to ensure adequate cellular disruption. Chloroform (0.1 ml) 
was added and the sample shaken vigorously by hand for 15 seconds and then stored 
for three minutes at RT. The sample was then centrifuged at 12000 x g for 15 minutes 
at 4⁰C to separate the solution into an aqueous and organic phase. RNA remains 
exclusively in the aqueous phase. The upper aqueous phase was transferred, mixed 
with 0.25 ml of ice-cold isopropyl alcohol to precipitate the RNA and 20 nanograms of 
glycogen (to help pellet visualisation), gently mixed by hand and then stored overnight 
at -20⁰C.  Following this overnight incubation, the solution was centrifuged to allow the 
RNA to collect as a pellet on the side of the tube. The prior addition of glycogen 
improves visualisation of the pellet. The supernatant was discarded, taking great care 
not to disturb the pellet, which was then washed twice with 75% ethanol and allowed to 
air dry for 10-15 minutes, before re-suspending in DNA free master mix (Ambion); 2µl 
10x DNase 1 buffer, 1µl rDNase 1, and 17µl nuclease free water per sample. The 
mixture was then incubated at 37⁰C for 1 hour. 2µl of DNase inactivation reagent was 
added, mixed by vortexing, stored at RT for 2 minutes, vortexing once. The reaction 
was then centrifuged at 13000 x g for 1.5 minutes, and the supernatant was 
transferred to fresh tubes, the RNA content measured by the Nano-drop method (see 
section 2.3.3.5), and then stored at -80⁰C. 
 
2.3.3.5  Quantification of RNA 
The quantity of RNA in a sample may be accurately quantified using the Nano-drop 
spectrophotometer (ND-1000, Thermo Scientific, Wilmington, USA). This allows a 
further normalisation step to be introduced prior to reverse transcription. 
1µl of the RNA solution was removed and placed in 9µl nuclease free water to give a 
1:10 dilution. 1µl of this sample was pipetted onto the lower measurement pedestal, 
the sampling arm closed and a spectral measurement made. The Nano-drop calculates 
absorbance at wavelength 260 nanometres (nm) and 280 nm. This allows 
quantification of total RNA (at 260nm) measured in nanograms per microliter (ng/µl). 
Using a ratio of the absorbance at 260nm and 280nm allows assessment of the purity 
of RNA, with a ratio of 1.8 or above indicating acceptable purity. A lower ratio may Dr CPC Boger  Methodology of laboratory studies 
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indicate contamination with protein, phenol or other contaminants strongly absorbing 
at or near 280nm. 
 
2.3.3.6  Positive control for assessment of gene expression assays and as 
experimental calibrator 
A population of mixed granulocytes was chosen due to known expression of all of the 
genes of interest in this cellular type. Granulocytes were isolated from whole blood of 
healthy subjects. The detailed protocol may be found in the appendix C. In summary, 
whole blood was taken by phlebotomy from a willing volunteer and added to a 
collection tube with the addition of acetyl dextran solution. 15 ml of dextran were then 
added to this mixture and allowed to sediment for 60 minutes at RT. The separated 
plasma layer was removed and placed in a fresh tube, and the red cells discarded. 
Plasma was spun at 1150 x g for 12 minutes at RT. The supernatant was removed and 
a smear taken for a cell count before placing the sample in 4 ml of TRIzol reagent, and 
stored at -20⁰C until RNA extraction (as previously described in section 2.3.3.4). 
 
2.3.3.7  Generation of copy DNA for real time PCR reaction - Reverse transcription PCR 
Two methods of reverse transcription were used. It was only possible to extract small 
quantities of RNA from laser dissected tissue, so reverse transcription with a pre-
amplification step was incorporated. Higher yields of RNA were obtained from 
granulocytes and thus a pre-amplification step was not needed. 
 
2.3.3.8  Reverse transcription of granulocyte RNA 
2.3.3.8.1  Primer reaction Setup 
Reverse transcription was performed on 1 µg of total RNA isolate using the ImPromII™ 
RT-PCR kit (Promega, Southampton, UK). All reverse transcription reaction set-ups 
contained positive (Kanamycin RNA), reverse transcription negative (RT-ve) and water 
controls (no-template control) to control for reagent failure, internal and external 
genomic DNA contamination respectively. Firstly, the RNA template and primers were 
mixed, as shown in table 2-A, in 0.2 ml PCR tubes and denatured at 70°C for five 
minutes on a thermal cycler to remove secondary RNA structures, facilitating 
random/oligo dT primer annealing. At the end of the denaturing step the sample tubes 
were immediately placed on ice. 
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Reagents 
Positive 
Control 
Reaction 
Negative (no-
template) Control 
Reaction 
Experimental/ 
RT-ve Reaction 
1.2kb Kanamycin Positive 
control RNA (1 µg) 
2 µl  -  - 
Experimental RNA (0.2 
µg/reaction)   
-  -  4 µl 
Oligo(dT)
15 Primer (0.5 
µg/reaction)   
1 µl  -  - 
Random Primer (0.5 
ng/reaction) 
-  1 µl  1 µl 
Nuclease-Free Water  2 µl  4 µl  - 
Final Volume  5 µl  5 µl  5 µl 
 
Table 2-A: RT-qPCR Primer reaction set up table 
 
2.3.3.8.2  RT-qPCR master mix Setup 
15 µl RT-qPCR master mixes were made up as shown in table 2-B and added to the 5 µl 
Primer/template mixes, mixed by flicking the tubes and spun down in a bench-top 
mini-centrifuge. 
 
Reagents 
Positive 
Control 
Reaction (µl) 
No RT Control 
Reaction (RT-ve) 
(µl) 
Experimental/No-
template Control 
Reaction (µl) 
Nuclease-Free water 
(to final volume of 15 µl) 
4.2  8.8  7.3 
5 x ImPromII™ Reaction 
buffer 
4.0  4.0  4.0 
MgCl
2 (Final conc. 1.5 mM)
   
4.8  1.2  1.2 
dNTP mix    1.0  1.0  1.0 
RNasin Ribonuclease 
Inhibitor (20 U)   
0.0  0.0  0.5 
ImPromII™ reverse 
transcriptase   
1.0  0.0  1.0 
Final Volume    15.0  15.0  15.0 
 
Table 2-B: RT-qPCR master mix set up table Dr CPC Boger  Methodology of laboratory studies 
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The tubes were transferred to a thermal cycler and heated to 25°C for 5 minutes, 42°C 
for 1 hr, 70°C for 15 minutes and then finally cooled and held at 20°C. The copy DNA 
(cDNA) samples were then stored at 
-20°C ready for use as templates in RT-qPCR 
reactions. 
 
2.3.3.9  Pre-amplification of RNA isolated by laser capture 
The Roche Lightcycler
® RNA pre-amplification kit (Roche Diagnostics Ltd, Burgess Hill, 
UK) allows amplification of RNA, starting with 5 to 50 ng total RNA, to produce 
microgram quantities of cDNA that can then be used in a quantitative PCR reaction. It 
utilises Ribo-SPIA
® technology which facilitates linear, isothermal amplification of total 
RNA. Linear amplification maintains the relative representation of each transcript 
species across samples after amplification. This is achieved by replicating only the 
original cDNA from RNA transcripts (not copies of cDNA copies). In addition the rate of 
replication is consistent for each transcript from sample to sample, thus the 
differential expression of transcripts after amplification reflects the differential 
expression of transcripts in the original starting materials. 
 
2.3.3.9.1  Generation of first strand cDNA 
First strand cDNA was first prepared from total RNA using the first strand primer mix 
(DNA/RNA chimeric primer mix) and transcriptor reverse transcriptase. The primers 
have a DNA portion that hybridizes either to the 5´- portion of the poly (A) sequence 
or randomly across the transcript. Reverse transcriptase extends the 3´- DNA end of 
each primer generating first strand cDNA. The resulting cDNA/RNA hybrid molecule 
contains a unique RNA sequence at the 5´- end of the cDNA strand. 
 
A total of 5µl of RNA isolate was used, normalised to 5ng/µl. The first strand transcript 
enzyme mix was briefly spun on a desktop centrifuge and placed on ice. First strand 
buffer mix and first strand primer mix were thawed at RT, vortexed for two seconds, 
spun and placed on ice. Two µl of the first strand primer mix was added to 5µl of 
normalised sample, spun for two seconds and returned to ice. Tubes were then placed 
in a pre-warmed thermal cycler and incubated at 65⁰C for five minutes, cooled to 4⁰C 
and then placed on ice. First strand master mix was prepared by combining 2.5µl of 
buffer mix per sample with 0.5µl of transcript enzyme mix per sample, mixed by 
pipetting and spun down briefly and placed on ice. A reverse transcriptase negative 
control was included in each reaction, substituting at this point nuclease free water for 
the transcript enzyme mix. 3µl of first strand master mix was then added to each tube, 
mixed by pipetting three times, and spun. The mixture was then placed in a pre-cooled 
thermal cycler program to run at 4⁰C for one minute, 25⁰C for ten minutes, 48⁰C for 
ten minutes, 95⁰C for five minutes, cooled to 4⁰C, spun for two seconds and placed on 
ice. Dr CPC Boger  Methodology of laboratory studies 
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2.3.3.9.2  Generation of a DNA/RNA Hetero-duplex Double Strand cDNA 
Fragmentation of the RNA within the cDNA/RNA complex creates priming sites for DNA 
polymerase to synthesize a second strand, which includes DNA complementary to the 
5´- unique sequence from the first strand chimeric primers. The result is a double 
stranded cDNA with a DNA/RNA hetero-duplex at one end. 
 
The second strand enzyme mix and the enhancement enzyme mix were spun for two 
seconds and placed on ice. Second strand buffer mix was thawed at RT, vortexed for 
two seconds, spun for two seconds, and then placed on ice. The second strand master 
mix was prepared by combining 9.75µl of second strand buffer mix per sample with 
0.25µl of enzyme mix per sample, mixed by pipetting and spun down briefly and 
placed on ice. 10µl of second strand master mix was added to each first strand 
reaction tube, mixed by pipetting three times, spun for two seconds placed on ice. The 
reaction was then transferred to a pre-cooled thermal cycler to run at 4⁰C one minute, 
25⁰C ten minutes, 50⁰C thirty minutes, 70⁰C five minutes, cooled to 4⁰C, spun for two 
seconds and then placed on ice. 
 
The second strand enhancement master mix was prepared by combining 1.85µl of 
second strand buffer mix per sample with 0.15µl of enhancement enzyme mix per 
sample, mixed by pipetting, spun and placed on ice. 2µl of this master mix was then 
added to each reaction tube, mixed by pipetting three times, spun for two seconds and 
placed on ice. The reaction was then transferred to a pre-cooled thermal cycler to run 
at 4⁰C for one minute, 37⁰C for fifteen minutes, 80⁰C for twenty minutes, cooled to 
4⁰C, spun for two seconds and then placed on ice. 
 
2.3.3.9.3  Ribo-SPIA® Amplification 
SPIA
® amplification is a linear isothermal DNA amplification process that uses a SPIA
® 
DNA/RNA chimeric primer, DNA polymerase and RNase H in a homogeneous 
isothermal assay that provides highly efficient amplification of DNA sequences. RNase 
H is used to degrade RNA in the DNA/RNA heteroduplex at the 5´- end of the first 
cDNA strand. This results in the exposure of a DNA sequence that is available for 
binding a second SPIA
® DNA/RNA chimeric primer. DNA polymerase then initiates 
replication at the 3´- end of the primer, displacing the existing forward strand. The 
RNA portion at the 5´- end of the newly synthesized strand is again removed by RNase 
H, exposing part of the priming site for initiation of the next round of cDNA synthesis. 
The process of SPIA
® DNA/RNA primer binding, DNA replication, strand displacement 
and RNA cleavage is repeated, resulting in rapid accumulation of cDNA with sequence Dr CPC Boger  Methodology of laboratory studies 
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complementary to the original RNA. An average amplification of 1,500-fold is observed 
with 5ng starting total RNA. 
 
SPIA DNA/RNA chimeric primer and buffer mix were thawed to RT, vortexed for two 
seconds, spun for two seconds and placed on ice. SPIA enzyme mix containing DNA 
polymerase and RNase H was thawed on ice, mixed by inverting gently five times, spun 
for two seconds and then placed on ice. The SPIA master mix was prepared by 
combining 5µl of the buffer mix with 5µl of primer mix and 10µl of enzyme mix, per 
reaction. This was mixed by pipetting, spun, and placed on ice. 20ul of SPIA master 
mix was added to the enhanced second strand reaction, mixed by pipetting six to eight 
times, spun for two seconds, and placed on ice. The reaction was then transferred to a 
pre-cooled thermal cycler to run at 4⁰C for one minute, 47⁰C for one hour, 95⁰C for 
five minutes, cooled to 4⁰C, spun for two seconds, diluted 1:10, and stored at -20⁰C 
until needed. 
 
2.3.4  Real time quantitative PCR 
2.3.4.1  Real-time PCR reaction 
Eurogentec qPCR Mastermix was used for all 6-FAM™ labelled TaqMan
® MGB probes, 
and Precision
™ 2x qPCR Mastermix with SYBRgreen for PrimerDesign supplied primers. 
Reagents were thawed, mixed by inversion, spun down and then placed on ice. The 
reaction mix was prepared as follows and mixed thoroughly by inversion and spun 
down: 
 
Reagent  Volume per reaction 
2x Mastermix reaction buffer (+/- SYBRgreen)  10µl 
20x gene expression assay or Primer  1.0µl 
dH
2O  4.0µl 
Total  15µl 
 
15µl of reaction mix followed by 5µl of sample template cDNA was pipetted to each 
well. Each reaction was replicated in triplicate. The plate was sealed, mixed and spun 
down. The real time thermal cycler was programmed as follows: 
 
Step  Cycle  Temperature  Time 
Taq activation  1  95⁰C  10 minutes 
Quantification  40  95⁰C 
60⁰C 
15 seconds 
1 minute 
Cooling  1  50⁰C  30 seconds 
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2.3.4.2  Gene expression assays 
Applied Biosystem (Warrington, UK) supplied pre-designed gene expression assays to 
target genes of interest during RT-qPCR, with the exception of PTPRC. Each gene 
expression assay contains two unlabelled primers and one 6-FAM™ dye-labelled, 
TaqMan
® MGB probe. The gene expression assays used are summarised in table 2-C, 
with the following criteria used to select the appropriate pre-designed assay: 
 
a)  Primers targeting the region encompassing the final two exons were preferred. 
This was to avoid polymorphisms and splice variants which tend to occur towards 
the beginning of the coding sequence. 
b)  Primers crossing boundaries were preferred due to their specificity for mRNA. 
c)  GenBank, a depository of nucleic acid sequences, was cross referenced for all the 
primers, with a higher number of GenBank mRNA transcripts preferred. This helps 
to avoid splice variant gene expression. 
d)  Length of primer can affect the efficiency of the PCR reaction, and therefore shorter 
primer lengths were preferred. 
e)  A literature search on OVID Medline was undertaken to search for previous work on 
the target genes under investigation, and to aid targeting of the most reliable area 
of the coding region of interest. 
 
Applied Biosystem (Warrington, UK) supplied pre-designed gene expression assays to 
target genes of interest during RT-qPCR, with the exception of PTPRC. Each gene 
expression assay contains two unlabelled primers and one 6-FAM™ dye-labelled, 
TaqMan
® MGB probe. 
The primer to target Protein tyrosine phosphate receptor type C (PTPRC; RefSeq 
interrogated sequence - NM_002838) was obtained from PrimerDesign (Southampton, 
UK). The assay length was 111 and had the following sense primer: 
GAACAAGCATCACAAGAGTACAC, 
and antisense primer: TCTTCTGTTTCCGCACTTTCTAA. Dr CPC Boger  Methodology of laboratory studies 
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Table 2-C: Summary of gene expression assays used in real time RT-qPCR experiments 
Gene Name  Gene 
Symbol 
Chromosomal (Chr.) location of 
interrogated gene 
Interrogated 
sequence (RefSeq) 
Number of 
GenBank mRNA 
Spans 
exon? 
Amplicon 
size 
Arachidonate 5-lipoxygenase  ALOX5 
Chr. 10 
45240414-45244218 
NM_000698.2  8  Y  61 
Arachidonate 5-lipoxygenase 
activating protein 
ALOX5AP 
Chr. 13 
30228081-30236556 
NM_001629.2  1  Y  80 
Leukotriene A4 hydrolase  LTA4H 
Chr. 12 
94924223-94927057 
NM_000895.1  7  Y  109 
Leukotriene C4 synthase  LTC4S 
Chr. 5 
179153592-179155290 
NM_145867.1  4  Y  80 
Leukotriene B4 receptor 1  LTB4R 
Chr. 14 
23852357-23855992 
NM_181657.1  1  Y  76 
Cysteinyl leukotriene receptor 1  CYSLTR1 
Chr. X 
77414786-77425693 
NM_006639.2  4  Y  128 
Glyceraldehyde-3-phosphate 
dehydrogenase 
GAPDH 
Chr. 12 
6643657-6647536 
NM_002046.3  121  Y  93 
Beta Actin  ACTB 
Chr. 7 
5566779 -5570232 
NM_001101.3  128  Y  139 
Hypoxanthine phosphoribosyl-
transferase 1 
HPRT1 
Chr. X 
133594175 - 133634698 
NM_000194.2  7  Y  100 
Eukaryotic 18S ribosomal RNA  18S  NA  X03205.1  NA  NA  187 Dr CPC Boger  Methodology of laboratory studies 
 
 
2.3.4.3  Validation of gene expression assays 
A number of problems may occur during the PCR reaction which can affect the 
reliability and efficiency of each experiment. This includes formation of primer/dimers, 
probe degradation, template contamination, and non-specific amplification due to mis-
priming or non-specific probe binding. To assess this, efficiency was calculated and 
melt curve experiments performed on each gene expression assay. 
 
2.3.4.3.1  PCR efficiency 
The slope of the standard curve represents the efficiency of the PCR amplification 
reaction, and is numerically represented by the formula: efficiency = 10
-1/slope. An 
efficiency of 2 represents the perfect PCR reaction, which corresponds with a doubling 
of target nucleic acid for each cycle. The error is also calculated, which is a measure of 
the accuracy of the standard curve for quantification, with an acceptable value of below 
0.2. The efficiency and error were calculated for each gene expression assay. A 
titration series of granulocytes was made from 25ng/µl to 6.10e
-03 ng/µl, diluting four-
fold each time. This dilution series was then combined with master mix and each of 
the gene expression assays to give a titration series suitable for standard curve 
formation.  
 
2.3.4.3.2  Melt curve analysis 
Analysis of the temperature at which the cDNA binds and separates allows us to assess 
the performance of the gene expression assays. In melt curve analysis, the amplified 
PCR product is gradually heated through a range of temperatures (e.g., from 65°C to 
95°C) and SYBR green fluorescence is continuously measured. Only a single peak, 
which represents the specific PCR product, should be observed. The presence of other 
peaks indicates the presence of primer–dimers and/or nonspecific PCR products. A 
melt curve experiment was undertaken for each gene expression assay. 
1µl of SYBR green dye was added to the PCR reaction mix of each of the titration series 
of granulocytes (described above), mixed by vortexing, and then the following 
experiment performed on the thermal cycler. 
 
Step  Cycle  Temperature  Time 
Denaturation  1  95⁰C  5 seconds 
Annealing  1  60⁰C  5 seconds 
Melt curve analysis  1  65⁰C-95⁰C  4.8⁰C/sec 
Cooling  1  50⁰C  15 seconds 
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2.3.4.4  Housekeeping genes 
Selection of a valid normalisation or endogenous control to correct for differences in 
RNA sampling is critical to avoid misinterpretation of results. The ideal endogenous 
control should have a constant RNA transcription level under different experimental 
conditions and be sufficiently abundant across different tissues and cell types. It is 
recognised that the use of one housekeeping gene is insufficient (Vandesompele et al. 
2002). The following pairs of housekeeping genes were assessed: Eukaryotic 18S 
ribosomal RNA (18s), Hypoxanthine phosphoribosyltransferase 1 (HPRT1), 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and Beta Actin (ACTB). 
 
18s is a highly abundant ribosomal RNA and has previously been demonstrated to have 
good consistency across tissue types (Lossos et al. 2003). GAPDH and ACTB are 
commonly used and have previously been used in experiments using squamous, 
Barrett’s and oesophageal adenocarcinoma tissue (Konturek et al. 2004; Vallbohmer et 
al. 2006; von Rahden et al. 2008). In a study assessing housekeeping gene variability 
in a variety of cancerous and normal tissues, GAPDH, ACTB, and 18s, showed very little 
variability, in particular, between oesophageal squamous and carcinoma tissue (Rubie 
et al. 2005). De Kok et al. assessed 11 different housekeeping genes across a variety 
of tumour types. The authors found HPRT1 to be the least variable single gene, and 
recommended it for future cancer research (de Kok et al. 2005). 
 
Quantitative PCR was performed with the selected housekeeping genes, as previously 
described, on cDNA from a representation of tissue types: Squamous and Barrett’s 
stroma, Barrett’s epithelium, OA (mixed cellular type), and granulocytes. All were 
performed in triplicate. The difference in average crossing point value of each sample 
from each housekeeping gene expression assay of interest was calculated. The 
difference between the maximum and minimum ratio was then calculated to give the 
potential –fold difference in values (doubling of product for every cycle). A high value 
is interpreted as a large variation between pairs of housekeepers in the different tissue 
types, and thus unreliable. The pair with the lowest value was chosen for use in the 
final analysis. 
 
2.3.4.5  Analysis of the purity of laser captured epithelial cell populations 
PTPRC gene is known to be expressed exclusively in cells of haematopoietic origin with 
the exception of erythrocytes. The expression of the PTPRC gene was assessed in laser 
captured samples of epithelial area of tissue, to assess the purity of these cell 
populations. 
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2.3.4.6  Controls 
A reverse transcription negative control and a no template (nuclease free water) were 
included in each run. 
 
2.3.4.7  Relative quantification of samples using the E-method 
Relative quantification of gene expression was used to quantify differences in the 
expression level of the target genes between the different samples of tissue. The 
quantity of the target gene and the reference (housekeeping) genes within the same 
sample were determined, and results expressed as a ratio. By calculating the ratio in 
this way one can correct for differences in quality and quantity between samples, 
caused by, for example, variations in cDNA synthesis efficiency. A calibrator 
(granulocytes) was included in each separate real time qPCR reaction enabling 
normalisation for run to run differences. The final result was expressed as a 
normalised ratio and is summarised by the following equation: 
 
 
 
 
In addition, rather than assuming an efficiency of two for each target gene (which can 
produce incorrect gene expression data), standard curves and efficiencies generated 
during the validation experiments were used. 
 
   
Normalised ratio  =   conc. of target  :  conc. of target 
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  Statistical analysis and choice of statistical test  2.4
Statistical tests were performed with PASW Statistics version 18 for Windows (IBM UK 
Ltd, Middlesex, UK). For each dataset a histogram was plotted to assess distribution, 
and skewness and standard error of skewness calculated. Skewness is a measure of the 
asymmetry of a distribution. If the actual value of skewness falls outside plus or minus 
twice the standard error of skewness, then the distribution is said to be significantly 
skewed. If datasets were non-parametric then values were log
10-transformed and tests 
of Normality repeated. 
 
Unpaired Student’s t-tests were then used for comparison between groups on original 
or log
10-transformed values as appropriate, dependent on the data distribution 
determined by Normality testing. Equal variance was not assumed. 
 
Counts of cells immunopositive for each 5-LOX pathway protein were also correlated 
with counts of neutrophils, eosinophils, monocyte-macrophages and T-lymphocytes) 
using Pearson’s correlation coefficient. 
 
For laser captured samples, where only small numbers of samples were present in each 
group, the Mann-Whitney-U was utilised. 
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CHAPTER 3:   Cost-utility analysis 
 
 
In this chapter the methodology for the cost-ultility analysis is presented. The aim of 
this study was to assess whether radiofrequency ablation (RFA) of Barrett’s metaplasia 
(BM) containing high grade dysplasia (HGD) is a cost-effective alternative in the UK 
compared with oesophagectomy. Section 3.1 reviews existing cost-effective analyses 
on ablative therapies for BM. The research question is defined in detail in section 3.2 
using the PICO framework and section 3.3 documents the construction of a decision 
analytic model. A purposive review of the literature to identify parameters for use in 
the cost-utility analysis is found in sections 3.4 (transition probabilities) and section 
3.5 (utilities). The calculated costs are presented in section 3.6 and methods for 
deterministic and probabilistic analysis in section 3.7. 
 
  Review of Existing cost-effective analyses on ablative  3.1
therapies for Barrett’s metaplasia 
 
Prior to this thesis two techniques for ablating BM had been the subject of cost-
effectiveness studies; RFA and photo-dynamic therapy (PDT). 
 
3.1.1  Radiofrequency Ablation 
Das et al. (2007) used a Markov model to compare the cost-effectiveness of the 
following strategies in a 50 year old with non-dysplastic BM: (i) no intervention (natural 
history), (ii) surveillance alone, (iii) RFA. The model was run until death of the entire 
cohort. It is not clear how parameters, costs and utilities were chosen. They used an 
estimate of 50% for complete removal of intestinal metaplasia (CR-IM) for RFA, lower 
than the published studies have reported.  The discount rate was not stated. RFA 
resulted in an additional 0.42 quality adjusted life years (QALYs) at a cost of $46882 
compared with no intervention, and 0.14 QALYs at a cost of $69270 compared with 
surveillance alone. They concluded that patient age, cost of RFA, and CR-IM were 
critical determinants of the cost-effectiveness of RFA. 
 
Inadomi et al. (Inadomi et al. 2007) used a Markov model to compare the cost-
effectiveness of the following strategies in a 50 year old with low-grade dysplasia (LGD) 
in BM: (i) no intervention, (ii) surveillance, (iii) oesophagectomy, and (iv) RFA. It is not 
clear how parameters, costs, and utilities were chosen. The discount rate was not 
stated. RFA was the most cost-effective strategy resulting in an additional 1.8 QALYs at 
an incremental cost of $9842 compared with no intervention, 0.89 QALYs at an Dr CPC Boger  Cost-utility analysis 
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incremental cost of $2376 compared with surveillance. Oesophagectomy was 
eliminated through dominance. The incremental cost-effectiveness ratio (ICER) was 
$5468/QALY versus no intervention, and $2669/QALY versus surveillance. 
 
3.1.2  Photodynamic therapy 
Three cost-effective analyses were identified assessing other management options for 
HGD in BM. They were all undertaken prior to the introduction of RFA as a treatment 
option. 
 
Hur et al. (2003) constructed a Markov model to compare the cost-effectiveness of the 
following strategies in a 55 year old male with HGD in BM: (i) PDT with surgical 
oesophagectomy, (ii) intensive surveillance strategies. The model was run until death 
of the entire cohort. There was no literature review supporting selection of the 
parameters. Utilities were derived from patients using visual analogue scales (VAS), 
which are associated with measurement biases (Drummond et al. 2005). Costs were 
derived from United States (US) estimates. They used a discount rate of 30% (the NICE 
reference case recommends 3.5%). PDT was the most cost-effective strategy resulting 
in an additional 1.65 QALYs at a cost of $20,400 compared to surveillance, and 2.17 
QALYs at a cost of $7,100 compared to oesophagectomy. The ICER was $12,400/QALY 
versus surveillance, and $3,300/QALY versus oesophagectomy. 
 
Vij et al. (2004) constructed a Markov model to compare the cost-effectiveness of the 
following strategies in a 55 year old male with HGD in BM: (i) surveillance, (ii) 
oesophagectomy, (iii) PDT followed by oesophagectomy for residual HGD, (iv) PDT 
followed by surveillance for residual HGD. The model was run until death of the entire 
cohort. Parameters were obtained from a structured review of the literature. The 
majority of utility values were estimated by the authors. Costs were from US estimates 
from a 3
rd party payer perspective. They used a discount rate of 3%. PDT followed by 
surveillance was the most cost-effective strategy resulting in an additional 0.49 QALYs 
at an incremental cost of $23255. The ICER was $47410/QALY, with surveillance and 
PDT followed by oesophagectomy for residual HGD eliminated through extended 
dominance. 
 
Shaheen et al. (2004) used a linear decision tree terminating in a Markov model (for 
those not undergoing oesophagectomy) to compare the cost-effectiveness of the 
following strategies in a 50 year old male with HGD in BM: (i) no surveillance, (ii) 
surveillance, (iii) oesophagectomy, (iv) PDT. The surveillance strategy was halted at 80 
years of age or death, but it is unclear what the time horizon was after this for the 
other strategies. It is unclear how the parameters were chosen. Utilities were derived Dr CPC Boger  Cost-utility analysis 
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from patients using VAS. Costs were from US estimates from a 3
rd party payer 
perspective. They used a discount rate of 3%. PDT was the most effective strategy 
resulting in an additional 1.61 QALYs at an incremental cost of $41250 compared with 
no surveillance. The ICER was $25621, with oesophagectomy dominated by no 
preventative strategy, and surveillance eliminated through extended dominance. 
 
3.1.3  Summary 
Although some parallels between the Markov models used in the PDT cost-
effectiveness studies can be drawn to ours, the detail on the precise health states used 
is difficult to ascertain from the studies, and thus it was appropriate that a new model 
was constructed. Only Vij et al. (2004) conducted a structured review of the literature 
to ascertain transition probabilities, with the majority of health states estimated by the 
authors. Further data may be available and thus a literature search was conducted. 
 
  Defining the research question  3.2
 
The PICO framework (Richardson et al. 1995) was used to define the research question 
in more detail. 
 
3.2.1  Population 
The model consisted of a hypothetical cohort of 100 male patients aged 64 years, the 
mean age of patients undergoing oesophagectomy for HGD in published trials over the 
last 10 years (Nigro et al. 1999; Patti et al. 1999; Nguyen et al. 2000; Zaninotto et al. 
2000; Headrick et al. 2002; Tseng et al. 2003; Reed et al. 2005; Sujendran et al. 2005; 
Chang et al. 2006; Prasad et al. 2007; Williams et al. 2007). BM is predominantly a 
disease of men with a male to female ratio of approximately 9:1 and therefore it is 
appropriate that the cohort contained male patients only (Blot et al. 1991).  The 
following pre-treatment assessment was assumed for both strategies: endoscopy had 
been undertaken on two occasions revealing BM with HGD, and any visible nodules, 
masses or surface irregularities had been removed by endoscopic mucosal resection 
(EMR). Patients found to have OA after EMR were excluded from the analysis. It was 
assumed that patients were fit for both treatment modalities. The model included 
patients with either uni- or multifocal HGD. 
 
3.2.2  Intervention 
A number of management strategies for treating HGD in BM exist in the UK. In the UK, 
surveillance of those with HGD is not presently undertaken. The review of previous 
cost-effective analyses suggested that PDT was an expensive although effective 
treatment option for BM (see section 3.1.2). However, in the UK RFA is rapidly Dr CPC Boger  Cost-utility analysis 
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superseding PDT, as PDT is associated with treatment-related adverse events in up to 
94%, a stricture rate as high as 37%, and ultimate progression to cancer in 15% 
(Overholt et al. 2005; Overholt et al. 2007). Although PDT is still practiced, and newer 
photosensitising agents are under investigation, RFA has clinically become the method 
of choice for ablating Barrett’s oesophagus; thus PDT is not included in the model (see 
section 1.8). 
 
3.2.3  Comparator 
Current UK guidance recommends that for patients with persistent HGD despite 
intensive acid suppression, oesophagectomy be performed in a specialist centre in 
those fit for surgery (Watson et al. 2005). Oesophagectomy is therefore the comparator 
as it constitutes the “gold standard” treatment in the UK. It was assumed that patients 
are fit for both treatment modalities, although it is acknowledged that some will be fit 
for RFA, but not oesophagectomy. 
 
3.2.4  Outcomes 
In line with the NICE reference case a cost utility analysis was used to analyse the cost-
effectiveness of radiofrequency ablation. A de novo model was constructed, and the 
following outcomes ascertained: 
Primary 
•  Cost/incremental cost 
•  Effectiveness measured in QALY/incremental effectiveness 
•  IECR 
•  Cancer incidence 
•  Complication incidence 
•  Mortality and survival 
Secondary 
•  Deterministic sensitivity analysis - to identify key data points associated 
with uncertainty 
•  Probabilistic sensitivity analysis - to explore the uncertainty surrounding the 
input parameters. 
 
  Construction of a decision analytic model  3.3
 
3.3.1  Model overview 
The model was constructed to include major procedural and post-procedural 
complications and mortality as suggested by review of the literature. At the end of 
each cycle, which corresponded to 6 months, patients progress to a health state 
depending on the derived transition probabilities. A utility and cost was attributed to Dr CPC Boger  Cost-utility analysis 
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each state, which patients would accumulate as they progressed through the model. 
The analysis followed the cohort for 25 years or to death. Costs were estimated from 
an NHS perspective and outcomes from the viewpoint of the patient. All costs and 
benefits were discounted at 3.5% as recommended by NICE (2008). 
 
3.3.2  Explanation of model and health states 
3.3.2.1  Treatment strategy - Oesophagectomy 
In this strategy, patients with confirmed HGD in BM underwent immediate 
oesophagectomy. A transition state diagram for the oesophagectomy strategy is 
illustrated in figure 3-A. 
 
 
 
Figure 3-A: Transition state diagram (Markov model) of oesophagectomy strategy 
The health states are shown with arrows showing how patients can progress between 
states at the end of each cycle. 
 
3.3.2.1.1  Complicated/Uncomplicated oesophagectomy 
Patients may suffer significant complications from oesophagectomy requiring an 
intensive care unit stay, increasing cost and reducing quality of life. Complications 
were defined as those requiring an intensive care unit stay, and included anastamotic 
leaks, respiratory distress, significant wound infections or dehiscence, cardiac 
arrhythmia, and delirium. 
 Dr CPC Boger  Cost-utility analysis 
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3.3.2.1.2  Anastamotic stricture/No stricture 
The literature demonstrates that post-operative anastamotic strictures are a significant 
problem in the first year post oesophagectomy (Headrick et al. 2002). Patients 
remained in this health state for two cycles to represent this. 
 
3.3.2.1.3  Well post oesophagectomy and progression to terminal cancer 
There are no further treatment options available if a patient develops recurrent OA 
post oesophagectomy. In this scenario it was assumed that they entered a 6-month 
terminal cancer phase, representing the median survival time with inoperable 
oesophageal cancer, and allowing the modelling of costs and measures of quality of 
life experienced by this group of patients, such as palliation of dysphagia with 
oesophageal stenting. Conversely, if a patient did not progress to terminal cancer 
during the first 5 years post-oesophagectomy then they were considered cured. 
 
3.3.2.2  Treatment strategy - Radiofrequency ablation 
In this strategy, patients with confirmed HGD in BM underwent a treatment course of 
RFA with the HALO device (Bârrx Medical, Sunnyvale, California, USA), as described in 
section 1.8.3. Published experience to date suggests an average of one HALO
360 and 
two HALO
90 sessions are needed per patient to achieve complete removal of the 
Barrett’s segment and replace it with a neo-squamous lining in patients with HGD 
(Gondrie et al. 2008a). A transition state diagram for the RFA strategy is illustrated in 
figure 3-B. 
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Figure 3-B: Transition state diagram (Markov model) of RFA strategy 
The health states are shown with arrows showing how patients can progress between 
states at the end of each cycle. 
 
3.3.2.2.1  Uncomplicated RFA, stricture or perforation 
Patients undergoing RFA may experience an oesophageal perforation, and in the model 
it was assumed that they either died or underwent an immediate oesophagectomy. In 
clinical practice, perforation may be treated medically, but given that the patient has 
an unknown histological outcome from RFA with the possibility of persistent HGD, 
oesophagectomy is likely to be the treatment option of choice. 
 
It was assumed that patients experiencing a stricture will either die or progress to one 
of the RFA outcome states (neo-squamous, Barrett’s, persistent HGD). In practice this 
group may develop a perforation as a complication of oesophageal dilatation, but the 
risk of this is low (Quine et al. 1995). This risk is excluded from the oesophagectomy 
model, to ensure equality between groups. 
 
3.3.2.2.2  Surveillance strategy for post RFA health states (squamous or BM) 
Currently, there is no fixed surveillance strategy for patients with neo-squamous and 
BM post-RFA. For the base case analysis the following strategy was assumed: if neo-
squamous oesophagus is found after RFA, then yearly endoscopy was performed for 5-
years, and if free of BM or worse pathology after that time, no further endoscopic 
follow-up was undertaken. If the patient had BM after RFA treatment then yearly 
Death 
from all 
states 
except RFA
RFA
Uncomplicated 
RFA
Stricture Perforation
Squamous Barrett’s HGD/OA
Oesophagectomy
Complicated 
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endoscopy was performed for the first 5-years, and if free of HGD or worse at that 
time, endoscopic surveillance continued on a 2-yearly basis as per current UK practice. 
In the scenario analysis this screening protocol was altered to analyse what effect it 
would have on the outcome of the cohort. 
 
If HGD or OA is picked up during the surveillance strategies, it was assumed the 
patient undergoes an oesophagectomy. This part of the RFA model has the same 
structure as the oesophagectomy strategy. It was assumed that the risk of developing 
cancer in the neo-squamous oesophagus is most probable during the first 5-years post 
treatment, and thus after this period (as with the post oesophagectomy group), the 
patient was considered cured. 
 
3.3.2.2.3  Treatment failure – HGD/OA post RFA 
There are no data on the outcome of those with treatment failure post RFA. For this 
parallels were drawn with data from other ablative therapies (PDT) with longer term 
follow up available. This demonstrates that treatment failures were still operable at 
time of progression, and revealed disease not extending beyond the submucosa (T1) 
on post-operative staging (Prasad et al. 2007). On this basis, in the model those with 
post RFA treatment failure had operable disease but with a reduction in 5-year survival 
consistent with the predicted more advanced disease. 
 
  Transition probabilities  3.4
 
3.4.1  Overview 
Parameter values for transition probabilities and utilities were obtained from peer 
reviewed literature. The Medline database from January 1999 to May 2009 was 
searched, as well as abstracts from Digestive Diseases Week and the British Society of 
Gastroenterology Annual Meeting. Bibliographic lists of relevant articles were searched, 
and in addition a list of relevant papers from the manufacturers of the HALO device 
was obtained. The most suitable study(s) were chosen to provide the parameters for 
the base case, by using data from randomised controlled trials if available. If not, 
available data were chosen from well-constructed observational (cohort) studies, with 
inclusion criteria similar to those in the required hypothetical cohort. Assessment was 
also made of inclusion criteria, baseline assessment, size, duration of follow-up, loss 
to follow-up and assessment of outcome. In addition to the base case values a 
plausible range (high/low values) was selected for use in the sensitivity analysis. This 
range was derived from variations in the published literature, or by consensus of four 
researchers when information was not available or there was considerable uncertainty 
in the literature. All transition probabilities used in the model are shown in table 3-A. Dr CPC Boger  Cost-utility analysis 
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Five key areas of where transition probabilities were required were identified: 
•  Oesophagectomy for HGD (section 3.4.1.1) 
•  Progression to terminal cancer after oesophagectomy for RFA treatment failure 
(section 3.4.1.2) 
•  Radiofrequency ablation for HGD (section 3.4.1.3) 
•  Progression post RFA (section 3.4.1.4) 
•  Mortality from oesophageal perforation or dilatation (section 3.4.1.5) 
Full search strategies may be found in the appendix D. 
 
3.4.1.1  Oesophagectomy for HGD 
Parameters required: 
i)  Oesophagectomy complications (peri-operative and anastamotic stricture) 
ii)  Mortality 
iii)  Progression to terminal cancer post oesophagectomy 
 
The search strategy identified 12 relevant studies. Of these six were excluded for the 
following reasons: 
•  Inclusion of patients with pre-operative diagnosis of OA (Nigro et al. 1999; 
Zaninotto et al. 2000; Romagnoli et al. 2003; Chang et al. 2006) 
•  Inappropriate cohort - assessment of specific surgical technique (Nguyen et al. 
2000), those with GORD only (Patti et al. 1999). 
 
i)  Oesophagectomy complications 
There were difficulties in ascertaining complication rates due to lack of definition in 
some studies as to the criteria used for inclusion as a complication. This may explain 
the wide variation in rate, although other factors such as surgical technique, and 
differences between centres, may also play a role. 
•  Peri-operative complications 
The study by Prasad et al. contains the largest cohort of patients over the most recent 
time frame (1994-2004), and has inclusion criteria similar to the cohort (i.e. HGD with 
pre-operative EMR as appropriate), and thus is used to form the base case. The studies 
by Tseng et al. (morbidity; 29%) and Headrick et al. (57%) represent the range of values 
found from the literature search and thus form low and high values respectively. 
•  Anastomotic stricture 
The study by Headrick et al. contains the most complete data on post oesophagectomy 
stricture formation (stricture rate; 51%) and is thus used to form the base case. The 
studies by Prasad et al. (12.6%) and Williams et al. (82%) represent the range of values 
found from the literature search and thus form low and high values respectively. Dr CPC Boger  Cost-utility analysis 
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ii)  Mortality 
The values found from the literature search for mortality from oesophagectomy for 
HGD were lower than expected with a range of 0-2%. To allow for this uncertainty a 
study by Portale et al. (2006) was included which examined mortality after 
oesophagectomy for oesophageal cancer, and found a mortality of 4.5%. This concurs 
with recently published national UK audit figures (available after the model was run), 
which demonstrate a 30-day mortality rate of 3.1% with a range of 2.0-4.5% (Palser et 
al. 2009). The study by Prasad et al. (2007) was chosen to form the base case for 
previously documented reasons. 
 
iii)  Progression to terminal cancer post oesophagectomy 
Only studies with adequate follow up were chosen and where actual numbers of 
patients were stated. The model takes into account age related mortality and thus data 
was extracted from the relevant studies so that 6-monthly transition probabilities could 
be calculated. Two studies had a follow up period of over 5-years (Headrick et al. 2002; 
Prasad et al. 2007). In the study by Headrick et al., four died from metastatic 
oesophageal cancer, and a further three from metastatic cancer from other primary 
sites. In the study by Prasad et al., two in the oesophagectomy group died from cancer 
(metastatic transitional cell and malignant astrocytoma) but none of oesophageal 
cancer, which is in contrast to the study by Headrick et al. and also the other two 
studies with reasonable follow up data (Tseng et al. 2003; Reed et al. 2005). The base 
case parameter was estimated to take account of this discrepancy in the literature. The 
studies by Prasad et al. (5-year survival; 100%) and Headrick et al. (92.9%) represent the 
range of values found from the literature search and thus form low and high values 
respectively. 
 
3.4.1.2  Progression to terminal cancer after oesophagectomy for RFA treatment 
failure 
As stated previously there are no data on the outcome of those with treatment failure 
post RFA, and this study assumed that patients undergoing oesophagectomy for RFA 
recurrence will have T1 disease. It was therefore necessary to conduct an additional 
literature search to identify survival data for those undergoing oesophagectomy for 
OA. 
The search strategy identified 12 relevant studies. Of these nine were excluded for the 
following reasons; 
•  No breakdown of survival by stage of tumour (Hofstetter et al. 2002) 
•  Inclusion of patients with squamous cell carcinoma (Mariette et al. 2004; Altorki 
et al. 2008; Pennathur et al. 2009) Dr CPC Boger  Cost-utility analysis 
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•  Follow up period insufficient (Johansson and Walther 2000) 
•  Insufficient data to calculate disease free survival (Stein et al. 2000; Hagen et al. 
2001; Hofstetter et al. 2002) 
•  Inappropriate cohort - assessment of specific surgical technique (Yamamoto et 
al. 2005), inclusion of patients whom they waited until had symptoms 
(Romagnoli et al. 2003) 
 
The study by Prasad et al. contains data from a cohort of patients who have undergone 
oesophagectomy after progression of their disease after PDT. It is thus a similar 
scenario to the model in this study and is the most appropriate for the base case 
parameter. The study by Portale et al. provided data from a large cohort who 
underwent oesophagectomy for adenocarcinoma of varying stages. The breakdown of 
data for those with T1 disease is used to form the high value. For the low value a 5-
year survival of 100% was assumed. 
 
3.4.1.3  RFA for HGD 
Parameters required: 
i)  Outcomes after RFA (squamous-lined oesophagus, Barrett’s oesophagus 
without HGD, HGD or OA). 
ii)  RFA complications (no complications, perforation, stricture requiring dilatation). 
The search strategy identified eight relevant studies. Of these four were excluded for 
the following reasons; 
•  Data included in more recent publication (Gondrie et al. 2008a; Gondrie et al. 
2008b)  
•  Observational data with no fixed end point and insufficient follow up (Ganz et 
al. 2008) 
•  Insufficient number with HGD (Roorda et al. 2007; Hernandez et al. 2008) 
 
i)  Outcomes after RFA 
The randomised control trial (RCT) by Shaheen et al. (Shaheen et al. 2009) is the 
highest quality study and thus data was extracted from this study to form the base 
case estimates of outcome after RFA treatment. The studies by both Pouw et al. (2008) 
and Sharma et al. (2009) are limited by their methodological design (observational, 
variation in inclusion criteria, different treatment modalities), but data representative 
of the cohort were extracted, and included to represent the uncertainty of outcome for 
Barrett’s health states post RFA. 
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ii)  RFA complications 
•  Stricture after RFA 
The RCT by Shaheen et al. (2009) is again chosen for its strength of methodological 
design. The study by Pouw et al. (2008) included a number of patients who had 
undergone extensive EMR which may explain the higher stricture rate. However, the 
model presented here allowed for prior EMR, and thus this higher figure of 9% is used 
to form the high value, with the low value (0%) derived from the study by Sharma et al. 
(2009). 
•  Perforation after RFA 
To date no oesophageal perforations have been documented in published trials. The 
manufactures of the HALO system were contacted directly for a summary of cumulative 
worldwide safety data. As of April 2009, eight perforations had occurred out of 
approximately 16000 patients treated with RFA worldwide. This parameter was 
therefore used to form the base case estimate and the high value, with the 0% 
perforation rate quoted in the published literature forming the low value. 
 
 
3.4.1.4  Progression post RFA 
Parameters required 
i)  Progression post RFA from neosquamous oesophagus to HGD/OA 
ii)  Progression post RFA from BM to HGD/OA 
 
A review of the studies identifying patients with HGD in BM undergoing RFA, 
demonstrated that there are no data available describing annual risk of HGD in 
patients after successful RFA therapy. Assumptions have thus been made based 
around known progression rates of those with treatment-naive BM. 
A systematic review was undertaken in 2006 as part of the health technology appraisal 
(HTA) report on surveillance in BM (Garside et al. 2006). Subsequently, an important 
additional study was published which reported data on the natural history of BM in the 
largest cohort of patients (n=618) published to date (Sharma et al. 2006). During the 
mean follow up of 4.12 years, 22 patients developed HGD resulting in an incidence of 
0.9%/year (95% confidence intervals, 0-1.7%). 
 
i)  Progression post-RFA from neosquamous oesophagus to HGD/OA 
The precise annual risk of development of HGD or cancer in a patient with neo 
squamous oesophagus post RFA or BM after eradication of HGD by RFA is not known. 
Results so far have suggested that up to 6.8% of patients may have areas of non-visible 
islands of intestinal metaplasia, termed sub-squamous IM, detected on random biopsy, 
despite an apparent lack of IM on endoscopic visualisation (Shaheen et al. 2008b). The Dr CPC Boger  Cost-utility analysis 
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concern is that these “hidden” areas of IM have a risk of progression to HGD/cancer at 
a later date. Adjustments to account for this were made. 
 
The risk of developing HGD or OA in patients with neo-squamous oesophagus was 
estimated using published data of having residual subsquamous intestinal metaplasia 
(Shaheen et al. 2009). The low value assumed no risk of residual subsquamous 
intestinal metaplasia and the high value assumed a higher risk of having non-visible 
islands of BM found with previous ablative therapies, and assuming the residual BM 
contained HGD (Overholt et al. 2003). 
 
ii)  Progression post RFA from BM to HGD/OA 
Here it is assumed that patients with BM post-RFA have the same probability of 
progression to HGD as patients with treatment naive BM. 
 
3.4.1.5  Mortality rate after oesophageal perforation or dilatation for oesophageal 
stricture 
Parameters required: 
i)  Death from iatrogenic oesophageal perforation 
ii)  Death from oesophageal dilatation 
 
The search strategy identified four relevant studies. Of these three were excluded for 
the following reasons: 
•  Incomplete follow up data (Hernandez et al. 2000) 
•  Inclusion of non-endoscopic perforations (Fernandez et al. 1999) 
•  Unclear differentiation between benign and malignant disease (Adamek et al. 
1997) 
 
The study by Quine et al. (1995) is a UK multicentre prospective audit, and is the only 
study to differentiate clearly between benign and malignant disease, and it is therefore 
used to form the base case and the low/high values. 
 
In the model, patients who perforate do so from a new treatment modality (RFA) with 
no defined outcomes, and thus a deliberately wide range of values was used to 
represent this uncertainty. 
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3.4.2  Data extraction strategy 
Data were extracted, endeavouring to obtain actual numbers where possible. Annual 
risks and 5-year survival data were converted to 6-monthly probabilities using the 
following validated formulae (Briggs et al. 2006), with the assumption that 6-monthly 
progression rates were constant: 
R  =  - [ ln (1 – P ) ] / t 
where R = rate, P = probability in particular time frame and t = time frame.Dr CPC Boger  Cost-utility analysis 
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Description  Base case estimate  Range  Distribution  Source - 
Author (Year) 
RFA complications 
No complications  0.94  0.90-1 
Jointly determined Dirichlet 
Pouw (2008), Shaheen (2009), 
Sharma (2009); assumption 
Perforation  0.0005  0-0.005 
Stricture requiring dilatation  0.06  0-0.09 
Outcomes after RFA 
Neo- squamous lined oesophagus  0.82  0.45-0.91 
Jointly determined Dirichlet 
Pouw (2008), Shaheen (2009), 
Sharma (2009); assumption 
Barrett's oesophagus without HGD  0.11  0.09-0.25 
HGD or adenocarcinoma  0.08  0-0.30 
Progression probabilities during post RFA surveillance (per cycle – 6 months) 
Neo-squamous to HGD/OA  0.0002  0-0.0027  Beta (α = 1, β = 4596)  Overholt (2003), Garside 
(2006), Sharma (2006)   Barrett's to HGD/OA  0.0068  0-0.0085  Beta (α = 4,  β = 953) 
Oesophagectomy complications 
Peri-operative complications  0.37  0.27-0.57  Beta (α = 26,  β = 44) 
Headrick (2002), Tseng (2003), 
Prasad (2007)  
 
Table 3-A: Summary of Transition probabilities 
Summary of the base case estimate and range of transition probabilities used in the model.   Dr CPC Boger  Cost-utility analysis 
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Description  Base case estimate  Range  Distribution  Source - 
Author (Year) 
Anastamotic stricture  0.51  0.13-0.83  Beta (α = 27,  β = 26) 
Headrick (2002), Williams 
(2003), Prasad (2007) 
Progression to adenocarcinoma post oesophagectomy 
After oesophagectomy for HGD  0.001  0-0.007  No distribution 
Headrick et al. 2002; Tseng et 
al. 2003; Reed et al. 2005; 
Prasad et al. 2007 
After oesophagectomy for post-RFA recurrence  0.0057  0-0.021  Beta (α = 18, β = 3239) 
Portale et al. 2006; Prasad et al. 
2007 
Mortality 
Death from iatrogenic oesophageal perforation  0.35  0-0.5  Beta (α = 2, β = 15)  Quine et al. 1995 
Death from oesophageal dilatation  0.005  0-0.01  Beta (α = 3, β = 551)  Quine et al. 1995 
Death from oesophagectomy  0.014  0-0.045  Beta (α = 1, β = 69) 
Tseng et al. 2003; Reed et al. 
2005; Portale et al. 2006; 
Prasad et al. 2007; Williams et 
al. 2007 
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  Utilities  3.5
Utilities are cardinal values that represent the strength of an individual’s preference for 
specific outcomes under conditions of uncertainty. In health economic modelling they 
allow a value to be placed on a particular health state, enabling the generation of 
QALYs, used as the outcome measure in the model. 
 
A number of methods are available for measuring utility. The visual analogue scale 
(VAS) consists of a line on a page with clearly-defined end-points, with or without 
marks on the line. Subjects are asked to specify their level of agreement to a statement 
(such as description of a health state scenario) by indicating a position on this line. 
They are however subject to bias. These include end-of-scale biases where subjects 
tend to avoid using ends of the scale regardless of how good or bad a health state is, 
and context bias in which subjects space out the outcomes over the scale regardless of 
how good or bad the states are (Drummond et al. 2005). The standard gamble is the 
preferred method as it avoids these measurement biases. The standard gamble 
approach involves presenting individuals with a choice between two alternatives: a 
health state that is certain and a gamble with one better and one worse outcome 
possible. Respondents are asked what probability of the better outcome would make 
them indifferent between remaining in the described health state for certain or going 
for the risky option. 
 
A literature search was performed to identify studies that measured quality of life in 
the required chosen health states and relevant values extracted. It was not possible to 
obtain utility values for all model states. Therefore known recorded values were used 
to provide a framework in which unknown values were estimated. Low and high values 
were derived either from 95% confidence intervals if available, or estimated to allow for 
the uncertainty surrounding the individual parameter. Derived utilities are shown in 
table 3-B. Dr CPC Boger  Cost-utility analysis 
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Table 3-B: Summary of health state utilities used in the model 
The base case estimates, range of utilities, and the distributions used in the probabilistic sensitivity analysis used in the model are shown..
Description  Base case 
estimate 
Range  Distribution  Source 
Author (year) 
RFA without complications  0.94  0.84-1  Beta (α = 31, β=2) 
Assumptions based on de Boer (2002) 
and Hur (2006)  
RFA complicated by stricture  0.92  0.82-1  Beta (α = 31, β=3) 
Post RFA with neo-squamous oesophagus  0.97  0.9-1  Beta (α = 42, β=1.3) 
Post RFA with Barrett’s oesophagus  0.95  0.883-1  Beta (α = 50, β=3) 
Oesophagectomy without complications  0.92  0.77-1  Beta (α = 19, β=2) 
 de Boer (2002)  
Oesophagectomy with complications  0.91  0.66-1  Beta (α = 9, β=1) 
Anastamotic stricture post oesophagectomy  0.92  0.841-0.999  Beta (α = 41, β=4)   Hur (2006) 
Fully recovered post oesophagectomy  0.96  0.89-1  Beta (α = 46, β=2) 
 de Boer (2002)  
Terminal oesophageal cancer  0.34  0.03-0.65  Beta (α = 3, β=5) Dr CPC Boger  Cost-utility analysis 
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3.5.1  Utility of oesophagectomy strategy disease states 
Three relevant studies looking at quality of life issues in patients with HGD who had 
undergone oesophagectomy were identified (Headrick et al. 2002; Chang et al. 2006; 
Moraca and Low 2006). All used a multi-attribute health status classification system 
(the SF-36) not utility values, and thus were not transferable to the required health 
states . 
 
Only one study that used utilities to measure patient preference was identified (de Boer 
et al. 2002). Although it focused on oesophagectomy for oesophageal cancer, parallels 
could be drawn to the health states defined in this study. Due to the importance of this 
study in the derivation of the utility values in this study, it is summarised below. 
 
This study set in Holland collected patient utilities for health states after transhiatal or 
transthoracic oesophagectomy for oesophageal cancer. Information was collected by 
two researchers 3-12 months after surgery. They excluded those with inoperable 
disease at the time of operation and those with recurrence, and thus the final cohort 
consisted of patients cured of cancer by oesophagectomy. Patients were trained in 
standard gamble methodology, and then at interview, asked to rate their own health 
state and additionally were given one of seven health state scenarios. They excluded 
those with insufficient cognitive ability to complete the study. Both VAS and standard 
gamble were used.  
 
Out of the 93 initially consented, 13 died, 21 had recurrent disease, 6 refused 
participation and 3 could not be reached. A total therefore of 50 patients were 
interviewed. The results are summarised in table 3-C. 
 
One can approximate health state scenarios from the study by de Boer et al., to the 
health states in this study, as follows: 
•  Home, disease free approximates to well post oesophagectomy. 
•  Irresectable approximates to terminal oesophageal cancer. 
Additionally, to calculate the utility for post oesophagectomy health states in this study 
(to make allowance for hospital stay and the recovery period at home) utility values 
were used from the study by de Boer et al. from the following health state scenarios: 
•  Home recovering 
•  Hospital with no complications 
•  Hospital with pneumonia 
 
Full details of how the utility values were calculated using these health state scenarios 
can be found in the appendix E.  Dr CPC Boger  Cost-utility analysis 
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Health state  Standard gamble mean (standard deviation) 
Own current health  0.97 (0.06) 
Home, disease free  0.96 (0.07) 
Home, recovering  0.92 (0.15) 
Hospital, no complications  0.90 (0.15) 
Hospital, pneumonia  0.82 (0.25) 
Recurrence in gastric tube  0.41 (0.31) 
Recurrence in bones  0.35 (0.30) 
Irresectable  0.34 (0.31) 
 
Table 3-C: Utility values reported by de Boer et al. (2002) 
Utility values reported by de Boer et al. using standard gamble technique in patients 
cured of cancer by oesophagectomy. 
 
3.5.2  Utility of various Barrett’s disease states 
Four studies that examined quality of life in patients with Barrett’s oesophagus were 
identified (Richards et al. 2003; Hur et al. 2005; Garside et al. 2006; Hur et al. 2006). 
Of these, only two derived utilities transferable to the health states used in a cost 
utility analysis (Garside et al. 2006; Hur et al. 2006). 
 
The study by Hur et al., set in the US, enrolled 20 patients with non-dysplastic BM, with 
a mean age of 64.6 years. Each was given instructions on performing standard gamble, 
and then presented with various health state scenarios. The utilities ascertained are 
presented in table 3-D 
 
One can approximate health state scenarios from the study by Hur et al., to the health 
states in this study, as follows: 
•  Barrett’s oesophagus (no dysphagia) approximates to post RFA with Barrett’s 
oesophagus 
•  Post oesophagectomy with dysphagia approximates to Anastomotic stricture 
post oesophagectomy 
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Health State   Mean (Median)  Range  Standard 
Deviation 
Actual Patient Health State       
Barrett's oesophagus (no dysplasia)  0.95 (0.98)  0.775–0.995  0.067 
Hypothetical Patient Health States       
Post-Oesophagectomy with 
dysphagia  
0.92 (0.96)  0.725–0.995  0.079 
Post-PDT (no dysphagia)   0.93 (0.98)  0.550–0.995  0.107 
Post-PDT with dysphagia   0.91 (0.96)  0.550–0.995  0.117 
Intensive Endoscopic Surveillance   0.90 (0.95)  0.550–0.995  0.138 
 
Table 3-D: Utility values reported in the study by Hur et al. (2006) 
Utility values reported by Hur et al. using standard gamble technique in patients with 
non-dysplastic BM. 
 
An additional source of utilities was identified in the HTA on Barrett’s surveillance 
(Garside et al. 2006). In this study the authors recruited a group of 64 people from the 
general population (the ‘Value of Health Panel’) and trained them in carrying out the 
standard gamble method for preference elicitation. Although some of the scenarios are 
applicable there are several problems in transferring these values for use in this study. 
Firstly, they have been derived from patients in full health, which although is in line 
with NICE methods, means they cannot be compared with the studies by de Boer et al. 
or Hur et al., where utilities were derived from patients. Secondly, Garside et al. 
assumes that utility remains constant from non-dysplastic BM to HGD. It has been 
subsequently demonstrated that utility decreases with worsening dysplasia (Gerson et 
al. 2007). Thirdly, there appear to be discrepancies in the values used, with utility for a 
person with asymptomatic cancer of 0.875, higher than post-surgery well (0.863), 
which in turn is higher than a person without Barrett’s (0.8). These values are in 
contrast to the findings of de Boer et al. and Hur et al. 
 
3.5.3  Quality of life studies in RFA patients 
At the time of this study, only one published abstract was identified assessing quality 
of life in patients with BM with HGD (Shaheen et al. 2008). In this US based study, VAS 
was used to assess different aspects of health related quality of life in patients both at 
baseline and 12 months after RFA treatment. Each scale was different in its range. 
Follow up is not complete, with 41/125 of patients having completed the 12 months 
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to dysplasia had an improvement in daily quality of life, depression and difficulty 
sleeping. 
 
It is difficult to draw conclusions from these interim results. Only approximately one-
third of patients have been followed up thus far. In addition the authors did not use a 
validated standardised measure of quality of life, such as the SF-36 or EQ-5D. Their 
method for measuring preference was the VAS with its inherent problems. Their study 
was designed to study the effects of a treatment on quality of life, rather than giving a 
patient preference to a particular health state. 
 
Thus utility for the post RFA states were estimated, partly by using utilities derived 
from the post-PDT health state scenarios from the work by Hur et al. 2006 (see table 3-
D), and additionally using the other known recorded values to provide a framework. 
 
  Costs  3.6
The costs used in the model are shown in table 3-E. The majority of costs were 
estimated from NHS reference costs (Department of Health 2009). This derives costs 
from nationally collected data from NHS trusts and calculates an average total cost of 
delivering a treatment episode to a patient. The cost of RFA is not available on this 
national tariff and thus was estimated using direct and variable costs derived from 
information obtained from the UK distributor (Synetics Medical Limited, Middlesex, 
UK). All costs were for 2009/10 and are shown in UK pounds sterling. For the 
sensitivity analysis all cost were varied by +/- 25%. A full breakdown of the costs may 
be found in the appendix F. 
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Table 3-E: Summary of the costs used in the model. 
† For the probabilistic sensitivity analysis a Gamma distribution was used based on the 
assumption that +/- 25% formed a 95% confidence interval. 
 
  Analysis  3.7
3.7.1  Deterministic 
To enable thorough interrogation of the model and the input parameters, a one-way 
sensitivity analysis was undertaken, in which the various parameters in the model are 
varied throughout the specified range to assess how this impacts upon study results 
(Drummond et al. 2005). For areas where uncertainties in the literature were identified 
or to interrogate areas where assumptions had been made, a threshold analysis was 
undertaken, which allows the critical value of a parameter central to the decision to be 
identified (Drummond et al. 2005). Where uncertainty in the methodology of the model 
existed such as in the time period of surveillance post RFA, a scenario analysis was 
undertaken to explore the effects of increasing surveillance. 
 
3.7.2  Probabilistic 
Probabilistic sensitivity analysis allows for all input parameters in a model to be 
specified as full probability distributions, rather than point estimates, allowing a 
representation of the uncertainty surrounding their values (Claxton et al. 2005). In the 
UK, it is a requirement for all cost-effectiveness models submitted to NICE (Claxton et 
al. 2005). The distributions and parameters used for each variable in the model are 
shown in tables 3-A and 3-B. For probabilities of an event either occurring or not 
occurring beta distributions were used, which generate values between 0 and 1 and 
Cost estimate (£)  Base case
†  Reference 
Treatment course of RFA  3869  Costs supplied by Synetics 
Medical Ltd 
Additional cost from developing 
perforation from RFA (excludes 
oesophagectomy) 
2619 
NHS reference costs 2009/10 
(Department of Health 2009) 
Routine gastroscopy and biopsies  406 
Elective Oesophagectomy  6342 
Oesophagectomy with complications  9305 
Oesophageal dilatation  427 
Outpatient follow up per visit  72 
Palliation of untreatable 
adenocarcinoma 
3863   (Garside et al. 2006), NHS 
reference costs 2009/10 
(Department of Health 2009) Dr CPC Boger  Cost-utility analysis 
86 
 
hence avoids unfeasible values. As the method of generating utilities used was based 
on standard gamble, negative values were not possible, and hence the beta 
distribution is appropriate. Where more than two events are possible, Dirichlet 
distributions were chosen, which ensures the total value of the probabilities of all 
events considered sum to 1. Gamma distributions cannot take negative values and 
have a skewed distribution, which is characteristic of many forms of cost data 
(Doubilet et al. 1985). 
 
The model was repeatedly run 5000 times using values randomly drawn from these 
distributions. To illustrate the uncertainty relating to the cost-effectiveness results, a 
cost-effectiveness acceptability curve was calculated, which estimates the probability 
that an intervention is more cost-effective than its comparator at different values of 
QALY (Lothgren and Zethraeus 2000). Dr CPC Boger   
 
 
 
CHAPTER 4:   Immunohistochemical 
analysis of 5-lipoxygenase pathway in 
Barrett’s adenocarcinoma 
 
In this chapter the results of the immunohistochemical analysis are presented and 
discussed. A summary may be found in section 4.1. Group demographics and 
recruitment are in section 4.2. The results of 5-lipoxygenase (5-LOX) pathway protein 
expression in tissue samples are presented in section 4.3 and their correlation with 
white cell subtypes in section 4.4. These results are discussed in section 4.5. 
 
  Summary  4.1
Striking increases in the immunoexpression of 5-LOX pathway enzymes responsible for 
the synthesis of leukotrienes (LT) B
4 and C
4 were seen in the stromal area of 
oesophageal adenocarcinoma (OA) tissue, with 5-LOX (p=0.041), 5-lipoxygenase 
activating protein (FLAP) (p=0.038), leukotriene A
4 hydrolase (LTA
4H) (p=0.0008) and 
leukotriene C
4 synthase (LTC
4S) (p=0.036) immunopositive cells being approximately 
three-, eight-, 37-, and six-fold more numerous respectively compared to squamous 
tissue. FLAP and LTA
4H immunostaining correlated with elevated neutrophil counts 
(p<0.001). Cell counts in Barrett’s metaplasia (BM) were intermediate between 
squamous and OA tissues, except for LTC
4S
+ cells which were as numerous in BM 
(p=0.014 vs squamous) as in OA. LTC
4S immunostaining was also notably 
overexpressed within epithelial cells in BM (p<0.001) and OA (p<0.01) tissue. Key 
biosynthetic enzymes of the LTB
4 and LTC
4 biosynthetic pathways are incrementally 
expressed across the spectrum of squamous, BM and OA tissues, suggesting a 
possible role of these leukotriene sub-families in disease progression. 
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  Immunostaining for 5-LOX pathway proteins in  4.2
oesophageal biopsies 
Distinct nucleated cells with perinuclear immunopositive staining for each of the 5-LOX 
pathway proteins (5-LOX, FLAP, LTA
4H and LTC
4S) were observed in the stromal areas of 
oesophageal biopsies. 
 
4.2.1  5-LOX expression 
Geometric mean (GM) cell counts per mm
2 of stromal area progressively increased 
through squamous (GM cell count; GM-SEM, GM+SEM: 8.04; 5.43, 11.9), BM (16.8; 
13.3, 21.2), and OA tissue (26.6; 19.8, 35.7) (see figure 4-A). Statistical comparisons 
between tissue types were made between log
10-transformed values using unpaired 
Student t-test. GM cell counts were significantly higher in OA tissue when compared to 
squamous tissues (p=0.041), but not between BM and squamous (p=0.152), and OA 
and BM tissue (p=0.242). Representative photomicrographs of stromal staining in OA 
tissue may be found in figure 4-F. 
 
 
Figure 4-A: Stromal 5-LOX positive cell count in different tissue types. 
Counts of cells per mm
2 of stromal area that were immunopositive for 5-LOX are shown 
(log
10 Y-axis). GM cell counts (indicated by cross-hair) were significantly higher in OA 
tissue when compared to squamous tissues (unpaired Student t-test, p values shown). 
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4.2.2  FLAP expression 
FLAP
+ GM cell counts per mm
2 of stromal area progressively increased through 
squamous (7.31; 3.64, 14.7), BM (15.6; 12.4, 19.6), and OA tissue (57.9; 38.5, 87.0) 
(see figure 4-B). Statistical comparisons between tissue types were made between log
10-
transformed values using unpaired Student t-test. GM cell counts were significantly 
higher in OA tissue when compared to squamous tissues (p=0.038), and between OA 
and BM tissues (p=0.019), but not between BM and squamous (p=0.350). 
Representative photomicrographs of stromal staining in OA tissue may be found in 
figure 4-F. 
 
 
 
Figure 4-B: Stromal FLAP positive cell count per mm
2 in different tissue types. 
Counts of cells per mm
2 of stromal area that were immunopositive for FLAP are shown 
(log
10 Y-axis). GM cell counts (indicated by cross-hair) were significantly higher in OA 
tissue when compared to both squamous and BM tissues (unpaired Student t-test, p 
values shown). 
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4.2.3  LTA4H expression 
LTA
4H
+ GM cell counts per mm
2 of stromal area progressively increased through 
squamous (0.420; 0.313, 0.656), BM (0.878; 0.595, 1.30), and OA tissue (8.90; 5.38, 
14.7) (see figure 4-C). Statistical comparisons between tissue types were made 
between log
10-transformed values using unpaired Student t-test. GM cell counts were 
significantly higher in OA tissue when compared to squamous tissues (p=0.0008), and 
between OA and BM tissues (p=0.002), but not between BM and squamous (p=0.109). 
Representative photomicrographs of stromal staining in OA tissue may be found in 
figure 4-F. 
 
 
 
Figure 4-C: Stromal LTA
4H positive cell count in different tissue types 
Counts of cells per mm
2 of stromal area that were immunopositive for LTA
4H are shown 
(log
10 Y-axis). GM cell counts (indicated by cross-hair) were significantly higher in OA 
tissue when compared to both squamous and BM tissues (unpaired Student t-test, p 
values shown). 
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4.2.4  Stromal LTC4S expression 
LTC
4S
+ GM cell counts per mm
2 of stromal area was highest in BM (25.6; 23.2, 28.3), 
followed by OA (18.9; 15.1, 23.7) and squamous tissue (3.19; 1.77, 5.73) (see figure 4-
D). Statistical comparisons between tissue types were made between log
10-transformed 
values using unpaired Student t-test. GM cell counts were significantly higher in both 
OA and BM when compared to squamous tissues (p=0.036 and p=0.024 respectively), 
but not between BM and OA (p=0.232). Representative photomicrographs of stromal 
staining in OA tissue may be found in figure 4-F. 
 
 
 
Figure 4-D: Stromal LTC
4S positive cell count in different tissue types. 
Counts of cells per mm
2 of stromal area that were immunopositive for LTC
4S are shown 
(log
10 Y-axis). GM cell counts (indicated by cross-hair) were significantly higher in both 
OA and BM when compared to squamous tissues (unpaired Student t-test, p values 
shown). 
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4.2.5  Epithelial immunostaining of LTC4S 
Epithelial cells in both BM and OA tissue showed immunostaining for LTC
4S that was 
more cytoplasmic than perinuclear. Minimal staining was evident in squamous 
epithelium and controls (see figure 4-E). Quantification of percentage epithelial area 
staining by image analysis demonstrated mean percentage stain (±standard deviation) 
of 2.57 ± 0.43 in squamous, 9.06±4.08 in BM, and 8.93±5.61 in OA tissues. Data were 
distributed parametrically and thus statistical comparisons were made between tissue 
types using unpaired Student t-tests. There was a statistically significant mean 
difference in percentage epithelial area staining for LTC
4S between BM and squamous 
tissues (p=0.0000003) and between OA and squamous (p=0.0024), but not between 
BM and OA (p=0.958). Representative photomicrographs of epithelial staining in BM 
and OA tissue may be found in figure 4-G. 
 
 
 
Figure 4-E: Epithelial immunostaining for LTC
4S in different tissue types. 
Epithelial LTC
4S immunostaining expressed as a percentage epithelial cell stain (log
10 Y-
axis). Geometric mean value indicated by cross-hair and statistical comparisons 
between groups were by unpaired student t-test (p values shown). 
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Figure 4-F: Immunostaining for 5-LOX pathway enzymes in stromal area of 
oesophageal adenocarcinoma tissue. 
Representative photomicrographs (x200 magnification) showing cells in stromal area 
of oesophageal adenocarcinoma tissue immunopositive (red stain) for (A) 5-LOX, (B) 
FLAP, (C) leukotriene A
4 hydrolase and (D) leukotriene C
4 synthase. Panel E is the 
control (no primary antibody at x100 magnification). 
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Figure 4-G: Immunostaining for LTC
4 synthase in epithelial area of tissue. 
Representative photomicrographs (x200 magnification) showing strong epithelial 
immunostaining (brown stain) for LTC
4 synthase is shown in Barrett’s metaplasia (A) 
and oesophageal adenocarcinoma tissue (B). Panel C is the control (no primary 
antibody). 
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  Leukocyte subtype counts and correlation with 5-LOX  4.3
pathway proteins 
To investigate the counts of leukocyte subtypes in tissue types and to correlate these 
with proteins of the 5-LOX pathway, immunohistochemistry  was performed using 
primary antibodies directed against the following cell-specific markers: neutrophil 
elastase (NE), CD68 (monocytes/macrophages marker), EG2 antibody to eosinophil 
cationic protein (eosinophil marker), and CD3 (T-lymphocyte marker). The results are 
summarised in figure 4-H. 
 
 
 
Figure 4-H: Leukocyte counts in squamous tissue, Barrett’s metaplasia and 
oesophageal adenocarcinoma. 
Counts of cells immunopositive for neutrophil elastase (NE
+), eosinophil cationic 
protein (EG2
+), monocyte-macrophages (CD68
+) and T-lymphocytes (CD3
+) are shown 
(log
10 Y-axis) in squamous, BM and OA tissue. Histogram bars show geometric mean 
values (with standard errors) and statistical comparisons between groups were by 
unpaired Student t-tests with *p<0.05 and **p<0.01. 
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4.3.1  NE+ neutrophils 
GM cell counts per mm
2 of stromal area were highest in OA (78.4; 49.1, 125) when 
compared to both squamous (9.69; 3.54, 26.6), and BM tissue (11.8; 8,62, 16.1). 
Statistical comparisons between tissue types were made between log
10-transformed 
values using unpaired Student t-test. GM cell counts were significantly higher in OA 
when compared to BM tissues (p=0.0055), but not when compared with squamous 
tissue (p=0.109), or between squamous and BM tissue (p=0.861). 
 
Regression analyses showed that across all tissues (n=28) the log
10 counts of FLAP
+ and 
LTA
4H
+ cells correlated strongly with neutrophils (r=0.832 and r=0.736 respectively, 
both p<0.001) (see 4-I). 
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Figure 4-I: Correlation of 5-LOX pathway protein immunoexpression with neutrophil 
counts. 
Scatter plots with line of best fit showing correlations between the counts (per mm
2) of 
neutrophils (NE
+, Y-axes) with counts of cells immunopositive for (A) 5-LOX, (B) FLAP, 
(C) LTA
4H and (D) LTC
4S in squamous (n=5), BM (n=16) and OA (n=7) tissues. Pearson’s 
correlation coefficients (r) are shown, with ***p<0.001 for the significant correlations 
between neutrophils and FLAP
 and between neutrophils and LTA
4 hydrolase positive 
cell counts. 
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4.3.2  CD68 positive monocyte/macrophages 
CD68
+ GM cell counts per mm
2 of stromal area progressively increased through 
squamous (0.435; 0.265, 0.714), BM (3.78; 2.67, 5.37), and OA tissue (10.1; 7.96, 
12.7) Statistical comparisons between tissue types were made between log
10-
transformed values using unpaired Student t-test. GM cell counts were significantly 
higher in OA when compared to both BM (p=0.0306) and squamous (p=0.00336), and 
between squamous and BM tissue (p=0.00967). 
Regression analyses showed that across all tissues (n=28) the log
10 counts of 5-LO
+ and 
FLAP
+ correlated weakly with monocyte/macrophages (r=0.468 and r=0.452 
respectively, both p<0.05) (see figure 4-J). 
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Figure 4-J: Correlation of 5-LOX pathway protein immunoexpression with 
monocyte/macrophage counts. 
Scatter plots with line of best fit showing correlations between the counts (per mm
2) of 
monocyte/macrophages (CD68
+, Y-axes) with counts of cells immunopositive for (A) 5-
LOX, (B) FLAP, (C) LTA
4H, and (D) LTC
4S in squamous (n=5), BM (n=16) and OA (n=7) 
tissues. Pearson’s correlation coefficients (r) are shown, with *p<0.05 for the 
significant correlations between CD68 and 5-LOX and between CD68 and FLAP positive 
cell counts. 
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4.3.3  EG2 positive eosinophils 
EG2
+ GM cell counts per mm
2 of stromal area was highest in BM (7.59; 5.40, 10.7), and 
then OA (2.58; 1.62, 4.10) and squamous tissue (0.439; 0.230, 1.07). Statistical 
comparisons between tissue types were made between log
10-transformed values using 
unpaired Student t-test. GM cell counts were significantly higher in OA and BM when 
compared with squamous tissue (p=0.0439 and 0.00695 respectively). No significant 
difference was seen between BM and OA tissues (p=0.0822). 
Regression analyses showed that across all tissues (n=28) the log
10 counts of 5-LO
+ 
correlated weakly with eosinophils (r=0.475, p<0.05) (see figure 4-K). 
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Figure 4-K: Correlation of 5-LOX pathway protein immunoexpression with eosinophil 
counts. 
Scatter plots with line of best fit showing correlations between the counts (per mm
2) of 
eosinophils (EG2
+, Y-axes) with counts of cells immunopositive for (A) 5-LOX, (B) FLAP, 
(C) LTA
4H, and (D) LTC
4S in squamous (n=5), BM (n=16) and OA (n=7) tissues. Pearson’s 
correlation coefficients (r) are shown, with *p<0.05 for the significant correlations 
between EG2 and 5-LOX positive cell counts. 
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4.3.4  T-lymphocytes (CD3+) 
CD3
+ GM cell counts per mm
2 of stromal area progressively increased through 
squamous (1.27; 0.520, 3.12), BM (16.9; 13.5, 21.2), and OA tissue (38.8; 28.8, 52.2) 
Statistical comparisons between tissue types were made between log
10-transformed 
values using unpaired Student t-test. GM cell counts were significantly higher in OA 
when compared to both BM (p=0.0440) and squamous (p=0.0153), and between 
squamous and BM tissue (p=0.0381). 
Regression analyses showed that across all tissues (n=28) the log
10 counts of FLAP
+ and 
LTA
4H
+ correlated weakly with T-lymphocytes (r=0.507, p<0.01 and r=0.492, p<0.05) 
(see figure 4-L). 
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Figure 4-L: Correlation of 5-LOX pathway protein immunoexpression with T-lymphocyte 
counts. 
Scatter plots with line of best fit showing correlations between the counts (per mm
2) of 
T-lymphocytes (CD3
+, Y-axes) with counts of cells immunopositive for (A)5-LOX, (B) 
FLAP, (C) LTA
4H, and (D) LTC
4S in squamous (n=5), BM (n=16) and OA (n=7) tissues. 
Pearson’s correlation coefficients (r) are shown, with significant correlations between 
T-lymphocytes and FLAP (**p<0.01) and T-lymphocytes and LTA
4H (*p<0.05) positive 
cell counts. 
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  Recruitment and group demographics  4.4
Forty-four patients were recruited, although a proportion of tissue samples were not 
suitable for analysis. There was difficulty obtaining squamous control tissue with 
adequate stromal area, with 5 out of 15 biopsies considered of suitable standard for 
study inclusion. A number of tissue samples suspected to be OA were excluded due to 
the finding of junctional tumours (3), undifferentiated carcinoma (1), and lack of OA 
tissue in the sample taken (2). 
Characteristics of the patients donating the samples included in the study are shown in 
table 4-M. There were no significant differences between the groups in age, sex ratio, 
aspirin or PPI use. Patients in the Barrett’s group tended to be younger, whilst those in 
the OA group used PPI’s less than those with BM. There were no aspirin users in any 
group. 
 
  Squamous  Barrett’s  OA   p value 
Age  74.7  64.9  77.8  ANOVA=0.124 
% male  100  87.5  100  Chi-square=0.647 
Aspirin use  0  0  0  - 
PPI use  40  93.8  14.3  Chi-square=0.096 
 
Figure 4-M: Patient characteristics 
 
4.4.1  Length of Barrett’s segment 
Sixteen patients with Barrett’s were included for sub-analysis.  Segment length 
exhibited a normal distribution with a mean of 5.9 cm +/- 2.2 cm, median of 6 cm, and 
a mode of 7 cm (see figure 4-N). Regression analysis revealed no correlation between 
length of Barrett’s segment and cell counts (per mm
2) of 5-LOX, FLAP, LTA
4H, LTC
4S, 
NE, CD68, EG2, and CD3 (all r<0.4, not significant). Dr CPC Boger  Immunohistochemical analysis of 5-LOX pathway in Barrett’s 
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Figure 4-N: Histogram showing frequency and distribution of length of Barrett’s 
segment. 
 
4.4.2  Proton pump inhibitor (PPI) use 
To analyse the effect of concurrent PPI use at time of tissue acquisition, cell counts 
were compared between those on PPI (n=19) and those not using PPI (n=6). Data were 
distributed non-parametrically and thus were compared by Mann-Whitney U test. Mean 
cell counts per mm
2 were numerically lower in those on PPI for 5-LOX, FLAP, LTA
4H, NE, 
CD68, EG2, and CD3, although this did not reach statistical significance (see figure 4-
O). 
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Figure 4-O: Effect of PPI use at time of tissue acquisition on mean cell count per mm
2 
of (A) 5-LOX pathway proteins and (B) inflammatory cell subtype. 
A 
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  Discussion  4.5
There is growing recognition that eicosanoid mediators including prostanoids and 
leukotrienes have roles not only in promoting inflammation but also in carcinogenesis, 
including cancers of the gastrointestinal tract. Previous studies have identified 
increased expression and activity of 5-LOX in patients with OA, in animal models of 
OA, and in OA cell lines (Chen et al. 2004; Hoque et al. 2005). With its activating 
protein FLAP, 5-LOX supplies an unstable substrate (LTA
4) for the synthesis of the 
short-lived, receptor-active lipid mediators LTB
4 and LTC
4 by the activities of LTA
4H and 
LTC
4S respectively. This study has demonstrated firstly that all four of these enzymes 
are significantly over-expressed in oesophageal biopsies from OA patients compared to 
squamous control tissue. Secondly, LTC
4S is upregulated in premalignant Barrett’s 
tissue, with unexpectedly strong expression in the oesophageal epithelium of both BM 
and OA disease groups. These results provide a functional basis for reports of 
increased LTB
4 production in OA (Chen et al. 2002) and also point to an unsuspected 
role of the cysteinyl-leukotrienes (LTC
4, LTD
4, LTE
4) in Barrett’s disease progression. 
 
These results confirm that 5-LOX expression is increased in OA biopsies (Chen 2004), 
most likely in several infiltrating leukocyte types including macrophages and 
neutrophils. Also demonstrated for the first time is a proportionately greater increase 
in FLAP immunoexpression in the same tissues. FLAP is an integral nuclear envelope 
protein and an essential, cytokine-inducible cofactor for leukotriene synthesis in intact 
cells (Dixon et al. 1990); it is also a promising target for novel inhibitors of leukotriene 
synthesis (Ferguson et al. 2007). Its striking overexpression in OA tissues suggests an 
increased intracellular capacity to donate arachidonate to 5-LOX to initiate leukotriene 
synthesis.  
 
Subsequent generation of LTB
4 depends on cell-specific expression of the distal 
enzyme LTA
4H, which was markedly increased in prevalence (37-fold) in OA tissues, as 
suggested by a previous semi-quantitative study (Chen et al. 2003). Both FLAP and 
LTA
4H-positive cell numbers correlated significantly with counts of neutrophils (figure 
4-I), which were also elevated in OA biopsies (figure 4-H). These results suggest that an 
activated 5-LOX/FLAP/LTA
4H pathway is expressed within neutrophils, and that its 
product LTB
4, a highly potent leukocyte chemotaxin via its LTB
4 receptor, BLT1 (Funk 
2001), is implicated in recruiting neutrophils to OA tissues. Neutrophil infiltration is 
observed in both acute and chronic inflammatory states, and also in different cancers 
throughout the gastrointestinal tract (Peddareddigari et al. 2010). Neutrophils play an 
active role in the tumour micro-environment, with neutrophil-derived factors promoting 
genetic mutations and some, including LTB
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factor (VEGF) production from tumour cells, contributing to angiogenesis (Ye et al. 
2004; Tazzyman et al. 2009).  
 
4.5.1  Linking 5-LOX pathway production with carcinogenesis 
5-LOX pathway products are directly linked to carcinogenesis and tumour cell survival 
in a variety of tissue sites. The marked anti-proliferative effect of leukotriene synthesis 
inhibitors in breast cancer cell lines is associated with alterations in a number of 
apoptotic signalling proteins including B-cell lymphoma (Bcl)2 and Bcl2-associated X 
protein (Avis et al. 2001). In rats, inhibitors of 5-LOX (zileuton) and of LTA
4H (bestatin) 
both reduce the incidence and tumour burden in OA (Chen et al. 2003; Chen et al. 
2004), suggesting a key role of LTB
4 in oesophageal tumorigenesis. Bestatin however, 
although widely used as an adjuvant in cancer chemotherapy, has additional 
aminopeptidase inhibitory activity unrelated to inhibition of LTB
4 synthesis. Although 
suppression of LTB
4 production with a 5-LOX inhibitor induces apoptosis in 
oesophageal cancer cell lines, a selective antagonist of the LTB
4 receptor BLT1 (U-
75302) was less effective (Hoque et al. 2005). This suggests that LTB
4 receptors other 
than BLT1, such as BLT2, or more probably 5-LOX products other than LTB
4, play 
additional roles in oesophageal cancer cell survival. Indeed, the cysteinyl-leukotriene 
LTD
4 causes time- and dose-dependent increases in β-catenin and Bcl-2 in intestinal cell 
lines, and the associated reduction in cell death correlates with levels of LTD
4 as well as 
those of LTB
4 (Ohd et al. 2000).  
 
4.5.2  LTC4S expression 
In this context, the novel finding of increased LTC
4S expression in OA biopsies, both in 
stromal cells and in epithelial cells, is of particular interest. LTC
4S is an integral nuclear 
membrane protein and the rate-limiting step for the synthesis of LTC
4, the first of the 
cysteinyl-leukotrienes, which have a range of vascular, anti-apoptotic and pro-
inflammatory actions via cysLT1 and cysLT2 receptors (Kanaoka and Boyce 2004; Ago 
et al. 2007; Peters-Golden and Henderson 2007), as well as activity at purinoceptors, 
including P2Y
12, the target of the anti-platelet drug clopidogrel (Paruchuri et al. 2009). 
LTC
4S has a relatively restricted cellular expression in some myeloid leukocyte sub-
types, but has also been described in bronchial epithelial cells (Jame et al. 2007). The 
expression of LTC
4S in oesophageal epithelial cells is therefore novel and also 
intriguing on two accounts. Firstly, oesophageal epithelial cells did not express the 
proximal enzymes 5-LOX or FLAP, suggesting that epithelial cells may generate LTC
4 
from its precursor LTA
4 donated by myeloid leukocytes in a process of transcellular 
synthesis, as proposed in other tissues (Fabre et al. 2002). Secondly, while 5-LOX, FLAP 
and LTA
4H tended to be more prevalent, only LTC
4S was significantly over-expressed in 
BM biopsies, as well as in OA biopsies. Confidence in the finding of epithelial LTC
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merited by careful measures to avoid non-specific immunostaining, as shown in the 
non-immune rabbit serum control. These included the use of the membrane solubiliser 
Tween-20, the dilution of the primary antibody with bovine serum albumin to prevent 
Fc receptor binding, and treatment of the tissue with avidin and biotin block to prevent 
secondary biotinylated antibody binding (Buchwalow and Böcker 2010). The data 
suggests that stromal and epithelial LTC
4S upregulation may represent a relatively early 
marker of Barrett’s disease progression. 
 
4.5.3  Expression of 5-LOX, FLAP and LTA4H in BM tissue 
Although a significant increases in immunoexpression of 5-LOX, FLAP or LTA
4H in the 
BM tissues was not found, it is possible that this may vary with the inflammatory 
gradient along a Barrett’s segment, with inflammation maximal at the new squamo-
columnar junction and minimal distally (Fitzgerald et al. 2002a). In the study in this 
thesis, biopsies were taken 2cm from the oesophago-gastric junction for consistency, 
but given the mean segment length of 5.9cm, this is approximately 4cm distal from 
the site of maximal inflammation at the squamo-columnar junction. Further work is 
thus required to map the expression of the 5-LOX pathway along the entire Barrett’s 
segment. It also does not preclude changes in enzymatic activity of the 5-LOX pathway 
occurring without changes in enzyme expression. The findings of increased levels of 
LTB
4 in both oesophagitis and BM, with a significant reduction in LTB
4 levels after 
gastric acid production was suppressed by a PPI (Triadafilopoulos et al. 1996), suggest 
that gastric acid exposure may modulate leukotriene synthesis enzymatically, perhaps 
by pH-dependent activation of infiltrating leukocytes. Additional risk factors such as 
aspirin and other NSAIDs which inhibit COX-1 may promote leukotriene synthesis 
enzymatically by shunting of arachidonate from the COX to the 5-LOX pathway. Such 
effects would be magnified by the concurrent over-expression of all four 5-LOX 
pathway enzymes observed in OA tissues. 
 
4.5.4  Conclusions 
Overall, the translation of these laboratory findings into clinical practice will depend on 
understanding the complex interplay of the eicosanoid products of 5-LOX and related 
pathways, such as the COX-2 products also implicated in BM and OA (Shirvani et al. 
2000; Souza et al. 2000; Buttar et al. 2002; Kaur and Triadafilopoulos 2002; Jankowski 
and Anderson 2004). Dual inhibition of the 5-LOX and COX-2 pathways may be 
required for optimum therapy, as suggested by the additive effects of zileuton and the 
COX-2 inhibitor celecoxib in a rat model of OA (Chen et al. 2004). The likelihood that 
different eicosanoids have pro- and anti-tumorigenic properties make a better 
understanding of this microenvironment of paramount importance prior to extended 
trials of such therapy (Shureiqi and Lippman 2001)Dr CPC Boger   Isolation and extraction of cellular RNA by laser capture micro-
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CHAPTER 5:   Isolation and extraction of 
cellular RNA by laser capture micro-
dissection, reverse transcription and real-
time polymerase chain reaction 
 
In this chapter the results of gene expression of 5-lipoxygenase (5-LOX) pathway 
enzymes and receptors (BLT1 and cysLT1R) from areas of squamous, Barrett’s 
metaplasia (BM) and oesophageal adenocarcinoma (OA) tissue are presented and 
discussed. A summary may be found in section 5.1. Protocol validation is found in 
section 5.2 and then results of gene expression of 5-LOX pathway transcripts in 
different cellular areas are presented in section 5.3. The results are discussed in 
section 5.4. 
 
  Summary  5.1
Retrieval of mRNA from laser capture cells using a filter based method was superior to 
using TRIzol reagent (p=0.009). All gene expression assays performed well with 
acceptable efficiencies, error and melt curve analysis. The pairing of the housekeeping 
genes18s with ACTB performed with the least variability over tissue types. PTPRC gene 
was expressed at very low levels suggesting minimal contamination of laser captured 
epithelial cell populations with white cells. 
 
Transcript levels for all 5-LOX pathway enzymes, and in particular ALOX5 (p=0.045), 
were higher in stromal compared with epithelial areas of all tissue types. 
Transcriptional expression was highest in the stromal area of OA tissue for 5-LOX 
pathway enzymes. mRNA transcripts of the cysteinyl leukotriene (cysLT) (CYSLT1R) and 
leukotriene B
4 (LTB
4) (LTB4R) receptor genes were expressed most prominently in 
Barrett’s stromal and OA epithelial areas respectively. These results would suggest 
transcriptional upregulation, although marked sample to sample variation was found, 
with some expressing little mRNA. Together with the immunohistochemistry results, 
this would suggest an important role for post transcriptional factors of 5-LOX pathway 
protein translation in the stroma of OA tissue. Additionally, expression of LTB4R  by 
epithelial cells of OA tissue, suggest a functional role for LTB
4 acting on BLT1 receptors 
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  RNA extraction and Validation of Laser capture micro- 5.2
dissection 
5.2.1  Comparison of TRIzol® and column based method for the extraction of 
mRNA from laser captured samples 
Five paired samples (1 squamous, 2 BM, and 2 OA) were cut by laser capture 
microdissection and mRNA extracted using one of two methods (as described in 
methods section 2.3.3.2); filter based using the RNAqueous-Micro kit (Ambion) or 
using TRIzol
® regent. The quantity of mRNA in the samples was assessed using the 
Nano-drop spectrophotometer. 
 
Mean mRNA content was 11.8+/-9.79ng/µl for the filter based method and 7.07+/-
8.24ng/µl for the TRIzol
® based method. Samples were paired and data distributed 
parametrically and thus paired-samples t-tests were employed for statistical analyses. 
The mean difference in mRNA content was 4.76ng/µl (95% CI: 1.97, 7.56). There was a 
statistically significant difference in the mRNA content between filter-based and TRIzol
® 
based methods (p=0.009) (see figure 5-A). The filter based RNAqueous Micro Kit was 
therefore incorporated as standard in the isolation of mRNA from laser captured 
samples. 
 
Figure 5-A: Comparison of filter based and TRIzol
® reagent based extraction methods 
from laser captured material. 
Quantity of mRNA (ng/µl) extracted from samples using filter based or TRIzol
® reagent 
is shown (Y-axis). The filter based method was superior for the extraction of mRNA in 
the laser captured samples (* statistical analysis using paired sample student t-test). 
P=0.009
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5.2.2  Validation of gene expression assays 
All gene expression assays used in the real time quantitative polymerase chain reaction 
(RT-qPCR) experiments were validated as described previously (see section 2.3.4.3). All 
gene expression assays and primers performed well with acceptable efficiencies 
between 1.9 and 2.2, and errors of less than 0.2 (table 5-A). An example of 
amplification and standard curves generated for ALOX5AP are shown in figure 5-B. Melt 
curve analysis was performed on all gene expression assays and primers. All showed 
just a single peak demonstrating the absence of any other PCR product or 
primer/dimers. An example of a melt curve for PTPRC is shown in figure 5-C. 
 
 
Table 5-A: Efficiency and error of gene expression assays used in real time RT-qPCR 
experiments. 
An efficiency of two represents the perfect PCR reaction, corresponding to doubling of 
target nucleic acid for each cycle. The error is a measure of the accuracy of the 
standard curve for quantification, with an acceptable value of below 0.2. 
 
 
Gene  Efficiency  Error 
ALOX5  2.071  0.020 
ALOX5AP  2.185  0.040 
LTA4H  2.016  0.002 
LTC4S  1.961  0.006 
LTB4R  1.941  0.012 
CYSLT1R  1.910  0.032 
PTPRC  1.922  0.072 
ACTB  1.952  0.021 
18S  1.911  0.015 
GAPDH  1.997  0.003 
HPRT1  1.954  0.002 Dr CPC Boger   Isolation and extraction of cellular RNA by laser capture micro-
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Figure 5-B: Amplification and standard curves 
Examples of (A) amplification curves for a titration series of granulocytes with 
ALOX5AP and (B) the calculated standard curve (log concentration plotted against the 
Cp value). 
 
 
(A) 
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Figure 5-C: Melt curve for PTPRC 
The PCR product was heated through 65°C to 95°C (X-axis), as SYBR green fluorescence 
was continuously measured (Y-axis). A single peak was seen representing the 
temperature at which the PCR product binds and separates. Absence of other peaks 
excludes the presence of primer–dimers and/or nonspecific PCR products. 
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5.2.3  Assessment of performance of housekeeper genes 
The performance of pairs of the four housekeeping genes was assessed in a cross-
section of tissue samples (see methods section 2.3.4.3). The pairing of18s with ACTB 
performed with the least variability over tissue types (figure 5-D), and was thus chosen 
as endogenous controls in mRNA expression analysis of the genes of interest in tissue 
samples. HPRT1 was a poor housekeeping gene in the tissue samples, with over 50-
fold difference in mean expression when combined with GAPDH, ACTB, or 18s. 
 
 
Figure 5-D: Performance of housekeeping genes measured by the ratio of difference in 
expression between housekeeper pairings. 
The pair with the lowest value, i.e. least variability, was chosen for use in the final 
analysis. The pairing of 18s and ACTB performed best. 
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5.2.4  Analysis of purity of laser captured epithelial cell populations 
The PTPRC gene is known to be expressed exclusively in cells of haematopoietic origin 
with the exception of erythrocytes. To assess the purity of laser captured epithelial 
tissue areas, the expression of PTPRC gene transcripts was assessed. Only very low 
transcript levels of PTPRC gene were found (when compared with granulocyte 
calibrator), with mean normalised concentration ratios of 0.05+/-0.04 in squamous, 
0.06+/-0.06 in BM, and 0.10+/-0.04 in OA tissue (figure 5-E). 
 
 
Figure 5-E: PTPRC transcript expression in laser captured samples of epithelial cell 
populations from different tissue types. 
Low PTPRC gene transcript levels (relative to granulocytes) were found suggesting 
minimal contamination of laser captured epithelial cell populations with white cells. 
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  LMD results  5.3
 
5.3.1  Gene expression between different cellular regions 
Transcript levels were numerically higher in stromal areas of all tissue types compared 
with epithelial area (mean difference in normalised mRNA concentration ratios; 95% CI) 
for ALOX5 (0.12; 0.00, 0.24), ALOX5AP (2.22; -0.45, 4.89), LTA4H (8.84; -1.45, 19.13), 
LTC4S (0.74; -0.26, 1.73) and CYSLT1R (0.16; -0.14, 0.45) (figure 5-F). Samples were 
distributed parametrically and thus independent-samples t-tests were employed for 
statistical analyses. There was a statistically significant difference between stromal and 
epithelial areas for ALOX5 gene transcript levels (p=0.045), but not ALOX5AP 
(p=0.099), LTA4H (p=0.089), LTC4S (p=0.142), nor CYSLT1R (p=0.280). Conversely, 
transcripts of LTB4R gene were 7-fold lower in stromal compared with epithelial area 
with a mean difference of 2.36 (95% CI: -3.54, 8.25), although this did not reach 
statistical significance (p=0.418). 
 
Figure 5-F: mRNA transcript levels of 5-LOX pathway genes of interest in epithelial and 
stromal areas. 
Mean normalised mRNA concentration ratio was higher in stromal areas for the 
majority of the 5-LOX pathway genes interrogated, with the exception of LTB4R which 
was expressed in higher levels in the epithelial areas of tissue samples. 
LTA4H
ALOX5AP
CYSLTR1
LTB4R
LTC4S
ALOX5
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5.3.2  Transcript expression of 5-LOX pathway genes 
 
5.3.2.1  ALOX5 
Transcripts of ALOX5 gene were expressed in only small quantities in all tissue types 
(figure 5-G). In epithelial areas, mean normalised mRNA concentration ratios (mean+/-
SD) were 0.087+/-0.096 in squamous, 0.008+/-0.009 in BM, and 0.015+/-0.021 in OA 
tissue. The highest levels of ALOX5 gene transcripts were found in stromal OA tissue: 
mean normalised mRNA concentration ratios were 0 in squamous, 0.153+/-0.227 in 
BM, and 0.237+/-0.257 in OA tissue. Data were distributed non-parametrically and 
thus the Mann-Whitney U test was used for all statistical comparisons between groups. 
There was no significant difference in ALOX5 gene transcript levels between different 
tissue types in either epithelial or stromal areas. 
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Figure 5-G: ALOX5 gene transcript levels in (A) Epithelial and (B) Stromal areas 
Only low transcript levels of ALOX5 gene were found in all tissue types. Mean 
normalised mRNA concentration ratios were highest in the stromal area of OA tissue, 
although this did not reach statistical significance when compared with either 
squamous control or Barrett’s tissue. 
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5.3.2.2  ALOX5AP 
Low levels of ALOX5AP gene transcripts were found in the epithelial area of all tissue 
types, with mean normalised mRNA concentration ratio (mean+/-SD) of 0.18+/-0.21 in 
squamous, 0.21+/-0.39 in BM, and 0.67+/-0.95 in OA tissue. In contrast, gene 
transcript levels were 3 to 5-fold higher than granulocyte calibrator in the stromal 
areas of both squamous and OA tissue, with the highest levels in OA tissue (figure 5-
H). Mean normalised mRNA concentration ratios were 3.02+/-4.25 in squamous, 
0.07+/-0.11 in BM, and 5.37+/-7.93 in OA tissue. Data were distributed non-
parametrically and thus the Mann-Whitney U test was used for all statistical 
comparisons between groups. There was no significant difference in ALOX5AP gene 
transcript levels between different tissue types in either epithelial or stromal area. 
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Figure 5-H: ALOX5AP gene transcript levels in (A) epithelial and (B) Stromal areas. 
Gene transcript levels were highest in the stromal area of OA tissue, although this did 
not reach statistical significance when compared with either squamous control or BM 
tissue. 
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5.3.2.3  LTA4H 
High levels of LTA4H gene transcripts were found across all tissue types, with highest 
levels found in OA tissue (figure 5-I). In epithelial areas, mean normalised 
concentration ratios (mean+/-SD) were 2.57+/-1.28 in squamous, 1.40+/-1.91 in BM, 
and 3.75+/-3.22 in OA tissue. In stromal areas, mean normalised concentration ratios 
were 3.55+/-3.95 in squamous, 4.40+/-3.81 in BM, and 21.97+/-28.98 in OA tissue. 
Data were distributed non-parametrically and thus the Mann-Whitney U test was used 
for all statistical comparisons between groups. There was no significant difference in 
LTA4H gene transcript levels in either epithelial or stromal area between different 
tissue types. 
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Figure 5-I: LTA4H gene transcript levels in (A) Epithelial area (B) Stromal areas. 
Gene transcript levels were highest levels in stromal areas, and in particular OA tissue, 
although this did not reach statistical significance when compared with either 
squamous control or Barrett’s tissue. 
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5.3.2.4  LTC4S 
LTC4S gene transcripts were found at recordable levels in only two samples. One 
sample was from the stromal area of squamous and one from the stromal area of OA 
tissue. Normalised concentration ratios were 1.92 and 6.15 respectively (figure 5-J). 
There was no significant difference in LTC4S gene transcript levels in epithelial or 
stromal area between different tissue types. 
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Figure 5-J: LTC4S gene transcript levels in (A) Epithelial area (B) Stromal areas 
Gene transcript levels were demonstrable in only two samples from the stromal area of 
tissues; one squamous and one OA tissue. 
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5.3.2.5  LTB4R 
LTB4R gene transcript levels were highest in the epithelial region of OA tissue, 
although this was due to high levels of (37-fold compared to granulocytes) in one 
sample (figure 5-K). In epithelial areas, mean normalised concentration ratios (mean+/-
SD) were 0.12+/-0.15 in squamous, 0.05+/-0.09 in BM, and 9.45+/-18.9 in OA tissue. 
Transcript levels were low in stromal areas of tissue, with mean normalised 
concentration ratios of 0.14+/-0.20 in squamous, 0.08+/-0.18 in BM, and zero in OA 
tissue. Data was distributed non-parametrically and thus the Mann-Whitney U test was 
used for all statistical comparisons between groups. There was no significant 
difference in LTB4R transcript levels in epithelial or stromal area between different 
tissue types. 
   Dr CPC Boger   Isolation and extraction of cellular RNA by laser capture micro-
  dissection, reverse transcription and real-time polymerase chain reaction 
133 
 
 
 
 
 
 
Figure 5-K: LTB4R gene transcript levels in (a) Epithelial and (b) Stromal areas. 
Gene transcript levels were low in most tissues with the exception of one sample from 
the epithelial area of OA tissue. 
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5.3.2.6  CYSLT1R 
CYSLT1R gene transcripts were found in only small quantities in all tissue types (figure 
5-L). In epithelial areas, mean normalised mRNA concentration ratios (mean+/-SD) were 
0.16+/-0.13 in squamous, 0.15+/-0.29 in BM, and 0.10+/-0.19 in OA tissue. The 
highest gene transcript levels were found in stromal area of BM tissue: mean 
normalised mRNA concentration ratios were 0.07+/-0.09 in squamous, 0.61+/-0.63 in 
Barrett’s, and zero in OA tissue. Data were distributed non-parametrically and thus the 
Mann-Whitney U test was used for all statistical comparisons between groups. There 
was no significant difference in CYSLT1R gene transcript levels in epithelial or stromal 
area between different tissue types. 
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Figure 5-L: CYSLT1R gene transcript levels in (A) Epithelial and (B) Stromal areas. 
Low gene transcript levels were found in both epithelial and stromal tissue areas in all 
tissue types. 
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5.3.3  Sample collection and Group demographics 
Twenty-eight samples from 16 patients were procured successfully at laser capture 
micro-dissection, with 7 squamous (5 epithelial, 2 stromal), 12 BM (7 epithelial, 5 
stromal), and 9 OA (4 epithelial, 5 stromal). Patient characteristics are shown in table 
5-B. There were no significant differences between the groups in age, or aspirin use. 
No patient in the OA group was taking a PPI at time of endoscopy, compared with 100% 
usage in both the squamous and BM group. 
 
  Squamous  BM  OA   p value 
Mean age in years 
(median) 
64.2 (65.6)  67.5 (68.7)  77.6 (77.5)  ANOVA=0.072 
Age Range  51.0-75.8  53.8-77.5  71.9-84.2  - 
% male  83.3  85.7  100  Χ
2=0.098 
Aspirin use  0  0  0  - 
PPI use  100  100  0  Χ
2=0.005 
 
Table 5-B: Patient characteristics of laser capture micro-dissected samples. 
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  Discussion  5.4
 
5.4.1  Protocol validation 
Laser capture micro-dissection is an emerging technique for isolating individual 
populations of cells from tissue to permit downstream mRNA analysis. To produce 
reliable validated results requires a complex series of steps, each requiring 
optimisation and validation. 
In the first part of this study a robust protocol was formulated and validated for the 
retrieval of mRNA from frozen biopsy samples of oesophageal tissue for subsequent 
gene expression analysis. This was successfully achieved, with retrieval of mRNA from 
tissue samples of squamous, BM and OA. Confidence in the reliability and validity of 
the formulated protocol can be gained from the multiple normalisation steps that were 
undertaken. Normalisation is crucial in RT-qPCR to control for experimental error which 
may be introduced during the multi-stage process required to extract and process 
mRNA (Huggett et al. 2005). Examples of how this was achieved in this protocol 
include normalising for the number of cells retrieved during laser capture, ensuring the 
quantity of mRNA put into the amplification step was the same, and using validated 
housekeeping genes (see 5.4.1.2). All gene expression assays showed acceptable melt 
curves (run following real time PCR) signifying that the desired amplicon was detected, 
and that there was no interference in the results from double stranded DNA including 
primer dimers, contaminating DNA, and PCR product from misannealed primer. 
Efficiencies were also satisfactory across all gene expression assays, with all results 
between 1.9 and 2.1. 
 
5.4.1.1  Column- was superior to TRIzol® -based method for the isolation of mRNA 
from laser captured samples 
Numerous protocols for the isolation of RNA from laser captured samples exist, and it 
is recommended each user should optimise and validate their own protocol to ensure 
reliable results and prevent loss of mRNA (Pinzani et al. 2006). The column based 
extraction procedure has a number of potential advantages when used with laser 
captured material. These include the ability to elute RNA in small volumes and to treat 
with DNase directly onto the column to remove any contaminating DNA without the 
need for further RNA purification and precipitation. In the TRIzol® based method, RNA 
is separated from DNA after extraction with an acidic solution containing guanidinium 
thiocyanate, sodium acetate, and phenol (TRIzol®) and chloroform, followed by 
centrifugation. Under acidic conditions, RNA remains in the upper aqueous phase, 
while most of the DNA and proteins remain either in the interphase or in the lower 
organic phase. Total RNA is then recovered by precipitation with isopropanol. Whilst 
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each extraction step and there are a number of theoretical disadvantages when using it 
on laser captured samples. For example, visualisation of the RNA “pellet” formed 
during precipitation may be difficult and contribute to RNA loss. In this experiment 
using the TRIzol® protocol a number of steps were taken to minimise this problem. 
The aqueous phase was stored with isopropanol at -20°C to improve precipitation of 
RNA, and glycogen was used to improve visualisation of the RNA pellet. Despite this 
optimisation the column based method using the RNAqueous-Micro kit (Ambion) 
yielded a mean of more than 4ng/µl extra total RNA than the TRIzol® based method. 
This was statistically significant and thus it may be concluded that under the 
experimental conditions encountered in this study, the column based method is 
superior. 
 
5.4.1.2  Performance of Housekeeping genes 
For interpretation of quantitative gene expression measurements in clinical tumour 
samples, a normaliser is necessary to correct expression data for differences in cellular 
input, RNA quality, and reverse transcription efficiency between samples. In many 
studies, a single housekeeping gene is used for normalisation. However, no 
unequivocal single reference gene (with proven invariable expression between cells) 
has yet been identified. In biopsies of human tissue significant variation in expression 
of commonly used housekeeping genes, including GAPDH, β-actin,18s, and HPRT1 is 
found not only between individuals but also between biopsies taken from the same 
patient (Tricarico et al. 2002). These findings have been corroborated by other studies 
showing varying gene expression levels in different tissues and under different 
experimental conditions (Schmid et al. 2003; Radonic et al. 2004). As the best 
alternative, it is recommended that each housekeeping gene is validated for the 
individuals’ experimental setup and that more than one should be used (Bustin and 
Nolan 2004). In this study the performance of four pairs of housekeeping genes was 
assessed for reliability in laser captured samples. The combination of 18s and HPRT1 
performed least well with a greater than 100-fold difference in gene expression across 
tissue samples. In contrast, the combination of 18s and ACTB performed with the most 
reliability in the experimental conditions and with the tissue types in this study, with a 
less than 10-fold difference. This combination was therefore used in this study, and 
additionally is recommended for future study. 
 
5.4.2  mRNA transcript levels of 5-LOX pathway enzymes and receptors in 
Barrett’s adenocarcinoma 
In general, transcript levels of 5-LOX pathway genes were higher in stromal areas of all 
tissue types compared with the epithelial area. In particular ALOX5 was significantly 
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types, it was in the stromal area of OA tissue that the highest mRNA levels were found. 
However there was marked variability with some samples showing minimal levels of 
gene transcripts. For example, only low levels of ALOX5 transcripts were demonstrated 
in any tissues. As discussed (see 5.4.1), multiple steps were taken to ensure the 
experimental protocol was robust, the positive control results rule out failure of real 
time PCR, and the presence of housekeeping genes in all samples suggest that mRNA 
degradation is an unlikely cause. Taken together with the immunohistochemistry 
results (see chapter 4), this would suggest that whilst transcriptional expression of 5-
LOX pathway genes is variably increased in OA, other post transcriptional factors 
appear to play an important role in protein translation. It is recognised that cells use a 
variety of post transcriptional mechanisms to control protein expression (Bennett et al. 
1993). Previous study has demonstrated that mRNA expression may not be predictive 
of protein expression (Guo et al. 2008). For example, stimulation of human neutrophils 
with granulocyte macrophage colony stimulating factor upregulated total 5-LOX 
protein, but did not alter ALOX5 mRNA (Pouliot et al. 1994). 
 
In contrast to the variability in transcript expression seen with ALOX5, ALOX5AP and 
LTC4S, LTA4H mRNA was found in all tissue types with highest levels in stromal area of 
OA. LTA
4H is widely and constitutively expressed across tissues and cell types, 
including neutrophils, monocytes, erythrocytes and epithelial cells in a variety of 
organs (Haeggstrom 2000). Expression of LTA
4H protein, but not mRNA, has been 
demonstrated previously in infiltrating neutrophils and epithelial cells in OA (Chen et 
al. 2003). The study presented here substantiates this, with immunohistochemical 
studies localising protein expression to neutrophils in the stromal area of OA tissue, 
with evidence of a non-significant increase in LTA4H gene transcription. 
 
The factors responsible for high levels of gene transcripts seen in the stromal areas of 
OA in some samples are not known. The simplest explanation is that differences in 
mRNA reflect the variances between tissues in migrating cell populations in which 
mRNA of the various gene transcripts studied is constitutively expressed. For example, 
abundant neutrophils were demonstrated in tissues by immunohistochemistry. An 
alternative explanation may include differences in induction of transcription in the 
resident population of inflammatory cells. A variety of inducers of transcription of 5-
LOX pathway genes are known, including retinoic acid, 1,25-dihydroxyvitamin D
3 
(calcitriol),  colony stimulating factors, transforming growth factor- β (TGF-β), IL-1 and 
IL-4, although their ability to upregulate transcription varies between tissue types 
(Peters-Golden and Brock 2003). TGF-β is of particular interest as it plays a central role 
in cancer pathogenesis, suppressing the proliferation of normal epithelial cells in early 
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transformed cells (Weinberg 2007). In OA, overexpression of TGF-β is linked to an 
advanced stage of disease and a poor prognosis (Koliopanos et al. 2002; von Rahden 
et al. 2006), whilst impairment of TGF-β mediated growth suppression signalling 
through inactivation of SMAD4, has been demonstrated in both BM and OA 
(Onwuegbusi et al. 2006). TGF-β can modify maturation of ALOX5 transcripts leading to 
augmented expression of the functional enzyme, and thus may provide the link by 
which 5-LOX pathway protein expression is upregulated in OA tissue (Harle et al. 
1998). This study did not categorise patients into survival categories, and it is possible 
that variations in TGF-β levels may play a role in the variations of 5-LOX pathway 
enzymes gene transcript levels seen in this study. 
 
Further explanation may be the presence of genetic polymorphisms, which may 
contribute to increased transcription found in some samples. For example, eosinophils 
from subjects with a single genetic polymorphism in the LTC4S gene produced three 
times more LTC
4S than subjects with the wild-type genotype (Sampson et al. 2000). 
How common such polymorphisms are in patients with BM or OA is not known, but in 
certain other disease subgroups, such as aspirin intolerant asthma, the prevalence may 
be as high as 76% (Sanak et al. 1997). In colorectal cancer, no association was found 
between two 5-LOX polymorphisms and risk of colorectal cancer, but a protective 
effect was demonstrated between a polymorphism in 12-LOX (Gong et al. 2007). 
Conversely, in patients with breast cancer, ALOX5AP -4900 A>G polymorphism and 
high dietary linoleic acid intake was linked with an increased risk of breast cancer 
(Wang et al. 2008). This inconsistency between tumour types may be explained by 
promoter polymorphisms. For example in the ALOX5 promoter which may account for 
a lack of 5-LOX enzyme in approximately 5-6% of the population who possess 
homozygous recessive genotypes (Drazen et al. 1999). Further study is needed and 
exploring the frequency of such polymorphisms in patients with BM and OA may 
provide an insight into the causation of this disease in some and not others.  
 
5.4.3  mRNA transcript levels of the leukotriene receptors: LTB4R  and CYSLT1R 
The finding of high transcript levels of LTB4R mRNA in cells in the epithelial area of OA 
tissue was unexpected. Confidence that this result is not due to infiltrating white cells 
can be gained by the low levels of PTPRC transcripts seen in the epithelial samples. In 
non-disease states BLT1 receptors are expressed on leucocytes, and on activation by 
LTB
4 play a key role in leukocyte recruitment to sites of inflammation by both directing 
cellular migration, and by facilitation of endothelial cell binding, a prerequisite of 
leukocyte migration into tissues (Tager and Luster 2003). A clue to its potential role in 
carcinogenesis comes from the finding that LTB
4 prolongs neutrophil survival by 
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been found in multiple cancer types. In pancreatic cancer tissue, increased levels of 
LTB4R mRNA were found when compared with normal pancreatic tissue (Hennig et al. 
2002). Subsequent findings demonstrated that LTB
4 can stimulate proliferation and 
activation of the signalling molecules, extracellular signal-regulated kinase (ERK) 1/2 in 
multiple human pancreatic cell lines (Tong et al. 2002). In human anaplastic large cell 
lymphoma cells the LTB
4 receptor antagonist, LY293111 (etalocib), induces cell cycle 
arrest and apoptosis via c-Jun N-terminal kinase (JNK) phosphorylation (Zhang et al. 
2005). In the human gastrointestinal tract, BLT1 receptor was found to be expressed in 
colon cancer cells and blockade by the specific BLT1 receptor antagonist U75302 
induced apoptosis via inhibition of ERK activation (Ihara et al. 2007). In oesophageal 
cancer cell lines the 5-LOX inhibitor AA861 suppressed LTB
4 production and the BLT1 
receptor antagonist U-75302, blocked AA861-induced apoptosis (Hoque et al. 2005). 
This finding was variable across the small number of tissues investigated and thus 
further work is required to clarify this result, which should include corroboration with 
immunohistochemical analysis. 
 
Transcripts for CYSLT1R were seen in the stromal area of some BM tissue samples, 
with no expression seen in the stromal area of OA tissue. CysLT1R expression has 
been documented in other sites of the gastrointestinal tract; the small intestines and in 
the colon, in colorectal carcinoma (Lynch et al. 1999; Ohd et al. 2003). In colorectal 
cancer the expression was predominantly in the epithelial cells of tumour tissue 
compared with controls taken from the margins of the surgical specimens (Ohd et al. 
2003). In the study in this thesis the explanation for expression of CYSLT1R is likely 
the presence of white cells, and in particular monocytes/macrophages, mast cells and 
eosinophils in the stromal area, all known to express cysLT1 receptors. Stimulators of 
transcription of CYSLT1R in monocytes and macrophages include interleukin-4 
(Thivierge et al. 2001). Four fold increase in the level of this cytokine was found in BM 
when compared to both normal squamous and oesophagitis tissue, which may provide 
an explanation for the higher levels of expression demonstrated in BM tissue 
(Fitzgerald et al. 2002b). Its functional role is not demonstrated in this study, but cys-
LTs are known to have diverse roles in the inflammatory response acting through the 
cysLT1 receptor (Kanaoka and Boyce 2004). In BM it may contribute to mediation of 
leukocyte activation and chemotaxis thus contributing to the inflammatory infiltrate 
demonstrated by immunohistochemistry. A further role may be promotion of cell 
proliferation through downstream phosphorylation of ERKs, contributing to an 
environment conducive to cell growth (Mellor et al. 2002). 
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5.4.4  Conclusions 
In this study a reliable and validated protocol was developed for the procurement of 
individual cellular areas from both diseased and non-diseased oesophageal tissue by 
laser capture microdissection. Utilising this protocol for a pilot assessment of 5-LOX 
pathway gene expression in squamous, BM and OA tissue has confirmed mRNA 
transcripts for all four 5-LOX pathway genes, most consistently (but not exclusively) in 
stromal areas of OA tissues, with LTA4H mRNA also being prominent in epithelial cells. 
Additionally, mRNA expression of the two main leukotriene receptors, LTB4R and 
CYSLT1R were demonstrated in epithelial and stromal areas respectively of some 
samples. Both receptors may mediate leucocyte recruitment and play a role in 
promotion of cell growth.  Results were variable, and taken with the findings from the 
immunohistochemical studies, suggest that post transcriptional regulation of protein 
translation is important.Dr CPC Boger   
 
 
 
CHAPTER 6:   Cost–utility analysis of 
radiofrequency ablation or 
oesophagectomy for the management of 
high-grade dysplasia in Barrett’s 
metaplasia 
 
In this chapter the results of the cost-utility analysis are presented and discussed with 
a summary found in section 6.1. Results of the base case analysis are in section 6.2, 
deterministic analysis 6.3, and probabilistic analysis 6.4. These results are discussed in 
section 6.5. 
 
  Summary  6.1
In the base case analysis radiofrequency ablation (RFA) dominated as it generated 0.4 
extra quality of life years (QALYs) at a cost saving of £1902. For oesophagectomy to be 
the most cost-effective option would require a RFA treatment failure rate (high-grade 
dysplasia persistence or progression to cancer) of greater than 44%, or an annual risk 
of high-grade dysplasia (HGD) recurrence or progression to cancer in the ablated 
oesophagus of greater than 15% per annum. There was an 85% probability that RFA 
remained cost-effective at the NICE willingness to pay threshold range of £20000-
30000. 
RFA is likely to be a cost-effective option for HGD in Barrett’s metaplasia (BM) in the 
UK. Long term outcome data are required to achieve certainty as to the optimal 
management strategy, as current follow up data is limited to two years. However, the 
model presented here predicts that if initial eradication of high-grade dysplasia is 
achievable in over 60% of patients, then RFA with oesophagectomy for HGD persistence 
or recurrence will be the preferred strategy.   Dr CPC Boger  Cost–utility analysis of radiofrequency ablation or oesophagectomy for 
  the management of high-grade dysplasia in Barrett’s metaplasia 
144 
 
  Deterministic Model - Base case analysis  6.2
6.2.1  Summary 
The results from the base case analysis are summarised in table 6-A. For a 64 year old 
male patient, a strategy of RFA followed by oesophagectomy if there was disease 
recurrence would be expected to cost £1902 less, and result in 0.4 more QALYs, when 
compared with immediate oesophagectomy. 
 
Outcome per strategy  Oesophagectomy  RFA 
Incremental 
ratio 
Cost (£)  8555  6653  -1902 
Unadjusted life-years  17.0  17.4   
QALY  13.8  14.2  0.4 
Incremental cost-effectiveness 
ratio (£/QALY) 
  Dominates 
 
 
Table 6-A: base case results of the deterministic model. 
RFA was cheaper and resulted in more QALYs than oesophagectomy. 
 
 
Figure 6-A shows the cost-effectiveness plane which plots incremental effectiveness 
against incremental cost. The base case result falls in the southeast quadrant, and thus 
the RFA strategy is said to dominate immediate oesophagectomy. 
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Figure 6-A: Base case analysis – cost-effectiveness plane. 
The result lies in the south east quadrant of the cost-effectiveness plane and thus is 
said to dominate oesophagectomy. 
 
 
6.2.2  Morbidity 
The RFA strategy results in less morbidity (20.8% v 87.1%) than immediate 
oesophagectomy, as shown in table 6-B. 
 
  Oesophagectomy strategy 
(% patients) 
RFA strategy 
(% patients) 
Procedural  37.1  3.9 
Strictures  50.0  16.9 
 
Table 6-B: Base case analysis - morbidity 
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6.2.3  Mortality 
The RFA strategy resulted in less procedure related mortality (0.4% v 2.6%) than 
immediate oesophagectomy. The causes of death as a percentage of total deaths are 
shown in table 6-C. 
 
  Oesophagectomy strategy 
(% deaths) 
RFA strategy 
(% deaths) 
Age-related  96.43  99.09 
Surgical  1.89  0.19 
Endoscopic  0.71  0.18 
Cancer  0.97  0.53 
 
Table 6-C: Base case analysis - cause of death 
 
 
10.18% of the RFA cohort required an oesophagectomy for recurrence of HGD or 
progression to OA and of those, 3.93% died of terminal cancer, compared to 0.73% of 
those in the immediate oesophagectomy strategy. Age-related deaths were by far the 
most common cause of mortality in both cohorts, with cancer the cause of death in 
less than 1% of patients. Table 6-D shows 5-year survival and cancer free survival by 
cohort, and figure 6-B shows the survival curve (otherwise known in the context of 
health economic modelling as a Markov trace) of the base case analysis with 
population norms included for illustrative purpose. Both strategies appear to be highly 
effective at preventing death from cancer as demonstrated by the similarity between 5-
year survival and 5-year cancer free survival figures. 
 
  Oesophagectomy  RFA 
5-year survival  84.89  84.99 
5-year cancer free survival  85.03  85.07 
 
Table 6-D: Base case analysis - 5-year survival 
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Figure 6-B: Base case analysis - survival curve (Markov trace) 
 
 
  Deterministic sensitivity analysis  6.3
6.3.1  Summary 
The one-way sensitivity analysis demonstrated that the following were important 
factors in determining the cost-effectiveness of RFA; outcome post RFA, utility post 
RFA with squamous oesophagus, and utility fully recovered post oesophagectomy. 
 
6.3.2  Outcome post RFA 
Only at the most pessimistic outcome post RFA (i.e. 30% post RFA with HGD), was RFA 
more costly than oesophagectomy, although it still resulted in more QALYs, costing 
£661/QALY. Threshold analysis demonstrated that for oesophagectomy to dominate as 
the preferred strategy required over 44% of patients to have residual HGD post RFA. 
This is demonstrated in the cost-effectiveness plane (figure 6-C), which shows the 
incremental cost and incremental QALY as the transition probability for outcome after 
RFA is HGD is altered throughout a hypothetical range. 
y = -1E-09x6 + 2E-07x5 - 1E-05x4 + 0.0002x3 - 0.0025x2 + 0.0021x + 1.0022
R² = 0.999
y = -1E-09x6 + 2E-07x5 - 1E-05x4 + 0.0002x3 - 0.0025x2 + 0.0015x + 1.0023
R² = 0.999
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R² = 0.999
P
r
o
p
o
r
t
i
o
n
 
a
l
i
v
e
Year
Population norms Oesophagectomy             RFA Dr CPC Boger  Cost–utility analysis of radiofrequency ablation or oesophagectomy for 
  the management of high-grade dysplasia in Barrett’s metaplasia 
148 
 
 
Figure 6-C: Threshold analysis – altering transition probability of outcome after RFA is 
HGD 
Abbreviations: WTP – willingness to pay, dQALY – discounted quality of life years 
 
6.3.3  Utility 
Utility values were altered as highlighted by the one-way sensitivity analysis. For 
oesophagectomy to become a more effective (but still more costly) option would 
require either a utility value of less than 0.93 post RFA with squamous oesophagus, or 
a utility fully recovered post oesophagectomy of over 0.99. Thus, it would require fully 
recovered post oesophagectomy to be a more preferable health state than post RFA 
with squamous oesophagus. 
 
6.3.4  Recurrence of HGD or progression to oesophageal adenocarcinoma after 
successful RFA 
As there is uncertainty in the robustness of the neo-squamous epithelium post RFA, 
further threshold analysis was undertaken to identify the HGD recurrence required to 
alter the results of the model. For this to occur would require an annual risk of HGD 
recurrence in the neo-squamous epithelium of 20%. This is demonstrated in the cost-
effectiveness plane (figure 6-D), which shows the incremental cost and incremental 
y = -7563.1x + 1189
R² = 0.999
y = 20000x + 7E-13
R² = 1
y = 30000x + 1E-12
R² = 1
Incr 
effectiveness 
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QALY as the transition probability for recurrence of HGD or progression to OA during 
post RFA surveillance is altered throughout a hypothetical range. 
 
 
Figure 6-D: Threshold analysis – altering transition probability of recurrence of HGD or 
progression to OA during post RFA surveillance 
Abbreviations: WTP – willingness to pay, dQALY – discounted quality of life years 
 
6.3.5  Endoscopic surveillance 
The need for, or frequency of, endoscopic surveillance after successful ablation with 
RFA is not currently known. A scenario was modelled of continuing surveillance in all 
patients post RFA, with 2-yearly endoscopy for both neo-squamous and BM, after initial 
yearly endoscopy for the first 5 years.  
With this strategy the cost of RFA increased considerably to £8168 with 14.2 QALYs. 
The cost of oesophagectomy remained at £8555 with 13.8 QALYs, and thus RFA still 
dominated as the preferred strategy. 
 
6.3.6  Costs 
As the method used to calculate the cost of RFA differed from other calculated costs, a 
threshold analysis was undertaken to determine how expensive treatment with RFA 
would need to be to alter the outcome of the model. For RFA to become a more 
expensive treatment strategy would require an increase of £1904 from the base case 
estimate to £5773 per treatment course per patient. RFA retained its cost-effectiveness 
at a willingness to pay (WTP) of £30000/QALY even if cost was increased to £17754, 
WTP 
£20000/dQALY
WTP 
£20000/dQALY, 
0.00, 0.00
WTP 
£30000/dQALY
WTP 
£30000/dQALY, 
0.00, 0.00
y = 20000x + 7E-13
R² = 1
y = 30000x + 1E-12
R² = 1
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i.e. 450% more than the base estimate and over twice the cost of an oesophagectomy 
without complications. Altering all other variables through their specified range, 
including age (55-70yrs), and in addition altering the discount rate (1-5%), and the 
length of time for which the cohort was followed (5-30yrs), made no critical difference 
to the model outcome. 
 
  Probabilistic sensitivity analysis  6.4
6.4.1  Base case results 
The base case results of the probabilistic sensitivity analysis (see table 6-E) are similar 
to the deterministic model. The RFA strategy is seen to dominate as it costs less and 
provides more dQALY than immediate oesophagectomy. 
 
   Cost  dQALY 
Oesophagectomy  £8,546  13.85 
RFA  £6,661  14.24 
Incremental  -£2,048  0.32 
 
Table 6-E: Probabilistic sensitivity analysis – Base case results 
 
 
6.4.2  Cost-effectiveness plane 
The cost-effectiveness plane demonstrating the distribution of the results is shown in 
figure 6-E. This scatter plot of the incremental
 costs and QALY pairs, generated from 
the probabilistic sensitivity analysis, illustrates the uncertainty surrounding
 the 
estimates of expected costs and expected
 effects associated
 with the RFA compared 
with the Oesophagectomy strategy. The majority fall in the south-east quadrant, the 
position where the RFA strategy is more effective and less costly than the 
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Figure 6-E: Cost-effectiveness plane of results of probabilistic sensitivity analysis 
 
6.4.3  Cost-effectiveness acceptability curve 
The cost-effectiveness acceptability curve shows the probability that RFA is cost-
effective as the value placed upon a QALY is varied between £0 and £50,000 (figure 6-
F). The probability that RFA is cost-effective is approximately 84-86% throughout a 
willingness to pay of £20000-30000/QALY, showing that RFA appears highly likely to 
be cost-effective. 
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Figure 6-F: Cost-effectiveness acceptability curve 
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  Discussion  6.5
6.5.1  Summary 
This study demonstrates that for a 64 year old patient in the UK with HGD in BM, a 
treatment strategy of RFA followed by surveillance with oesophagectomy for HGD 
recurrence or progression to adenocarcinoma is less expensive and results in more 
discounted quality adjusted life years compared to immediate oesophagectomy. This 
supports findings which demonstrated that in a US setting, a strategy of RFA for HGD 
yielded more QALYs at less cost than surveillance, oesophagectomy, or other ablative 
strategies, with the exception of photodynamic therapy (PDT), which gave comparable 
QALYs but at a higher cost (Inadomi et al. 2009). 
 
6.5.2  Identification of areas of uncertainty 
One of the roles of a health economic analysis is to identify areas of uncertainty which 
may guide future study. Key areas have been identified by this study. The first 
concerns the success rate achievable by RFA in eliminating HGD from BM. Data thus far 
show that RFA is very effective at eliminating HGD with success in 90% or more of 
cases, and with removal of BM in between 60-91%. The modelling demonstrated that 
RFA remains cost-effective even if eradication of HGD is achievable in only 60% of cases 
at a willingness to pay of £30000/QALY, a figure well below the 90-97% in published 
trials (Ganz et al. 2008; Gondrie et al. 2008a; Pouw et al. 2008; Sharma et al. 2009; 
Shaheen et al. 2011). 
 
Secondly, the one-way sensitivity analysis suggested that utility of patients post RFA 
with neo-squamous oesophagus would need to be lower than utility of those post 
oesophagectomy. Utility values for patients undergoing RFA have not yet been derived, 
although there is some preliminary evidence that patients with resolution of dysplasia 
post RFA have an improvement in surrogate markers of quality of life, such as 
depression, stress, and difficulty sleeping as measured using a visual analogue scale 
(Shaheen et al. 2008). Conservative estimates of utility were used in the study in this 
thesis, based around known values ascertained by standard gamble technique, 
considered a robust method for deriving utility values (Drummond et al. 2005).
 
Although minimally invasive techniques for oesophagectomy are improving, resulting 
in lower morbidity and mortality, it is unlikely that a surgical approach would be a 
favoured patient preference (Gemmill and McCulloch 2007). 
 
6.5.3  Comparison with health economic evaluation on ablative therapies by NICE 
A recent health economic evaluation by NICE looking at ablative therapies for 
treatment of HGD in BM has demonstrated that RFA with subsequent surveillance 
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(NICE Aug 2010). This in part contrasts the findings presented here, where although 
the cost of RFA increased considerably with surveillance, it was still cheaper than 
oesophagectomy with more QALYs, and thus still dominated oesophagectomy as the 
preferred strategy. The explanation for the lack of parity was the inclusion of the cost 
of proton pump inhibitors in their model in the post RFA, but not in the post 
oesophagectomy strategy. This would unfairly bias the study in favour of 
oesophagectomy for two reasons. Firstly, published quality of life data have suggested 
that up to 75% of patients post oesophagectomy still complain of reflux symptoms, 
and this would likely have a major impact on cost incurred for medication usage, and 
potentially on visits to their general practitioner or hospital consultations (Lagergren et 
al. 2007).  Secondly, in their model no allowance has been made for poor compliance, 
which would lead to falsely high costs in the RFA strategy. 
 
6.5.4  Endoscopic surveillance after ablation with RFA 
The need for or frequency of endoscopic surveillance after successful ablation with RFA 
for HGD is not currently known. The long term stability of the neo-squamous 
epithelium after RFA for HGD is not yet determined and this is likely to lead to 
clinicians continuing surveillance on their patients, despite apparent histological 
resolution. In the model presented here, although the cost of RFA strategy increased 
considerably, it still dominated the oesophagectomy strategy. In both the NICE health 
economic model and the published US study, surveillance considerably added to the 
cost of ablative therapies, and made RFA a more expensive strategy than 
oesophagectomy (Inadomi et al. 2009; NICE 2010b). The frequency and duration of 
follow up endoscopy for patients who have undergone successful ablation will thus 
need to be considered very carefully, once the durability of the neo-squamous mucosa 
has been determined with long term follow up data. 
 
6.5.5  Other ablative therapies 
Other management strategies for treating HGD in BM exist such as surveillance alone, 
PDT or other ablative therapies. In the UK surveillance of those with HGD is not 
presently practiced. Several previous cost-effective analyses comparing ablative therapy 
to surveillance have found surveillance to be costly and inefficient at preventing 
progression to cancer (Shaheen et al. 2004; Vij et al. 2004; Inadomi et al. 2009). 
Studies from the US have demonstrated PDT is an effective alternative to 
oesophagectomy, but at a cost varying between $6000 and $50000/dQALY. However, 
acceptance of PDT as an option in the UK has been hampered by a stricture rate as 
high as 35% in some series, and the ultimate progression to cancer in 15% (Overholt 
2007). Comparatively, the acceptance of RFA as a realistic option is substantiated by 
its low complication rate, demonstrated further by the model presented here, in which Dr CPC Boger  Cost–utility analysis of radiofrequency ablation or oesophagectomy for 
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the procedure related morbidity was 6%, compared with 50% for oesophagectomy. In 
addition, given the data available it appears effective at preventing cancer deaths, with 
terminal cancer the cause of death in only 0.5% of the hypothetical cohort. Currently 
no patient in reported trials has progressed to inoperable cancer, but longer periods of 
follow up are needed before this apparently low risk can be confirmed. 
 
6.5.6  Model assumptions 
6.5.6.1  Barrett’s oesophagus disease states 
There is an established progression from BM through low grade dysplasia (LGD) and 
HGD to invasive adenocarcinoma. For the purpose of this model BM and LGD were 
grouped together. This assumption was based on recent data which has suggested 
that LGD did not appear to confer an increased risk of developing cancer (Sharma et al. 
2006). In fact the majority regressed to BM or went back and forth between LGD and 
BM. In addition, the histological classification and inter-observer agreement in the 
diagnosis of LGD is variable, with factors such as inflammation playing an important 
role in misclassification. 
 
Another assumption is not distinguishing between uni- and multifocal HGD, in 
accordance with the other economic analyses in this area (Inadomi et al. 2009; NICE 
Aug 2010b). There is evidence to suggest that patients with multifocal HGD are more 
likely to have a high risk of progression to adenocarcinoma compared with patients 
with unifocal HGD (Buttar et al. 2001). Even with this increased risk it is felt unlikely 
this would affect the outcome of this model, given the outcome of the threshold 
analysis. In addition these findings were not supported by another retrospective study 
(Dar et al. 2003). The parameters used in the model in this thesis included patients 
with both histological subtypes, and thus one would expect allowance for the potential 
increase risk with multifocal HGD. 
 
6.5.6.2  Exclusion of intra-mucosal cancer 
Those with T1 disease were excluded from this study. Endoscopic resection of OA 
confined to the mucosa (T1a) is practiced in the UK, given the low likelihood of lymph 
node invasion (Stein et al. 2005). However, there is a high risk of recurrent disease, 
with cancer-free survival of 80% in one series (although these patients were able to 
have retreatment endoscopically without influencing survival), compared to 97% of 
those undergoing an immediate oesophagectomy (Prasad et al. 2009). There are 
preliminary data suggesting RFA of the remaining Barrett’s segment after endoscopic 
resection of the T1a lesion can be achieved with favourable outcomes (Pouw et al. 
2008). Follow up was limited to a median of 21 months, during which one patient (of 
16 in the cohort with OA) developed disease infiltrating into the submucosa (stage Dr CPC Boger  Cost–utility analysis of radiofrequency ablation or oesophagectomy for 
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T1b), which may be associated with lymphatic spread in 20% (Stein et al. 2005). The 
quality of life, costs, and outcomes involved in such a treatment strategy are complex, 
and the health economic argument is therefore best served by a separate analysis. 
 
6.5.7  Conclusions 
Randomised controlled trials are generally considered the most robust method of 
determining the benefit of a new treatment (Sibbald and Roland 1998), and certainly 
one could conclude that a randomised control trial of oesophagectomy versus RFA 
would be the next logical step. However randomised control trials are costly and time 
consuming. The results of the model support the case that RFA should be the optimum 
strategy and only with pessimistic parameters does this outcome change.  The model 
may be influenced by the outcome after RFA, and thus prospective long-term outcome 
data from a well-constructed clinical trial, with population matched controls, such as 
the on-going AIM-dysplasia sham-controlled trial in the US, should be sufficient to 
confirm that RFA is the most (cost-) effective strategy. The critical issue then is whether 
clinicians would still have equipoise over the two strategies despite the findings of the 
modelling; if so a definitive trial would still be needed. 
 
In conclusion, the study presented here has suggested that a strategy of RFA with 
oesophagectomy for HGD recurrence is a cost-effective strategy when compared with 
immediate oesophagectomy for the management of BM with HGD in the UK. Sensitivity 
analysis demonstrates that RFA is likely to remain the preferred option, providing that 
removal of HGD in BM is achievable in over 60%. Long term prospective outcome data 
will help clarify whether RFA should become the first line treatment option for HGD in 
BM in the UK. 
 Dr CPC Boger   
 
 
 
CHAPTER 7:   Conclusions and future study 
 
The aim of this thesis was two-fold, firstly to facilitate greater understanding of the 
cellular sites of 5-lipoxygenase (5-LOX) pathway expression in Barrett’s metaplasia (BM) 
and oesophageal adenocarcinoma (OA), and secondly to identify whether 
radiofrequency ablation (RFA) of high-grade dysplasia in BM, compared to 
oesophagectomy, is a cost-effective option in the UK. Both of these aims were 
achieved, and shed light onto these two important areas, as well as provoking 
questions for further study. 
 
  Expression of The 5-LOX pathway in Barrett’s  7.1
metaplasia and oesophageal carcinogenesis and 
impact on future research 
 
There are numerous examples of chronic inflammation in an organ increasing the risk 
of future malignant change. Chronic inflammation in Barrett’s oesophagus, particularly 
with regards to cyclo-oxygenase pathway, has been well studied. The alternative 
leukotriene pathway has not received similar attention. Since Feldberg and Kellaway 
(1938) introduced the name “slow reacting substance (of anaphylaxis)” for a smooth 
muscle-contracting factor in the perforate of guinea pig lung treated with cobra 
venom, diverse roles have been identified for the 5-LOX pathway and its lipid products, 
the leukotrienes. In particular, evidence is building for an important role in the 
development of numerous tumour types in humans. The studies detailed in this thesis 
have added to this evidence and suggest a role for the 5-LOX pathway in BM and OA. 
These results and studies in other tissues provoke interesting hypotheses and a 
proposed role is illustrated in figure 7-A. 
 
The role of infiltrating inflammatory cells is important in carcinogenesis with the 
production of inflammatory mediators playing a significant role. The studies in this 
thesis suggest a particular role for neutrophils in the stromal area of OA tissue where 
they express 5-LOX pathway proteins involved in the biosynthesis of LTB
4 from free 
arachidonic acid. They suggest also the synthesis of LTB
4 and cys-LTs by LTA
4 
hydrolase and LTC
4 synthase within OA epithelium.  
 
The molecular factors initiating the upregulation of 5-LOX pathway protein expression 
in BM and OA warrant further study. Transforming growth factor β (TGF- β) and other 
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macrophages and mast cells are resident within oesophageal tissue and possess the 
capacity to respond to exogenous triggers and generate both LTB
4 and cys-LTs, 
alongside other mediators, that orchestrate the subsequent inflammatory response 
and its subsequent resolution (or failure to resolve). Further recruitment and activation 
of inflammatory cells including neutrophils occurs at least in part via LTB
4 and cys-LTs 
acting on BLT1 and CysLT1 receptors respectively. The novel finding of LTC
4S 
expression by epithelial cells in both BM and OA tissue provides a further cellular 
source of cys-LTs, while confirmation of ubiquitous LTA
4 hydrolase in both stromal and 
epithelial sites provides a mechanism for amplification of LTB
4 pathways. Infiltrated 
neutrophils may engage in transcellular synthesis and donate LTA
4 to epithelial cells 
for this to occur (Haeggstrom 2000). Activation of the G-protein coupled LTB
4 receptor 
1 (BLT1) located to epithelial cells promotes cellular proliferation and survival. The 
finding of epithelial expression of BLT1 receptors may correlate with more advanced 
stage disease and correlation of BLT1 receptor expression with disease stage or 
prognosis would provide clarification. Other LTB
4 pathway enzymes may also be 
important, such as the increased expression of FLAP seen in breast cancer, with high 
levels in aggressive tumours correlating with reduced survival (Jiang et al. 2006) 
 
Whether 5-LOX pathway proteins contribute to the pathogenesis of OA or arise as a 
consequence is not clear and requires further study. Exploring levels of known pro-
inflammatory and angiogenesis factors, such as vascular endothelial growth factor, 
matrix metalloproteinases, and apoptosis regulatory genes, and correlating these with 
5-LOX pathway proteins should provide insight. This could be achieved both in vitro 
and in vivo using developed animal models (rat and mouse) of BM and OA (Xu et al. 
2000). Use of pathway inhibitors could explore the functional relationship of these 
pathways. Genetically altered mice, for example ALOX5 knockouts, could provide 
interesting insights into the importance of the 5-LOX pathway on development of BM 
and OA, as it has for other cancers. This was highlighted recently by the demonstration 
that loss of ALOX5 prevents development of chronic myeloid leukaemia in mice (Chen 
et al. 2009). Mice with deletion of FLAP, LTA
4H, LTC
4S and the BLT and CysLT receptor 
subtypes have also been generated and these could be useful in disentangling their 
roles in appropriate models. Dr CPC Boger  Conclusions and future study 
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Figure 7-A: Illustration of the potential role of 5-LOX pathway in Barrett’s adenocarcinoma Dr CPC Boger   
 
 
 
A full understanding of the role of eicosanoids in carcinogenesis requires unravelling 
of the many enzymatic pathways competing for substrate (see figure 7-B). A delicate 
balance exists between these pathways, with evidence for diversion down alternative 
pathways on selective inhibition. Exploring the preventative role of 5-LOX pathway 
inhibitors in BM with concomitant measurement of these pathways may provide novel 
insights. Inhibition of multiple or highly selective pathways may be required for an 
optimum chemo-preventative role, as there is a growing recognition of arachidonic 
acid as a source not only of inflammatory mediators such as leukotrienes and 
prostanoids, but also of anti-inflammatory, pro-apoptotic and pro-resolving lipid 
mediators derived from 15-LOX and other pathways (Serhan et al. 2008). 
 
 
 
Figure 7-B: Metabolism of arachidonic acid by lipoxygenase and cyclo-oxygenase 
pathways and role in carcinogenesis 
 
  Endoscopic therapy for high risk patients with  7.2
Barrett’s oesophagus  
 
Over the last decade emerging techniques have enabled endoscopic therapy for 
patients with Barrett’s oesophagus at highest risk of developing invasive oesophageal 
adenocarcinoma. Over the last few years RFA using the HALO device has established 
itself as efficacious with minimal morbidity. The cost-effectiveness study described in 
this thesis and published elsewhere (see appendix G) has demonstrated that this 
technique may be performed cost-effectively in a UK setting when compared with the 
current “gold standard” of oesophagectomy. 
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The cost-effectiveness of RFA for patients with HGD or early non-invasive OA has now 
been demonstrated by a number of other independent studies (Inadomi et al. 2009, 
NICE 2010b, Pohl 2009). In this economic modelling, progression to cancer after 
treatment with RFA was an important determinant in the cost-effectiveness. After the 
publication of these studies, two year follow up data from the AIM-dysplasia trial has 
become available in the majority of patients (54/61) (Shaheen et al. 2011). The results 
demonstrate that 95% of patients who underwent RFA for HGD were still free of 
dysplasia. If translated to the health economic models (including that presented in this 
thesis), RFA would still remain a cost-effective strategy. However, the development of 
HGD or cancer in patients with an oesophagus apparently clear of intestinal metaplasia 
at 2 years post therapy, raises some cause for concern (Titi et al. 2012). 5-year 
outcome data should offer more robust conclusions regarding the cost-effectiveness of 
RFA. 
 
Surveillance of non-dysplastic Barrett’s oesophagus every 2-3 years is currently 
practised in the UK despite previous findings that this is a cost-ineffective approach 
when compared with no surveillance, and reduction in mortality is unproven (Garside 
et al. 2006). An on-going randomised controlled trial (BOSS study) hopes to ascertain 
whether surveillance helps to detect early cancers when compared with “at need” 
endoscopy. Notwithstanding the results of this trial, persuading patients with BM not 
to worry unduly about their increased risk of cancer may prove difficult. RFA of non-
dysplastic Barrett’s results in increased QALYs when compared with surveillance alone, 
but with a significant cost and, exceeding the NICE willingness to pay threshold of 
£20000-30000/QALY, and unknown efficacy (Das et al. 2009; Inadomi et al. 2009, 
NICE 2010b). Part of the reason behind this possible failure in a surveillance strategy is 
that the risk of development of OA in BM may have been previously overestimated, 
with most recent studies suggesting a much lower annual risk of 0.1-0.2%, compared 
with 0.5-1% in early studies (Hvid-Jensen et al. 2011; Bhat et al. 2011). The incidence of 
oesophageal cancer however continues to rise and mortality from the disease remains 
largely unchanged. Identifying patients with BM at highest risk in progressing to OA is 
therefore of paramount importance. 
 
Current philosophy relies on the detection of dysplasia, and whilst the treatment of 
HGD appears rational, the treatment of LGD is less certain. Recent studies have 
demonstrated that LGD does confer an increased risk of developing HGD or OA of 
approximately 1.2-1.4% per annum (Hvid-Jensen 2011). The use of other biomarkers 
can however improve this risk stratification and future study should explore whether 
use of these other factors can determine the optimum cost-effective strategy for 
patients with non-dysplastic Barrett’s. Promising panels of biomarkers are in 
development which could be utilised with recent study demonstrating an advantage 
using a panel of 3 biomarkers (LGD, abnormal DNA ploidy, and Aspergillus oryzae Dr CPC Boger  Conclusions and future study 
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lectin) when compared with using LGD, age and sex alone (Lieberman-Bird et al. 2012). 
A future strategy may involve treating those identified at highest risk of progression 
with RFA, whilst reassuring those with minimal or no risk and prevent costly 
surveillance, also shown to impact negatively on patients quality of life. This becomes 
especially paramount given the potential introduction of population screening for BM 
using the Cytosponge (Kadri et al. 2010). In addition, further understanding of the 
lipoxygenase’s in the development of OA may allow innovative new chemo-preventative 
strategies or biomarkers to be developed. 
 Dr CPC Boger   
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Appendix B - Consent form and patient information sheet 
 
 
 
Medicine and Elderly Care 
Department of Luminal Gastroenterology 
Level F, Centre Block, Mail point CF91 
Southampton General Hospital 
Tremona Road 
Southampton SO16 6YD 
 
Tel: 023 80798462 
Fax: 023 80794983 
 
 
15/10/07 (Version 1) 
 
CONSENT FORM 
 
1 for patient, 1 for researcher, 1 for hospital notes 
 
Title of the project:   Donation of biopsy/tissue during gastroscopy for research in 
understanding the progression of Barrett’s oesophagus 
 
Name of researcher: Dr P Boger 
 
PART A. 
 
1. I have read the attached information sheet on the above project dated 15/10/07 
and have been given a copy to keep. I have had the opportunity to ask questions 
about  the  project  and  understand  why  the  research  is  being  done  and 
understand any foreseeable risks involved. 
 
2.   I understand that my participation is voluntary and that I am free to withdraw my 
approval at any time without giving a reason and without my medical care or 
legal rights being affected. 
 
3.  I give permission for my medical records to be looked at and information taken 
from them to be analysed in strict confidence by responsible people involved in 
this research project. 
 
4.  I understand that (my doctor and/or I) will be informed if any of the results of the 
medical tests done as part of the research are important for my health. 
 
5.  I agree to take part in the above study to collect a sample of the lining of my 
gullet. 
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SAMPLES GIFTED FOR STORAGE AND USE IN FUTURE STUDIES 
 
PART B. Linked Annonymised Samples 
 
6.  Provided  that  specific  study  protocols  have  been  reviewed  and  approved  by  the  Local 
Research Ethics Committee, I indicate my consent for the sample and its derived cells to 
be stored (potentially for many years) for the following types of studies. I understand that 
these studies are not for the purpose directly benefiting my health. 
 
a)  I  give  permission  for  the  sample  to  be  used  for  treatments/investigations  of 
medical conditions relating to Barrett’s oesophagus. 
 
b)  I give permission for the sample to be stored for use in other unrelated research 
studies the precise nature of which will depend upon future scientific advances, 
but excluding genetic studies and germ-line research. 
 
c)  I want / do not want (delete as applicable) to be told the results of this test. I 
understand I can change my mind about this later. 
 
d)  In the case of linked annonymised samples, I give permission for a member of 
the research team to look at my medical records, to obtain further information 
about  my  medical  condition.  I  understand  that  the  information  will  be  kept 
confidential. 
 
 
PART C. Unlinked Annonymised Samples 
 
6.  Provided  that  specific  study  protocols  have  been  reviewed  and  approved  by  the  Local 
Research Ethics Committee, I indicate my consent for the sample and its derived cells to 
be stored (potentially for many years) for the following types of studies. I understand that 
these studies are not for the purpose directly benefiting my health. 
 
a)  I  give  permission  for  the  sample  to  be  used  for  treatments/investigations  of 
medical conditions relating to Barrett’s oesophagus. 
  
b)  I give permission for the sample to be stored for use in other unrelated research 
studies the precise nature of which will depend upon future scientific advances, 
but excluding genetic studies and germ-line research. 
 
c)   I understand that future research, using the sample I give may include genetic 
research aimed at understanding the genetic influences on the development and 
progression of Barrett’s oesophagus. 
 
d)  I understand that the sample may be used for commercial development, without 
financial or other benefit to myself, for the investigation and treatment of medical 
conditions,  potentially  leading  to  new  preventative  measures  against  such 
conditions in keeping with the gift nature of my sample. 
 
______________________    _______________    _________________ 
Patient name  Date  Signature 
 
______________________    _______________    __________________ 
Consenter (if not researcher)  Date  Signature 
 
______________________    _______________    __________________ 
Researcher  Date  Signature 
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Medicine and Elderly Care 
Department of Luminal Gastroenterology 
Level F, Centre Block, Mail point CF91 
Southampton General Hospital 
Tremona Road 
Southampton SO16 6YD 
 
Tel: 023 80796872 
Fax: 023 80794983 
 
15/10/07 
Patient Information Sheet (Version 1) 
 
Dear patient, 
 
Title of the project:   Donation of biopsy/tissue during gastroscopy for research in 
understanding the progression of Barrett’s oesophagus 
 
You are being invited to take part in a research study. This information sheet will help  you 
understand why the research is being done and what it will involve. Please take time to read the 
following information carefully and discuss it with friends, relatives, or your doctor/consultant if 
you wish. Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part. 
 
Thank you. 
 
1. What is the purpose of this study? 
We are conducting a study in order to better understand the role of certain enzymes (biological 
markers) in Barrett’s oesophagus (inner lining of the gullet). A minority of patients with Barrett’s 
oesophagus can develop further changes in this inner lining of their gullet. We are investigating 
the role of certain enzymes, which could explain why some patients with Barrett’s oesophagus 
develop further changes in the inner lining of their gullet. For this research, we would like to take 
some additional samples (biopsies) during your planned gastroscopy. Your help by participating 
in this study will be greatly appreciated. 
 
2. Why have I been chosen? 
You have Barrett’s or related condition and are attending for gastroscopy (your consultant will 
have explained this to you) for clinical reasons. For our research project we are collecting six 
extra biopsies from patients with Barrett’s related conditions and your help will be appreciated. 
 
3. Do I have to take part? 
You don’t have to take part in this study as participation is entirely on a voluntary basis and it is 
up to you to decide whether or not to take part. If you do decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form. Furthermore, you are still 
free to withdraw at any time without giving a reason. This will not affect the standard of care you 
receive. 
 
 
4. What will happen to me if I take part? 
You will have  your gastroscopy procedure as planned by  your consultant/doctor. During the 
procedure we will take six additional biopsies from your gullet. This will not cause any extra pain Dr CPC Boger  Appendix 
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or  discomfort  but  might  prolong  your  procedure  by  a  minute.  This  will  not  affect  your 
treatment in any way and does not involve any other tests, follow-up visits or interviews. 
 
5. What do I have to do? 
Taking part in his study does not involve any extra dietary, drugs or lifestyle restrictions. You 
should follow the standard advice given to you before and after gastroscopy. 
 
6. What are the possible disadvantages and risks of taking part? 
There are no extra disadvantages or risks over and above that for gastroscopy, which you are 
having for clinical reasons. 
 
7. What are the possible benefits of taking part? 
There  are  no  immediate  benefits  to  you  but  this  research  might  help  to  improve  the 
management of this condition in the future. 
 
8. What if new information becomes available? 
Sometimes during the course of a research project, new information becomes available. If this 
happens, your research doctor will tell you and your doctor about it. 
 
9. What if something goes wrong? 
It is difficult to foresee any harm resulting from this study. If taking part in this research project 
harms  you,  there  are  no  special  compensation  arrangements.  If  you  are  harmed  due  to 
someone’s negligence, then you may have grounds for legal action, but you may have to pay 
for it. Regardless of this, if you wish to complain about any aspect of the way you have been 
approached or treated during the course of this study, the National Health Service complaints 
mechanisms may be able to help you. 
 
10. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept strictly 
confidential. Any information about you that leaves the hospital/laboratory will have your name 
and address removed so that you cannot be recognized from it. 
 
11. What will happen to the results of the study? 
We  intend  to  have  the  study  published  in  a  relevant  medical  or  professional  journal. While 
sometimes this attracts attention form journalists, you will never be identified in any report or 
publication. There are no declared interests from any commercial company. 
 
12. What will happen to the biopsies/tissue samples after the study? 
With your permission (Consent form part C) we would like to store the remaining tissue samples 
in an unlinked anonymised manner to use in possible future approved research. This means 
that the tissue samples will be given a unique code number and stored for future research. With 
this code number it will be possible for the researcher to identify the samples but not you or your 
personal details. 
 
13. Who is funding the research? 
This research is being partly funded by a regional charity (Wessex Cancer Trust) but the doctor 
conducting the research is not being paid for including and looking after the patient in this study. 
 
 
14. Who has reviewed the study? 
The  Isle  of Wight,  Portsmouth  and  Southeast  Hampshire  Research  Ethics  Committee  have 
reviewed this study. 
 
15. Contacts for further information 
You may contact the research doctor, Dr P Boger directly on the telephone number given at the 
head of this information sheet, or discuss any aspect of the study with your doctor. 
 
THANKYOU 
 
You may keep a copy of this information sheet and the consent form you have signed.Dr CPC Boger  Appendix 
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Appendix C - Solutions/laboratory protocols 
 
Tris Buffered Saline (pH 7.6) 
Sodium Chloride        80g     
Tris            6.05g   
1M Hydrochloric Acid        38mls 
Distilled water         10L 
 
Mix buffer salts and acid in 1L of distilled water, adjust pH to 7.65 and add to remaining 
9L of water to give a final pH of 7.6. 
 
Processing of tissue into Glycol Methacrylate (GMA) 
Steps 4 through to 7 of this procedure must carried out under a fume extraction hood.  
         
1.  Place biopsy immediately into ice cold acetone containing 2mM phenyl methyl sulphonyl 
fluoride (35mg/100ml, 175mg/500ml) and 20mM iodoacetamide (370mg/100ml, 
1.85g/500ml). 
2.  Fix overnight at -20
oC. 
3.  Replace fixative with acetone at room temperature, 15 mins. 
4.  Methyl benzoate at room temperature, 15 mins. 
5.  Infiltrate with processing solution:5% methyl benzoate in glycol methacrylate (GMA 
solution A) at 4
oC, 3 x 2 hours 
6.  Prepared embedding solution:  GMA solution A 10mls 
          benzoyl peroxide 70mg 
dissolve the benzoyl peroxide in solution A by gentle shaking, when dissolved add  GMA solution B 
250µl 
7.  Embed specimens in freshly prepared embedding solution in Taab flat bottomed capsules, 
placing biopsy in the bottom of the capsule and filling to the brim with resin and closing lid 
to exclude air 
8.  Polymerise at 4
oC for 48 hours 
9.  Store in airtight boxes at -20
oC. 
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White cell isolation for RT-QPCR 
1.  6mls of acetyl citrate dextran solution to collection tube 
2.  Take blood, add to tube 
3.  Add 15mls dextran (6%) to 30mls blood 
4.  Allow to sediment at room temperature for 60minutes (with lid turned upside 
down to prevent top bubble formation), until clear interface between blood and 
plasma 
5.  Remove plasma with 25ml pipette and place in fresh tube. Discard red cells 
6.  Spin plasma @ 1150 x 12min at RT 
7.  Remove supernatant 
8.  Add TRIzol.Dr CPC Boger  Appendix 
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Appendix D - search strategies for parameters used in 
model 
 
Oesophagectomy for HGD 
Search strategy 
Population - patients with HGD undergoing oesophagectomy 
Intervention - oesophagectomy 
Comparator - No oesophagectomy or other treatment modality i.e. PDT 
Outcome - Morbidity, Operative mortality, Post-operative progression to 
adenocarcinoma, 5-year survival 
 
Search terms - (high grade dysplasia OR dysplasia OR Barrett’s oesophagus OR 
intestinal metaplasia) AND (oesophagectomy) AND (mortality OR morbidity OR 
complication OR survival OR adenocarcinoma) 
 
Progression to adenocarcinoma post oesophagectomy after surgery for post RFA 
recurrence 
Search strategy 
Population - patients with OA undergoing oesophagectomy 
Intervention - oesophagectomy 
Comparator - No oesophagectomy or other treatment modality i.e. PDT 
Outcome – Mortality, 5-year survival 
 
Search terms - (oesophagus) AND (adenocarcinoma) AND (oesophagectomy) AND 
(mortality OR survival) 
 
RFA for HGD 
Parameters required: 
Outcomes after RFA (Squamous lined oesophagus, Barrett’s oesophagus without HGD, 
HGD or OA) 
RFA complications (no complications, perforation, stricture requiring dilatation) 
 
Search strategy 
Population - Patients with HGD in Barrett’s oesophagus 
Intervention - oesophagectomy 
Comparator - No oesophagectomy or other treatment modality i.e. PDT 
Outcome – Removal of HGD, removal of Barrett’s, post ablation progression to HGD or 
oesophageal adenocarcinoma, morbidity, procedural mortality, 5-year survival 
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Search terms - (high grade dysplasia OR dysplasia OR Barrett’s oesophagus OR 
intestinal metaplasia) AND (Radiofrequency ablation OR ablation OR HALO) AND 
(mortality OR morbidity OR complication OR survival OR adenocarcinoma) 
Mortality rate after oesophageal perforation or dilatation for oesophageal stricture 
 
Mortality from other endoscopic procedures 
Parameters required: 
i) Death from iatrogenic oesophageal perforation 
ii) Death from oesophageal dilatation 
 
Search strategy 
Population - Patients undergoing endoscopic dilatation of a benign oesophageal 
stricture or patients who have suffered a oesophageal perforation after an upper 
gastrointestinal endoscopy 
Intervention - upper gastrointestinal endoscopy, oesophageal dilatation 
Comparator - no dilatation or best supportive care 
Outcome – perforation of oesophagus, procedural mortality 
 
Search terms - (oesophageal dilatation OR oesophageal perforation) AND (endoscopy) 
AND (mortality OR morbidity OR survival) 
 
Utility of oesophagectomy health states 
A search strategy of (oesophagectomy) AND (quality of life OR utility OR utilities) 
identified. 
 
Utility of various Barrett’s disease states 
A search strategy of (Barrett’s) AND (quality of life OR utility OR utilities). 
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Appendix E - Utilities 
 
Post oesophagectomy health states 
The model cycle was 6-months although the median length of hospital stay is 10 days 
after an oesophagectomy, followed by a recovery phase at home. Utility values for the 
oesophagectomy health states were therefore calculated to reflect this as follows: 
 
For 10 days whilst in hospital - utility of oesophagectomy without complications = 0.9, 
or utility of oesophagectomy with complications = 0.82 
 
Followed by a utility of 0.92, to represent the recovering at home phase for the rest of 
that cycle. 
 
Therefore utility of oesophagectomy without complication 
= ((1/18) * 0.9) + ((17/18) * 0.92) 
= 0.92 
 
And utility of oesophagectomy with complications 
= ((1/18) * 0.82) + ((17/18) * 0.92) 
= 0.91   Dr CPC Boger  Appendix 
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Appendix F - Costs used in the model 
 
Radiofrequency ablation 
The table below summarises the calculations for the RFA costs. 
 
Number of 
units 
Cost per unit* 
(£) 
Total 
(£) 
Fixed       
Purchase HALO 360 generator  1  21500  21500 
Purchase HALO 90 generator  1     11000  11000 
      32500 
Annual equivalent cost (1/7
th)**  0.14         32500  4643 
Variable       
HALO 360 catheter  1   985   985 
HALO 90 catheter  2  650   1300 
Sizing balloon  1  320  320 
Endoscopy unit staff/time and 
other running costs (HRG code 
FZ03A) 
3  406  1218  
Total variable cost for 100 patients       382300 
Total (fixed and variable) cost for 
100 patients 
    386943 
Average cost per patient over 1st 
year 
    3869.43 
 
*all costs discounted at 3.5% per annum, **generators estimated by manufacturer to 
last 7 years total. 
 
Oesophagectomy 
The cost code that best matches uncomplicated oesophagectomy is FZ01B - Complex 
Oesophageal Procedures 19 years and over without CC at £6342 per elective 
procedure. The cost code that best matches complicated oesophagectomy is FZ01A - 
Complex Oesophageal Procedures 19 years and over with CC at £9305 per elective 
procedure. 
Patients who require an oesophagectomy after developing a perforation from RFA will 
require a non-elective oesophagectomy i.e. emergency. There is an additional cost for 
performing a non-elective oesophagectomy in the National tariff system. In the model, 
the full cost of an oesophagectomy is accrued as the patient moves into the Dr CPC Boger  Appendix 
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complicated oesophagectomy health state. This additional cost is therefore calculated 
as: 
 
£11924.00 (HRG code FZ01A Non-elective oesophagectomy with cc) - £9305.00 (FZ01A 
Elective oesophagectomy with cc FZ01A) 
 
Endoscopic procedures 
During the post RFA surveillance schedule patients require a routine gastroscopy with 
taking of quadrantic biopsies every 2cm. The cost code that best matches this is FZ03A 
- Diagnostic and intermediate procedures on the upper GI tract 19 years and over, 
planned same day tariff at £407 per procedure. 
 
Oesophageal dilatation is performed endoscopically as a day case procedure. The cost 
code that best matches this is FZ25A - Therapeutic Endoscopic or Intermediate 
Stomach or Duodenum Procedures 19 years and over, planned same day tariff at £427 
per procedure. 
 
Post oesophagectomy care 
Follow up post oesophagectomy was based on policy at Southampton University 
Hospital trust where patients are followed up after oesophagectomy as follows; 
3-monthly during year 1, 6-monthly during years 2 and 3, annual years 4 and 5, then 
discharge from follow up if well. 
Each outpatient visit accrues a cost, and the HRG code that best matches is 100 – 
general surgery outpatients at £72 per visit. This cost is subject to discounting at 3.5% 
per annum, and thus cost of outpatient visits in year 2 is £69.48, year 3 - £67.05, year 
4 - £64.07, and year 5 – 62.44. 
 
Palliation of untreatable adenocarcinoma 
Costs were based on those previously estimated by Garside et al. 2006. We have thus 
allowed £1000 for GP and nursing costs, placement of an oesophageal stent, and 4 
days respite care in hospital. The cost code that best matching oesophageal stent 
insertion is FZ24C - Major Therapeutic Open or Endoscopic Procedures 19 years and 
over without CC at £1379 per procedure. The cost code best matching respite care is 
WA15U - Respite care length of stay 4 days or less without CC at 1484 per stay. This 
gives a total cost of £3863 per patient for palliation of untreatable adenocarcinoma. Dr CPC Boger  Appendix 
203 
 
Appendix G - Full publications arising from thesis 
 
Boger P.C., Turner D., Roderick P., Patel P. (2010). A UK-based cost–utility analysis of 
radiofrequency ablation or oesophagectomy for the management of high-grade 
dysplasia in Barrett’s oesophagus. Alimentary Pharmacology & Therapeutics 32(11-
12): 1332-1342. 
 
Boger P.C., Shutt, J. D., Neale J. R., Wilson S. J., Bateman A. C., Holloway J. W., Patel P., 
Sampson A. P. Increased expression of the 5-lipoxygenase pathway and its cellular 
localization in Barrett's adenocarcinoma. Histopathology 61(3): 509-17. 
  
 
 
 A UK-based cost–utility analysis of radiofrequency ablation or
oesophagectomy for the management of high-grade dysplasia
in Barrett’s oesophagus
P. C. Boger*, D. Turner
, P. Roderick
 & P. Patel*
*Department of Luminal
Gastroenterology, MP CF91, Level F
Centre Block, Southampton General
Hospital, Tremona Road, Southampton
SO16 6YD, UK.
Wessex Institute University of
Southampton, Alpha House,
Enterprise Rd, Southampton Science
Park, Chilworth, Southampton SO16
7NS, UK.
Public Health Sciences and Medical
Statistics, C Floor, South Academic
Block, Southampton General Hospital,
University of Southampton, Tremona
Road, Southampton SO16 6YD, UK.
Correspondence to:
Dr P. C. Boger, Department of Luminal
Gastroenterology, MP CF91, Level F
Centre Block, Southampton General
Hospital, Tremona Road, Southampton
SO16 6YD, UK.
E-mail: philboger@btinternet.com
Publication data
Submitted 17 May 2010
First decision 14 June 2010
Resubmitted 12 August 2010
Accepted 18 August 2010
EV Pub Online 13 September 2010
SUMMARY
Background
In the UK, oesophagectomy is the current recommendation for patients
with persistent high-grade dysplasia in Barrett’s oesophagus. Radio-
frequency ablation is an alternative new technology with promising early
trial results.
Aim
To undertake a cost–utility analysis comparing these two strategies.
Methods
We constructed a Markov model to simulate the natural history of a cohort
of patients with high-grade dysplasia in Barrett’s oesophagus undergoing
one of two treatment options: (i) oesophagectomy or (ii) radiofrequency
ablation followed by endoscopic surveillance with oesophagectomy for
high-grade dysplasia recurrence or persistence.
Results
In the base case analysis, radiofrequency ablation dominated as it generated
0.4 extra quality of life years at a cost saving of £1902. For oesophagectomy
to be the most cost-effective option, it required a radiofrequency ablation
treatment failure rate (high-grade dysplasia persistence or progression to
cancer) of >44%, or an annual risk of high-grade dysplasia recurrence or
progression to cancer in the ablated oesophagus of >15% per annum. There
was an 85% probability that radiofrequency ablation remained cost-effective
at the NICE willingness to pay threshold range of £20 000–30 000.
Conclusion
Radiofrequency ablation is likely to be a cost-effective option for high-grade
dysplasia in Barrett’s oesophagus in the UK.
Aliment Pharmacol Ther 2010; 32: 1332–1342
1332 ª 2010 Blackwell Publishing Ltd
doi:10.1111/j.1365-2036.2010.04450.x
Alimentary Pharmacology and TherapeuticsINTRODUCTION
Barrett’s oesophagus (BO) is estimated to be prevalent in
0.5–2% of adults in the western world, rising to approxi-
mately 15% in those with chronic gastro-oesophageal
reﬂux disease.
1–3 The main complication is the develop-
ment of oesophageal adenocarcinoma (ADC), the inci-
dence of which is highest in the UK and rising faster
than any other solid tumour in western countries.
4, 5
Once invasive cancer develops, the outlook is poor, with
a 5-year survival of only 10–13%.
6, 7 In an attempt to
preempt this, it is currently recommended that patients
with BO undergo surveillance endoscopy every 2–3 years.
Detection of premalignant or dysplastic change on
biopsy signals an increased risk of malignant develop-
ment, especially high-grade dysplasia (HGD), where the
risk of progression to invasive cancer is 30–35% within
5 years.
8
Current UK guidance recommends that for patients
with persistent HGD despite intensive acid suppression,
oesophagectomy be performed in a specialist centre in
those ﬁt for surgery.
9 However, surgical oesophagectomy is
a high-risk procedure, even in tertiary centres, with a 30-
day mortality rate of 3.2%, signiﬁcant post-operative com-
plications in up to 40%, and long-term morbidity.
10, 11
Oesophagectomy is expensive, with an average cost to the
NHS of approximately £7500⁄person.
A number of alternative less invasive ablative therapies
exist that aim to remove the dysplastic Barrett’s epithe-
lium and facilitate the restoration of normal squamous
epithelium. Photodynamic therapy (PDT), approved by
the National Institute for Clinical Excellence (NICE) for
treatment of HGD in BO, involves intravenous adminis-
tration of a photosensitizing agent, followed by endo-
scopic light laser exposure to the Barrett’s segment.
12
PDT is effective in eliminating HGD in BO.
13 However,
widespread acceptance of the technique has been held
back by treatment-related adverse events in up to 94%
and a high incidence of oesophageal strictures in up to
36%.
14
Radiofrequency ablation (RFA) using the HALO
device is an alternative new management strategy for
patients with HGD in BO. Recent results from a ran-
domized sham controlled study have shown that it is
effective in eliminating HGD in BO in up to 90% of
patients with complete reversion to squamous oesopha-
geal lining in 80% at 12-month follow-up, and minimum
treatment-related side effects.
15 The cost per patient to
the NHS is not currently known, and there has been
no randomized controlled trial comparing RFA and
oesophagectomy.
The aim of this study was to model whether RFA fol-
lowed by oesophagectomy for persistence or recurrence
of HGD is a cost-effective option for the treatment of
BO with HGD when compared with the current UK rec-
ommendation of oesophagectomy, and to identify critical
parameters to guide further research.
METHOD
Patients
Our model consisted of a hypothetical cohort of 100
male patients aged 64 years, the mean age of patients
undergoing oesophagectomy for HGD in published trials
over the last 10 years.
16–26 We assumed the following
pretreatment assessment for both strategies: endoscopy
had been undertaken on two occasions revealing BO
with HGD, and any visible nodules, masses or surface
irregularities had been removed by endoscopic mucosal
resection. Patients found to have invasive cancer after
endoscopic mucosal resection were excluded from the
analysis. It is assumed that patients were ﬁt for both
treatment modalities. The model included patients with
either uni- or multifocal HGD.
The model
A Markov model was constructed in Microsoft Excel
to simulate the two treatment strategies; RFA with
surveillance and oesophagectomy for HGD or ADC
recurrence⁄persistence, or immediate oesophagectomy.
Figures 1 and 2 summarize the structure of the treatment
Oesophagectomy
Uncomplicated Complicated
No stricture
Anastamotic
stricture
Well post
oesophagectomy
Death from all
states
Terminal
cancer
Figure 1 | Transition state diagram of oesophagectomy
treatment strategy.
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procedural and postprocedural complications and mor-
tality reported in the literature. At the end of each cycle,
which corresponded to 6 months, patients would pro-
gress to a health state depending on the derived transi-
tion probabilities. UK life table mortality rates were
incorporated into the model to account for age-speciﬁc
mortality from other causes.
27 Utility and cost were
attributed to each state, which patients would accumulate
as they progressed through the model. The study
followed up the cohort for 25 years or until death. We
estimated costs from an NHS perspective and outcomes
from the viewpoint of the patient. All costs and beneﬁts
were discounted at 3.5% as recommended by the NICE.
28
Treatment strategies and model assumptions
Oesophagectomy. In this strategy, patients with con-
ﬁrmed HGD in BO underwent immediate oesophagectomy.
If a patient developed ADC post-operatively, it was
assumed that he entered a 6-month terminal cancer
phase, representing the median survival time with inop-
erable oesophageal cancer, and allowing the modelling of
costs and measures of quality of life experienced by this
group of patients, such as palliation of dysphagia with
oesophageal stenting.
29 If a patient did not progress to
terminal cancer during the ﬁrst 5-years postoesophagec-
tomy, he was considered cured. All patients were fol-
lowed up in outpatient clinics post-oesophagectomy for
5 years as follows: 3-monthly for year 1, 6-monthly for
the years 2 and 3, and then annually for years 4 and 5.
Radiofrequency ablation. In this strategy, patients with
conﬁrmed HGD in BO underwent a treatment course of
RFA with the HALO device (Barrx Medical, Sunnyvale,
CA, USA). This is delivered endoscopically under con-
scious sedation as a day-case procedure. The HALO 360
is a balloon-based device that is able to deliver a circum-
ferential radiofrequency burn to the mucosal lining of
the oesophagus, whereas the HALO 90 allows targeting
of mucosa over an approximate 90  radius. Published
experience to date suggests an average of two HALO
360, and two HALO 90 sessions are needed per patient
to achieve complete removal of the Barrett’s segment
and replace it with a neo-squamous lining.
30
There is no ﬁxed surveillance strategy for patients
with neo-squamous and BO post-RFA. For the base
case analysis, we assumed the following strategy. If neo-
squamous oesophagus is found after RFA, then yearly
endoscopy was performed for 5 years, and if free of BO
or worse pathology after that time, no further endoscopic
follow-up was undertaken. If the patient had BO after
RFA treatment, yearly endoscopy was performed for the
ﬁrst 5-years, and if free of HGD or worse at that time,
endoscopic surveillance continued on a 2-yearly basis as
per current UK practice. In the scenario analysis, this
screening protocol was altered to analyse what effect it
would have on the outcome of our cohort.
If HGD or ADC is picked up during the above sur-
veillance strategies, the patient undergoes an oesophagec-
tomy. This part of the RFA model has the same
structure as the oesophagectomy strategy. We assumed
that the risk of developing cancer in the neo-squamous
oesophagus is most probable during the ﬁrst 5 years
post-treatment, and thus after this period (as with the
postoesophagectomy group), the patient was considered
cured.
The risk of developing HGD or ADC in patients with
neo-squamous oesophagus was estimated using published
Stricture
Squamous Barrett's
Oesophagectomy
Complicated
oesophagectomy
Uncomplicated
RFA
Death from all
states except
RFA
RFA
Perforation
HGD/ADC
Figure 2 | Transition state
diagram of radiofrequency
ablation (RFA) treatment
strategy.
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termed subsquamous intestinal metaplasia (IM).
15 The
low value assumed no risk of residual subsquamous IM
and the high value assumed a higher risk of having non-
visible islands of Barrett’s found with previous ablative
therapies, and assuming that the residual Barrett’s con-
tained HGD.
31
There are no data on the outcome of those with treat-
ment failure post-RFA. For this, we have drawn parallels
with data from other ablative therapies (PDT) where
longer term follow-up is available. This demonstrates
that treatment failures were still operable at time of pro-
gression, and revealed disease not extending beyond the
submucosa (T1) on post-operative staging.
22 On this
basis, in our model, those with post-RFA treatment fail-
ure had operable disease, but with a reduction in 5-year
survival consistent with the predicted more advanced
disease.
Search strategy for parameters
Parameter values for transition probabilities and utilities
were obtained from peer reviewed literature. We
searched the Medline database for the period from May
1999 to May 2009, as well as abstracts from Digestive
Diseases week and British Society of Gastroenterology
Annual Meeting. Bibliographic lists of relevant articles
were searched, and in addition, we obtained a list of rele-
vant papers from the manufacturers of the HALO device.
We chose the most suitable study (studies) to provide
the parameters for the base case, using data from ran-
domized controlled trials, if available. If not available, we
chose data from well-constructed observational (cohort)
studies, with inclusion criteria similar to those in our
hypothetical cohort. We assessed inclusion criteria, base-
line assessment, size, duration of follow-up, loss to fol-
low-up and assessment of outcome. In addition to the
base case values, we selected a plausible range (high⁄low
values) for use in the sensitivity analysis. This range was
derived from variations in the published literature, or by
author consensus when information was not available or
there was considerable uncertainty in the literature.
Annual risks and 5-year survival data were converted to
6-monthly probabilities using validated formulae,
32 with
the assumption that 6-monthly progression rates were
constant. Derived transition probabilities are shown in
Table 1.
Utilities
Where available, we selected utilities derived using the
standard gamble methodology, which avoids measurement
biases associated with ratings scales, such as a visual
analogue score.
39 We were unable to obtain utility values
for all model states, and thus used known recorded
values to provide a framework by which unknown values
were estimated by consensus among the authors. Low
and high values were derived either from 95% conﬁdence
intervals if available, or estimated by the authors to allow
for the uncertainty surrounding the individual parameter.
Derived utilities are shown in Table 2. Utility values
were then used to generate quality adjusted life years
(QALYs), which were used as the outcome measure in
the model.
Costs
The costs used in the model are shown in Table 3. A
majority of costs were estimated from NHS reference
costs.
42 This derives costs from nationally collected data
from NHS trusts and calculates an average total cost of
delivering a treatment episode to a patient. The cost of
RFA is not available on this national tariff and thus was
estimated using direct and variable costs derived from
information obtained from the UK distributor (Synetics
Medical Limited, Middlesex, UK). All costs were for
2009⁄2010 and are shown in UK pounds sterling. For
the sensitivity analysis, all cost were varied by  25%.
Sensitivity analysis
Deterministic. To enable thorough interrogation of the
model and the input parameters, we initially undertook
one-way sensitivity analysis, in which the various param-
eters in the model are varied throughout the speciﬁed
range to assess how this impacts study results.
39 For
areas where uncertainties in the literature were identiﬁed
or to interrogate areas where assumptions had been
made, we undertook threshold analysis, which allows the
critical value of a parameter central to the decision to be
identiﬁed.
39 Where uncertainty in the methodology of
the model existed such as in the time period of surveil-
lance post-RFA, a scenario analysis was undertaken to
explore the effects of increasing surveillance.
Probabilistic. Probabilistic sensitivity analysis allows for
all input parameters in a model to be speciﬁed as full
probability distributions, rather than point estimates,
allowing a representation of the uncertainty surround-
ing their values.
43 In the UK, it is a requirement for
all cost effectiveness models submitted to NICE. The
distributions and parameters used for each variable in
the model are shown in Tables 1–3. For probabilities of
an event either occurring or not occurring, we used
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Description
Base case
estimate Range Distribution Source
RFA complications
No complications 0.94 0.90–1 Jointly determined
Dirichlet
15, 33, 34; assumption
Perforation 0.0005 0–0.005
Stricture requiring dilatation 0.06 0–0.09
Outcomes after RFA
Neo-squamous lined oesophagus 0.82 0.45–0.91 Jointly determined
Dirichlet
15, 33, 34; assumption
Barrett’s oesophagus without HGD 0.11 0.09–0.25
HGD or adenocarcinoma 0.08 0–0.30
Progression probabilities during post-RFA surveillance (per cycle – 6 months)
Neo-squamous to HGD⁄ADC 0.0002 0–0.0027 Beta (a =1 ,b = 4596)
31, 35, 36
Barrett’s to HGD⁄ADC 0.0068 0–0.0085 Beta (a =4 ,b = 953)
Oesophagectomy complications
Peri-operative complications 0.37 0.27–0.57 Beta (a = 26, b = 44)
18, 22, 25
Anastamotic stricture 0.51 0.13–0.83 Beta (a =2 7 ,b = 26)
18, 22, 26
Progression to adenocarcinoma postoesophagectomy
After oesophagectomy for HGD 0.001 0–0.007 No distribution
18, 22, 23, 25
After oesophagectomy for post-RFA
recurrence
0.0057 0–0.021 Beta (a = 18, b = 3239)
22, 37
Mortality
Death from iatrogenic oesophageal
perforation
0.35 0–0.5 Beta (a =2 ,b = 15)
38
Death from oesophageal dilatation 0.005 0–0.01 Beta (a =3 ,b = 551)
38
Death from oesophagectomy 0.014 0–0.045 Beta (a =1 ,b = 69)
22, 23, 25, 26, 37
RFA, radiofrequency ablation; HGD, high-grade dysplasia; ADC, adenocarcinoma.
)
 
g
Table 2 | Health state utilities
Description
Base case
estimate Range Distribution Source
RFA without complications 0.94 0.84–1 Beta (a = 31, b = 2) Assumptions based on
reference
40 and
41
RFA complicated by stricture 0.92 0.82–1 Beta (a = 31, b =3 )
Post-RFA with neo-squamous oesophagus 0.97 0.9–1 Beta (a = 42, b =1 . 3 )
Post-RFA with Barrett’s oesophagus 0.95 0.883–1 Beta (a =5 0 ,b =3 )
Oesophagectomy without complications 0.92 0.77–1 Beta (a =1 9 ,b =2 )
40
Oesophagectomy with complications 0.91 0.66–1 Beta (a =9 ,b =1 )
Anastamotic stricture post-oesophagectomy 0.92 0.841–0.999 Beta (a =4 1 ,b =4 )
41
Fully recovered post-oesophagectomy 0.96 0.89–1 Beta (a = 46, b =2 )
40
Terminal oesophageal cancer 0.34 0.03–0.65 Beta (a =3 ,b =5 )
RFA, radiofrequency ablation.
)
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1 and hence avoid unfeasible values. As the method of
generating utilities used was based on standard gamble,
negative values were not possible, and hence the beta
distribution is appropriate. Where more than two
events are possible, Dirichlet distributions were chosen,
which ensure that the total values of the probabilities
of all events considered sum up to 1. Gamma distribu-
tions cannot take negative values and have a skewed
distribution, which is characteristic of many forms of
cost data.
We repeatedly ran the model 5000 times using
values randomly drawn from these distributions. To
illustrate the uncertainty relating to our cost effectiveness
results, we calculated a cost effectiveness acceptability
curve, which estimates the probability that an interven-
tion is cost-effective at different values of a QALY.
44
RESULTS
Base case
The results from the base case analysis are summarized
in Table 4. For a 64-year-old male patient, a strategy of
RFA followed by oesophagectomy, if there was disease
recurrence, would be expected to cost £1902 less and
result in 0.4 more QALYs, when compared with immediate
Table 3 | Costs Cost estimate (£) Base case* Reference
Treatment course of RFA 3869 Costs supplied by
Synetics Medical Ltd
Additional cost from developing perforation
from RFA (excludes oesophagectomy)
2619 NHS reference costs
2009⁄2010
42
Routine endoscopy and biopsies 406
Elective oesophagectomy 6342
Oesophagectomy with complications 9305
Oesophageal dilatation 427
Outpatient follow-up per visit 72
Palliation of untreatable adenocarcinoma 3863
36, NHS reference
costs 2009⁄2010
42
RFA, radiofrequency ablation.
* For the probabilistic sensitivity analysis, we used a gamma distribution on the assump-
tion that  25% formed a 95% conﬁdence interval.
)
Table 4 | Base case results
Outcome per strategy Oesophagectomy RFA
Incremental
ratio
Cost (£) 8555 6653 )1902
Unadjusted life-years 17.0 17.4
QALY 13.8 14.2 0.4
Incremental cost effectiveness
ratio (£⁄QALY) Dominates
Morbidity (%)
Procedural 37.1 3.9
Strictures 50.0 16.9
Causes of death (% deaths)
Age-related 96.4 99.1
Surgical 1.9 0.2
Endoscopic 0.7 0.2
Cancer 1 0.5
RFA, radiofrequency ablation; QALY, quality adjusted life year.
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immediate oesophagectomy. In addition, the RFA strat-
egy results in less morbidity (20.8% vs. 87.1%), proce-
dure-related mortality (0.4% vs. 2.6%) and cancer deaths
(0.5% vs. 1%) than immediate oesophagectomy.
Sensitivity analysis
The one-way sensitivity analysis demonstrated that the
following were important factors in determining the cost
effectiveness of RFA: outcome post-RFA, utility post-
RFA with squamous oesophagus, and utility fully recov-
ered post-oesophagectomy.
Only at the most pessimistic outcome post-RFA (i.e.
30% post-RFA with HGD), was RFA more costly than
oesophagectomy, although it still resulted in more QA-
LYs, costing £661⁄QALY. Threshold analysis demon-
strated that for oesophagectomy to dominate as the
preferred strategy, it required over 44% of patients to
have residual HGD post-RFA.
We altered utility values highlighted by the one-way
sensitivity analysis. For oesophagectomy to become a
more effective (but still more costly) option, it would
require either a utility value of <0.93 post-RFA with
squamous oesophagus, or a utility fully recovered post-
oesophagectomy of over 0.99. Thus, it would require
fully recovered post-oesophagectomy to be a more pref-
erable health state than post-RFA with squamous
oesophagus.
As there is uncertainty in the robustness of the neo-
squamous epithelium post-RFA, we undertook further
threshold analysis to identify the HGD recurrence
required to alter the results of the model. For this to
occur, it would require an annual risk of HGD recur-
rence in the neo-squamous epithelium of 20%.
The need for or frequency of endoscopic surveillance
after successful ablation with RFA is not currently
known. We modelled a scenario of continuing surveil-
lance in all patients post-RFA, with 2-yearly endoscopy
for both neo-squamous and BO, after initial yearly
endoscopy for the ﬁrst 5 years. With this strategy, the
cost of RFA increased considerably to £8168 with 14.2
QALYs. The cost of oesophagectomy remained at £8555
with 13.8 QALYs, and thus RFA still dominated as the
preferred strategy.
As the method used to calculate the cost of RFA dif-
fered from other calculated costs, we undertook thresh-
old analysis to determine how expensive treatment with
RFA would need to be, to alter the outcome of the
model. For RFA to become a more expensive treatment
strategy, it would require an increase of £1904 from the
base case estimate, to £5773 per treatment course per
patient. RFA retained its cost effectiveness at a willing-
ness to pay (WTP) of £30 000⁄QALY even if cost was
increased to £17 754, i.e. 450% more than the base esti-
mate and over twice the cost of an oesophagectomy
without complications.
Altering all other variables through their speciﬁed
range, including age (55–70 years), and in addition alter-
ing the discount rate (1–5%), and the length of time the
cohort was followed up for (5–30 years), made no critical
difference to the model outcome.
Probabilistic sensitivity analysis
The cost effectiveness plane demonstrating the distribu-
tion of the results is shown in Figure 3. This scatter plot
of the incremental costs and QALY pairs, generated from
the probabilistic sensitivity analysis, illustrates the uncer-
tainty surrounding the estimates of expected costs and
expected effects associated with the RFA compared with
the oesophagectomy strategy. A majority fall in the
south-east quadrant, the position where the RFA strategy
is more effective and less costly than the oesophagectomy
strategy, and thus RFA is said to dominate.
The cost effectiveness acceptability curve shows the
probability that RFA is cost-effective as the value placed
upon a QALY is varied between £0 and £50 000 (Fig-
ure 4). The probability that RFA is cost-effective is
approximately 84–86% throughout a WTP of £20 000–
30 000⁄QALY, showing that RFA appears highly likely
to be cost-effective.
Incremental QALY
Incremental
cost
£5000
£0
–£5000
–3.0 –2.0 –1.0 0 2.0 3.0 4.0
–£10 000
Figure 3 | Cost effectiveness plane of results of
probabilistic sensitivity analysis.
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Our study demonstrates that for a 64-year-old patient in
the UK with HGD in BO, a treatment strategy of RFA
followed by surveillance with oesophagectomy for HGD
recurrence or progression to ADC is less expensive and
results in more discounted QALYs compared with imme-
diate oesophagectomy. Our study supports recent ﬁnd-
ings, which demonstrated that in a US setting, a strategy
of RFA for HGD yielded more QALYs at less cost than
surveillance, oesophagectomy or other ablative strategies,
with the exception of PDT, which gave comparable QA-
LYs, but at a higher cost.
45
One of the roles of a health economic analysis such as
ours is to identify areas of uncertainty, which may guide
future study. Our model has identiﬁed the following key
areas: the ﬁrst concerns the success rate achievable by
RFA in eliminating HGD from BO. Data thus far show
that RFA is very effective at eliminating HGD with suc-
cess in 90% or more of cases, and with removal of BO
between 60% and 91%. The modelling demonstrated that
RFA remains cost-effective even if eradication of HGD is
achievable in only 60% of cases at a WTP of
£30 000⁄QALY, a ﬁgure well below the 90–97% in pub-
lished trials,
15, 33, 34, 46, 47 although the longest follow-up
available is currently limited to a median of 2 years.
34
Secondly, our one-way sensitivity analysis suggested
that for oesophagectomy to become the preferred strat-
egy, it would require the utility of patients post-RFA
with neo-squamous oesophagus to be lower than utility
of those post-oesophagectomy. Utility values for patients
undergoing RFA have not yet been derived, although
there is some preliminary evidence that patients with
resolution of dysplasia post-RFA have an improvement
in surrogate markers of quality of life, such as depres-
sion, stress and difﬁculty sleeping as measured using a
visual analogue scale.
48 We used deliberately conservative
estimates of utility based around known values ascer-
tained by standard gamble technique, considered a
robust method for deriving utility values.
39 Although
minimally invasive techniques for oesophagectomy are
improving, resulting in lower morbidity and mortality, it
is unlikely that a surgical approach would be a favoured
patient preference.
49
A recent health economic evaluation by NICE looking
at ablative therapies for treatment of HGD in BO has
demonstrated that RFA with subsequent surveillance
resulted in more QALYs, but was considerably more
expensive than oesophagectomy.
50 This in part contrasts
our ﬁndings where we found that although the cost of
RFA increased considerably with surveillance, it was still
cheaper than oesophagectomy with more QALYs, and
thus still dominated oesophagectomy as the preferred
strategy. We believe, the explanation for the lack of par-
ity was the inclusion of the cost of proton pump inhibi-
tors in their model in the post-RFA, but not in the post-
oesophagectomy strategy. We would argue that this
unfairly biases the study in favour of oesophagectomy
for two reasons. First, published quality of life data have
suggested that up to 75% of patients post-oesophagecto-
my still complain of reﬂux symptoms, and this would
likely have a major impact on cost incurred for medica-
tion usage, and potentially on visits to their general prac-
titioner or hospital consultations.
11 Secondly, in their
model, no allowance has been made for poor compli-
ance, which would lead to falsely high costs in the RFA
strategy.
The need for or frequency of endoscopic surveillance
after successful ablation with RFA is not currently
known. The long-term stability of the neo-squamous epi-
thelium is not yet determined and this is likely to lead to
clinicians continuing surveillance on their patients,
despite apparent histological resolution. In our model,
although the cost of RFA strategy increased considerably
due to follow-up and surveillance, it dominated the oeso-
phagectomy strategy. In both the NICE health economic
model and the published US study, surveillance consider-
ably added to the cost of ablative therapies, and made
RFA a more expensive strategy than oesophagecto-
my.
45, 50 The frequency and duration of follow-up
endoscopy for patients who have undergone successful
ablation will thus need to be considered very carefully,
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Figure 4 | Cost effectiveness acceptability curve for the
strategy of radiofrequency ablation (RFA) compared
with oesophagectomy.
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been determined with long-term follow-up data.
Other management strategies for treating HGD in BO
exist such as surveillance alone, PDT or other ablative
therapies. In the UK, surveillance of those with HGD is
not presently practised. Several previous cost-effective
analyses comparing ablative therapy with surveillance
have found surveillance to be costly and inefﬁcient in
preventing progression to cancer.
45, 51, 52 Studies from
the US have demonstrated that PDT is an effective alter-
native to oesophagectomy, but at a wide variation in cost
between $6000 and $50 000⁄QALY. Acceptance of PDT
as an option in the UK has been hampered by a stricture
rate as high as 35%, and the ultimate progression to can-
cer in 15%.
13 RFA is a realistic option, given its low
complication rate, and it appears to be effective in pre-
venting cancer deaths, with terminal cancer the cause of
death in only 0.5% of our hypothetical cohort. Currently,
no patient in reported trials has progressed to inoperable
cancer, but longer periods of follow-up are needed before
this apparently low risk can be conﬁrmed.
We have made a number of assumptions in our
model which warrant further discussion. There is an
established progression from Barrett’s IM, through low-
grade dysplasia (LGD), HGD to invasive ADC. For the
purpose of this model, IM and LGD were grouped
together. We have based this assumption on recent data,
which have suggested that LGD did not appear to confer
an increased risk of developing cancer.
35 In fact, a major-
ity regressed to IM or went back and forth between LGD
and IM. In addition, the histological classiﬁcation and
inter-observer agreement in the diagnosis of LGD is vari-
able, with factors such as inﬂammation playing an
important role in misclassiﬁcation. Another assumption
is not distinguishing between uni- and multifocal HGD,
in accordance with the other economic analyses in this
area.
45, 50 There is evidence to suggest that patients with
multifocal HGD are more likely to have a high risk of
progression to ADC compared with patients with unifo-
cal HGD.
53 Even with this increased risk, it is felt unli-
kely that this would affect the outcome of our model,
given the outcome of our threshold analysis. In addition,
these ﬁndings were not supported by another retrospec-
tive study.
54 The parameters used in our model included
patients with both histological subtypes, and thus one
would expect allowance for the potential increase risk
with multifocal HGD.
We have excluded those with T1 disease. Endoscopic
resection of oesophageal ADC conﬁned to the mucosa
(T1a) is practised in the UK, given the low likelihood of
lymph node invasion.
55 However, there is a high risk of
recurrent disease, with cancer-free survival of 80% in one
series (although these patients were able to have re-treat-
ment endoscopically without inﬂuencing survival) com-
pared to 97% of those undergoing an immediate
oesophagectomy.
56 There are preliminary data suggesting
that RFA of the remaining Barrett’s segment after endo-
scopic resection of the T1a lesion can be achieved with
favourable outcomes.
33 Follow-up was limited to a med-
ian of 21 months, during which one patient (of 16 in the
cohort with ADC) developed disease inﬁltrating into the
submucosa (stage T1b), which may be associated with
lymphatic spread in 20%.
55 The quality of life, costs and
outcomes involved in such a treatment strategy are com-
plex, and the health economic argument is therefore best
served by a separate analysis.
Randomized controlled trials are generally considered
the most robust method of determining the beneﬁt of a
new treatment,
57 and certainly one could conclude that a
randomized control trial of oesophagectomy vs. RFA
would be the next logical step. However, randomized
control trials are costly and time consuming. The results
of the model support the case that RFA should be the
optimum strategy, and that only with pessimistic param-
eters does this outcome change. However, it may be
inﬂuenced by the outcome after RFA, and thus prospec-
tive long-term outcome data from a well constructed
clinical trial, with population-matched controls, such as
the ongoing Ablation of Intestinal Metaplasia (AIM)-
dysplasia sham-controlled trial in the US, should be
sufﬁcient to conﬁrm that RFA is the most (cost-)effective
strategy. The critical issue is if clinicians have equipoise
regarding the two strategies, despite the ﬁndings of the
modelling, a deﬁnitive trial is necessary.
In conclusion, our study has suggested that a strategy
of RFA with oesophagectomy for HGD recurrence is a
cost-effective strategy when compared with immediate
oesophagectomy for the management of BO with HGD
in the UK. Sensitivity analysis demonstrates that RFA
remains the preferred option providing removal of HGD
in BO is achieved in over 60%. Long-term prospective
outcome data will help clarify whether RFA should
become the ﬁrst line treatment option for HGD in BO
in the UK.
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Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett’s
adenocarcinoma
Aims: Up-regulation of the 5-lipoxygenase (5-LOX)
leukotriene pathway is evident in numerous tumour
types, and has been linked to the promotion of cancer
cell growth. The aim of this study was to evaluate the
immunohistochemical expression of 5-LOX pathway
proteins in oesophageal adenocarcinoma and its pre-
malignant lesion, Barrett’s metaplasia.
Methods and results: Tissue samples were collected at
endoscopy from 16 patients with Barrett’s metaplasia
and from seven with oesophageal adenocarcinoma; ﬁve
proximal squamous oesophagus samples were used as
controls. Immunohistochemical analyses were per-
formed on stromal and epithelial areas with optimized
concentrations of primary antibodies for 5-LOX, 5-LOX-
activating protein (FLAP), and the distal enzymes
leukotriene (LT) A4 hydrolase (LTA4H) and LTC4 syn-
thase (LTC4S). the diagnosis was histologically con-
ﬁrmed from adjacent sections by a gastrointestinal
pathologist. Striking increases in the stromal immuno-
expression of 5-LOX (P = 0.041), FLAP (P = 0.038),
LTA4H( P = 0.0008) and LTC4S( P = 0.036) were seen
in adenocarcinoma tissue. Stromal FLAP and LTA4H
immunostaining correlated with elevated neutrophil
counts (P < 0.001). LTC4S was also notably overex-
pressed within epithelial cells in both Barrett’s metapla-
sia (P < 0.001) and adenocarcinoma (P < 0.01) tissue.
Conclusions: Key biosynthetic enzymes of the LTB4
and LTC4 biosynthetic pathways are incrementally
expressed across the spectrum of squamous, Barrett’s
metaplasia and oesophageal adenocarcinoma tissues,
suggesting, for the ﬁrst time, a role for both LT
subfamilies in disease progression.
Keywords: arachidonate-5-lipoxygenase, Barrett oesophagus, leukotrienes, oesophageal neoplasms
Abbreviations: BM, Barrett’s metaplasia; COX, cyclooxygenase; FLAP, 5-lipoxygenase-activating protein; LOX,
lipoxygenase; LT, leukotriene; LTA4H, leukotriene A4 hydrolase; LTC4S, leukotriene C4 synthase; NE, neutrophil
elastase; OA, oesophageal adenocarcinoma; PPI, proton pump inhibitor
Introduction
The incidence of oesophageal adenocarcinoma (OA) is
rising faster than that of any other solid tumour in
western countries.
1 It is associated with a poor prog-
nosis, the 5-year survival rate being only 10–13%.
2,3
OA arises in the metaplastic columnar epithelium in
the distal oesophagus, termed Barrett’s metaplasia
(BM). BM confers a one in 20 lifetime risk of developing
OA, equating to a risk that is 30-fold to 125-fold
greater than that of the general population.
4,5 BM is
present in 0.5–2% of adults in the western world, and
the frequency rises to 15% in those with chronic
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6–8 The mechanism
by which this injury triggers metaplasia and subse-
quent adenocarcinoma, and why this occurs in some
but not all individuals, is unknown.
Exposure of the lower oesophageal mucosa to acid
and bile induces injury, with the subsequent inﬂam-
matory response being an important initiating event in
the progression to OA.
9 Chronic inﬂammation is a well-
established risk factor for cancer in a number of tissue
sites in the gastrointestinal tract, providing a microen-
vironment rich in inﬂammatory mediators that en-
hance cell growth and survival.
10–12 Among these are
eicosanoids, generated upon cell stimulation by the
metabolism of membrane-derived arachidonic acid by
the cytochrome P450, cyclooxygenase (COX) and lip-
oxygenase (LOX) pathways.
13 Intracellular 5-LOX and
its activating protein 5-LOX-activating protein (FLAP)
metabolize arachidonic acid to an unstable intermedi-
ate, which is further metabolized by the distal enzymes
leukotriene (LT)A4 hydrolase (LTA4H) and LTC4 syn-
thase (LTC4S) to the extracellular, receptor-active LTB4
and LTC4, respectively.
14 LTs have diverse inﬂamma-
tory actions, including leukocyte activation and che-
motaxis,
15,16 prolonging neutrophil survival by
preventing apoptosis,
17 and stimulating other cells to
produce inﬂammatory cytokines.
18
Up-regulation of the LT pathway is evident in a
variety of tumour types, and plays a role in the
promotion of cancer cell growth by suppressing apop-
tosis and promoting neo-angiogenesis.
19–21 In the
oesophagus, increased levels of LTB4 are found in
BM,
22 and expression of 5-LOX and LTA4H has been
demonstrated in OA.
20,23,24 In a rat model of OA,
inhibitors of 5-LOX and LTA4H reduced tumour burden
in vivo.
23 The full role of LTs in BM and OA and their
cellular sources are nevertheless poorly deﬁned, partic-
ularly with respect to the cysteinyl-LT subfamily. In
this study, we evaluated cellular expression of the key
proximal and distal 5-LOX pathway proteins (5-LOX,
FLAP, LTA4H, and LTC4S), and related such expression
to populations of pertinent cell types in oesophageal
biopsies from patients with OA and its premalignant
lesion, BM.
Materials and methods
subjects
Fresh and adjacent formalin-ﬁxed oesophageal biopsies
were obtained at upper gastrointestinal endoscopy from
16 subjects with BM and from seven subjects with OA.
Five biopsies were taken from an area of normal
squamous oesophagus proximal to the diseased
segment (two from a patient with BM, and three from
a patient with OA). Biopsies from those with BM were
taken 2 cm proximal to the top of the gastric folds. The
length of Barrett’s segment and current use of proton
pump inhibitors (PPIs) and aspirin were recorded. The
biopsies submitted for formalin ﬁxation were processed
using routine methods into haematoxylin and eosin-
stained sections, and assessed by a histopathologist
expert in the ﬁeld of gastrointestinal pathology, blinded
to any study results. BM was deﬁned as the visualiza-
tion of metaplastic columnar epithelium with the
histological ﬁnding of intestinal metaplasia.
All subjects gave written informed consent prior to
participation, and the study was approved by the Isle of
Wight, Portsmouth and Southeast Hampshire Research
Ethics Committee (reference number: 08-H0501-3).
immunohistochemistry of oesophageal
biopsies
The fresh biopsy specimens were immediately ﬁxed in
ice-cold acetone containing the protease inhibitors
phenylmethylsulphonylﬂuoride (2 mm) and iodaceta-
mide (20 mm) (Sigma, Poole, UK) for 16–24 h at –20 C,
and then embedded in glycol methacrylate resin (Park
Scientiﬁc, Northampton, UK), as previously described.
25
Serial 2-lm sections were cut, ﬂoated onto ammonia
water, and picked up on glass slides coated with poly
(l-lysine). Immunohistochemistry was performed using
the avidin–biotin complex method, as previously de-
scribed.
26 Tissues were treated with a Tween-20 wash
priortoapplicationofsodiumazide(0.1%)andhydrogen
peroxide (0.3%) to block endogenous peroxidases. The
avidin–biotin blocking kit (Vector Laboratories, Peter-
borough, UK) was used to block endogenous biotin,
biotin receptors, and avidin-binding sites.
27
Sections were incubated overnight at room tempera-
ture with monoclonal primary antibodies or at 4 C with
polyclonal primary antibodies, as outlined below. All
antibodieswereusedatoptimizedconcentrations.LTC4S
antibody was diluted with 1% bovine serum albumin in
Tris-buffered saline to minimize non-speciﬁc protein
interactions. Secondary antibodies were biotinylated
swine anti-rabbit or biotinylated rabbit anti-mouse, as
appropriate (Dako, High Wycombe, UK). 3-Amino-9-
ethylcarbazole(red product)wasusedasthechromagen
when cell counts were quantiﬁed visually, and diam-
inobenzidine tetrahydrochloride (dark brown product)
when epithelial staining was quantiﬁed by image ana-
lyser. Counterstaining was performed for 1–2 min with
Mayer’s haematoxylin. Negative control sections were
incubated with buffer instead of the primary antibody or
with non-immune rabbit serum (Sigma).
2 P C Boger et al.
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Rabbit polyclonal antibody (IgG) against 5-LOX was
from Cayman Chemical (Ann Arbor, MI, USA; Cat No:
160402). J. Menke (Merck & Co., West Point, PA, USA)
kindly provided rabbit polyclonal antibodies against
human FLAP, LTA4H, and LTC4S, as previously
described.
28 Mouse monoclonal antibodies against
neutrophil elastase (NE) (an IgG1), CD68 (IgG3j) and
CD3 (IgG1) were from Dako, and EG2 antibody against
eosinophil cationic protein (IgG1) was from Diagnostics
Development (Skolgatan, Sweden).
quantification of immunohistochemical
staining
Positive immunostaining was deﬁned as distinct
nucleated cells exhibiting staining following exposure
to the chromagen. Positive cells observed near the
edge of a section where a wash of stain was apparent
were ignored. All other immunopositive cells were
counted in each tissue section, and the average count
in two non-adjacent sections was recorded. The total
area of the counted tissue sections was measured in
mm
2, ignoring areas of tissue disruption or folding,
with a computer-assisted image analyser (Image
Associates, Bicester, UK). Immunopositive cell preva-
lence was documented as positive cells per mm
2 of
tissue. When epithelial staining was observed, image
analysis software (Zeiss ks-400) was used to measure
percentage epithelial area staining on the basis of
red ⁄ green ⁄ colour composition, as previously de-
scribed.
29
statistical analyses
Statistical tests were performed with Pasw Statistics
version 18 for Windows (IBM UK, Portsmouth, UK).
Unpaired Student’s t-tests were used for comparison
between groups on original or log10-transformed values
as appropriate, depending on the data distribution as
determinedbynormalitytesting.Equalvariancewasnot
assumed.Countsofcellsimmunopositiveforeach5-LOX
pathway protein were also correlated with counts of
neutrophils, eosinophils, monocyte–macrophages and T
lymphocytes using Pearson’s correlation coefﬁcient.
Results
immunostaining for 5-lox pathway proteins
in oesophageal biopsies
Distinct nucleated cells with perinuclear immunopos-
itive staining for each of the 5-LOX pathway proteins
(5-LOX, FLAP, LTA4H, and LTC4S) were observed in
the stromal areas of all tissue types. Representative
photomicrographs from BM and OA tissue are shown
in Figure 1.
There were marked differences in 5-LOX pathway
protein immunostaining between the tissue types.
Geometric mean cell counts (per mm
2) were signiﬁ-
cantly higher in OA tissue (n = 7) than in squamous
tissues (n = 5) for 5-LOX (P = 0.041), FLAP
(P = 0.038), LTA4H( P = 0.0008), and LTC4S
(P = 0.036) (Figure 2). The increases in geometric
mean values in OA tissues were approximately three-
fold, eight-fold, 37-fold and six-fold, respectively, for the
four proteins, as compared with squamous values. In
BM tissues (n = 16), geometric mean counts of cells
staining for 5-LOX, FLAP and LTA4H were numerically
intermediate between those of the squamous and OA
tissues, although in comparison with squamous tissues
the differences were not statistically signiﬁcant (Fig-
ure 2A–C). In contrast, geometric counts of cells
immunostaining for LTC4S were signiﬁcantly higher
in both the BM (P = 0.014) and OA (P = 0.036)
tissues than in squamous tissue, with no difference
being seen between the two disease tissue types
(Figure 2D).
Of the four 5-LOX pathway proteins, only LTC4S
showed immunostaining in both epithelial cells (Fig-
ure 1E) and stromal cells, and the epithelial LTC4S
staining appeared to be cytoplasmic more than peri-
nuclear. The geometric mean percentage area of
epithelium immunopositive for LTC4S was elevated
approximately three-fold in both the BM
(P = 0.0000003) and OA (P = 0.0024) tissues, as
compared with LTC4S staining in squamous epithelium
(Figure 2E).
leukocyte subtype counts and correlation
with 5-lox pathway proteins
Elastase-positive (NE+) neutrophils were abundant in
all tissue types (Figure 3), with geometric mean counts
being seven-fold to eight-fold higher in OA tissues than
in BM (P = 0.006) or squamous (P = 0.11) tissues.
Eosinophils (EG2+), macrophages (CD68) and CD3 T
cells all showed signiﬁcant increases in the BM and OA
tissues (P < 0.05) (Figure 3).
5-LOX and FLAP are expressed in a range of
myeloid leukocytes, but expression of the distal
enzymes is restricted to speciﬁc leukocyte subtypes,
particularly neutrophils and macrophages for LTA4H
and eosinophils and mast cells for LTC4S. Regression
analyses showed that across all tissues (n = 28) the
log10 counts of FLAP+ cells and LTA4H+ cells
5-lipoxygenase and Barrett’s adenocarcinoma 3
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  2012 Blackwell Publishing Ltd, Histopathologycorrelated signiﬁcantly with neutrophils (r = 0.832
and r = 0.736, respectively, both P < 0.001)
(Figure 4), whereas 5-LOX+ cell counts showed
weaker correlations with CD68+ macrophages and
EG2+ eosinophils (r = 0.47 and r = 0.48, respec-
tively, both P = 0.01). LTC4S counts showed no
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Figure 2. Expression of 5-lipoxygenase (5-LOX) pathway proteins in squamous tissue, Barrett’s metaplasia (BM), and oesophageal
adenocarcinoma (OA). Counts of subepithelial cells per mm
2 of stromal area that were immunopositive for (A) 5-LOX, (B) 5-LOX-activating
protein, (C) leukotriene A4 hydrolase and (D) leukotriene C4 synthase synthase (LTC4S) are shown (log10 y-axis) for squamous, BM and OA
tissue. Epithelial LTC4S immunostaining expressed as a percentage of epithelial area is shown in (E). Geometric mean values are indicated by the
crosshairs, and statistical comparisons between groups were made by the use of Student’s t-tests with *P < 0.05, **P < 0.01 and ***P < 0.001.
Figure 1. Immunostaining for 5-lipoxygenase (5-LOX) pathway enzymes. Representative photomicrographs show cells in the stromal area of
oesophageal adenocarcinoma tissue that are immunopositive (red stain) for (A) 5-LOX, (B) 5-LOX-activating protein, (C) leukotriene A4
hydrolase, and (D) leukotriene C4 synthase (LTC4S). Strong epithelial immunostaining (brown stain) for LTC4S is shown in Barrett’s metaplasia
(E) and oesophageal adenocarcinoma tissue (F). G is the control (no primary antibody).
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not shown).
relationships between clinical
characteristics, 5-lox pathway proteins and
inflammatory cells in oesophageal biopsies
There were no signiﬁcant differences between the
groups in age or gender, and none of the patients was
taking aspirin. A higher percentage of patients were
taking a PPI at the time of tissue acquisition in the BM
group (93.8%) than in the squamous (40%) and OA
(14.3%) groups, but this difference did not reach
statistical signiﬁcance (chi-squared test, P = 0.096).
To analyse the effect of concurrent PPI use at the time of
tissue acquisition, oesophageal biopsy cell counts were
compared between those taking a PPI (n = 19) and
those not taking a PPI (n = 6). The geometric mean cell
counts were numerically lower for 5-LOX, FLAP and
LTA4H and for all leukocyte subtypes (NE, EG2, CD68,
and CD3) in those taking a PPI, although none of these
differences reached statistical signiﬁcance. The mean
length of BM segment was 5.9 cm (range 3–11 cm),
with no relationship to counts of cells staining positive
for 5-LOX pathway proteins or leukocyte subtypes.
Discussion
There is growing recognition that eicosanoid media-
tors, including prostanoids and LTs, have roles not only
in promoting inﬂammation but also in carcinogenesis,
including cancers of the gastrointestinal tract. Previous
studies have identiﬁed increased expression and activ-
ity of 5-LOX in patients with OA, in animal models of
OA, and in OA cell lines.
20,24 With its activating
protein FLAP, 5-LOX supplies an unstable substrate
(LTA4) for the synthesis of the short-lived, receptor-
active lipid mediators LTB4 and LTC4 by the activities of
LTA4H and LTC4S, respectively. Our study demon-
strated, ﬁrst, that all four of these enzymes are
signiﬁcantly overexpressed in OA as compared with
squamous control tissue. Second, we showed that
LTC4S is also up-regulated in premalignant Barrett’s
tissue, with unexpectedly strong expression in the
oesophageal epithelium of both disease groups. These
results provide a functional basis for reports of
increased LTB4 production in OA,
22 and also point to
an unsuspected role of the cysteinyl-LTs (LTC4, LTD4,
and LTE4) in Barrett’s disease progression.
Our results conﬁrmed that 5-LOX expression is
increased in OA tissue,
24 most likely in several
inﬁltrating leukocyte types, including macrophages
and neutrophils. We also demonstrated for the ﬁrst
time a highly signiﬁcant increase in FLAP immunoex-
pression in the same tissues (Figure 2). FLAP is an
integral nuclear envelope protein and an essential,
cytokine-inducible cofactor for LT synthesis in intact
cells;
30 it is also a promising target for novel inhibitors
of LT synthesis.
31 Its striking overexpression in OA
tissues suggests an increased intracellular capacity to
donate arachidonate to 5-LOX to initiate LT synthesis.
Subsequent generation of LTB4 depends on cell-
speciﬁc expression of the distal enzyme LTA4H, which
was markedly increased (37-fold) in OA tissues in our
study, as suggested by a previous semiquantitative
study.
23 Both FLAP+ and LTA4H+ cell numbers
correlated signiﬁcantly with counts of neutrophils
(Figure 4), which were also elevated in OA tissue
(Figure 3). These results suggest that an activated 5-
LOX–FLAP–LTA4H pathway is expressed within neu-
trophils, and that its product LTB4, a highly potent
leukocyte chemotaxin via its BLT1 receptors,
13 is
implicated in recruiting neutrophils to OA tissues.
Neutrophil inﬁltration is observed in both acute and
chronic inﬂammatory states, and also in different
cancers throughout the gastrointestinal tract.
32 Neu-
trophils play an active role in the tumour microenvi-
ronment, with neutrophil-derived factors promoting
genetic mutations and some, including LTB4, mediat-
ing vascular endothelial growth factor production from
tumour cells, contributing to angiogenesis.
19,33
5-LOX pathway products are directly linked to
carcinogenesis and tumour cell survival in a variety
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Figure 3. Leukocyte counts in squamous tissue (SQ), Barrett’s
metaplasia (BM), and oesophageal adenocarcinoma (OA). Counts of
neutrophils immunopositive for neutrophil elastase (NE+), eosin-
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monocyte–macrophages (CD68+) and T lymphocytes (CD3+) are
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geometric mean values (with standard errors), and statistical
comparisons between groups were made by use of Student’s t-tests
with *P < 0.05 and **P < 0.01.
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synthesis inhibitors in breast cancer cell lines is
associated with alterations in a number of apoptotic
signalling proteins, including bcl-2 and bcl-2-associ-
ated X protein.
34 In rats, inhibitors of 5-LOX (zileuton)
and of LTA4H (bestatin) both reduce the incidence and
tumour burden in OA,
23,24 suggesting a key role of
LTB4 in oesophageal tumorigenesis. Bestatin, however,
although widely used as an adjuvant in cancer
chemotherapy, has additional aminopeptidase inhibi-
tory activity that is unrelated to inhibition of LTB4
synthesis. Although suppression of LTB4 production
with a 5-LOX inhibitor induces apoptosis in oesopha-
geal cancer cell lines, a selective antagonist of the LTB4
receptor, BLT1 (U-75302), was less effective.
20 This
suggests that LTB4 receptors other than BLT1, or more
probably 5-LOX products other than LTB4, play addi-
tional roles in oesophageal cancer cell survival. Indeed,
the cysteinyl-LT LTD4 causes time-dependent and dose-
dependent increases in b-catenin and bcl-2 in intestinal
cell lines, and the associated reduction in cell death
correlates with levels of LTD4 as well as those of
LTB4.
35
In this context, our novel ﬁnding of increased LTC4S
expression in OA tissue, both in stromal cells and in
epithelial cells, is of particular interest. LTC4Si sa n
integral nuclear membrane protein and the rate-
limiting step for the synthesis of LTC4, the ﬁrst of the
cysteinyl-LTs, which have a range of vascular, anti-
apoptotic and pro-inﬂammatory actions via CysLT1,
CysLT2 receptors, and P2Y12.
14,16,36,37 LTC4S has
relatively restricted cellular expression in some myeloid
leukocyte subtypes, but has also been described in
bronchial epithelial cells.
38 The expression of LTC4Si n
oesophageal epithelial cells in our study is therefore
novel, and also intriguing on two accounts. First,
oesophageal epithelial cells did not express the proxi-
mal enzymes 5-LOX or FLAP, suggesting that epithelial
cells may generate LTC4 from its precursor LTA4
donated by myeloid leukocytes in a process of trans-
cellular synthesis, as proposed in other tissues.
39
Second, whereas 5-LOX, FLAP and LTA4H appeared
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overexpressed in both BM biopsies and OA biopsies.
Conﬁdence in the ﬁnding of epithelial LTC4S is merited
by the careful measures that we took to avoid non-
speciﬁc immunostaining, as described in Materials and
methods. Our data suggest that stromal and epithelial
LTC4S up-regulation may represent a relatively early
marker of Barrett’s disease progression.
Although we did not ﬁnd signiﬁcant increases in the
immunoexpression of 5-LOX, FLAP or LTA4H in the BM
tissues, it is possible that this may vary with the
inﬂammatory gradient along a Barrett’s segment, with
inﬂammation being maximal at the new squamo-
columnar junction and minimal distally.
40 We took
biopsies 2 cm from the oesophago-gastric junction, for
consistency, but, given the mean segment length of
5.9 cm in our series, this is approximately 4 cm distal
from the site of maximal inﬂammation at the squamo-
columnar junction. Further work is thus required to
map the expression of the 5-LOX pathway along the
entire Barrett’s segment. It is also possible that altera-
tions in enzymatic activity of the 5-LOX pathway occur
without changes in enzyme expression. The ﬁndings of
increased levels of LTB4 in both oesophagitis and BM,
with a signiﬁcant reduction in LTB4 levels after gastric
acid production had beensuppressed byaPPI,
22suggest
that gastric acid exposure may modulate LT synthesis
enzymatically, perhaps by pH-dependent activation of
inﬁltrating leukocytes. Additional risk factors, such as
aspirin and other non-steroidal anti-inﬂammatory
drugs, which inhibit COX-1, may promote LT synthesis
enzymatically by the shunting of arachidonate from the
COX to the 5-LOX pathway. Such effects would be
magniﬁed by the concurrent overexpression of all four
5-LOX pathway enzymes observed in OA tissues.
Overall, the translation of these laboratory ﬁndings
into clinical practice will depend on understanding the
complex interplay of the eicosanoid products of the 5-
LOX and related pathways, such as the COX-2 products
also implicated in BM and OA.
9,41–44 Dual inhibition of
the 5-LOX and COX-2 pathways may be required for
optimum therapy, as suggested by the additive effects of
zileuton and the COX-2 inhibitor celecoxib in a rat
model of OA.
24 The likelihood that different eicosanoids
have pro-tumorigenic and anti-tumorigenic properties
makes a better understanding of this microenviron-
ment of paramount importance prior to extended trials
of such therapy.
45
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